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II. ABBREVIATIONS  
17-AAG 17-(allylamino)-17-demethoxygeldanamycin 
AIDS Acquired immune deficiency syndrome 
AIF Apoptosis inducing factor 
ANOVA Analysis of variance between groups 
ANT Adenine nucleotide translocator 
Apaf-1 Apoptotic-protease-activating factor-1 
APS Ammonium persulfate 
ASK1 Apoptosis signal-regulating kinase-1 
ASK1-DN     Apoptosis signal-regulating kinase-1 dominant negative 
ATF-4 / ATF-6 Activating transcription factor 4 / 6 
ATP / dATP Adenosine-5’-triphosphate / 2’-desoxyadenosine-5’-triphosphate 
BAP31 B-cell receptor associated protein 31 
Bcl B-cell lymphoma 
β2GP1 β2 glycoprotein 1 
BH Bcl-2 homology 
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bp Base pair 
BP Band pass 
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CAD Caspase-activated DNase 
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CrmA Cytokine response modifier A 
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ECL Enhanced chemoluminescence 
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eIF2α Eukaryotic translation initiation factor-2, α-subunit 
ELISA Enzyme-linked immunosorbent assay 
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EndoG Endonuclease G 
EOR ER-overload response 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERK Extracellular signal-regulated kinase 
ERSE ER stress response element 
FACS Fluorescence-activated cell sorter 
FADD Fas-associated death domain 
FasL Fas ligand 
FCS Foetal calf serum 
FITC-VAD-fmk Fluorescein isothiocyanate- Val-Ala-Asp(OMe)-fluoromethylketone  
FL Fluorescence 
FSC Forward scatter 
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GADD153 Growth arrest and DNA damage-inducible gene 153 
Gas-6 Growth-arrest-specific 6 
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GM-CSF Granulocyte macrophage-colony stimulating factor 
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ICAD Inhibitor of caspase-activated DNase 
ICAM-3 Intercellular adhesion molecule-3 
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IL Interleukin 
INF Interferon 
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JNK c-Jun N-terminal kinase 
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LDL Low density lipoproteins 
λem Emission wavelength 
LOX1 Lectin-like oxLDL-receptor 1 
LP Long pass 
LPS Lipopolysaccharide 
LTC4 Leukotriene C4 
MBL Mannose-binding lectin 
MFG-E8 Milk fat globule epidermal growth factor (EGF) factor 8 
MKP-1 MAPK phosphatase-1 
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NAIP Neuronal apoptosis inhibitory protein 
NCI National cancer institute 
NF-κB Nuclear factor kappa B 
nt Nucleotide 
p- Phospho- 
p38 MAPK p38 mitogen-activated protein kinase 
PAA Polyacrylamide 
PAF Platelet activating factor 
PAK2 p21 (CDKN1A)-activated kinase 2 
PARP Poly(ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PCD Programmed cell death 
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PECAM-1 Platelet-endothelial cell adhesion molecule-1 
PERK PKR-like ER-localised eIF2α kinase 
PGE2 Prostaglandin E2 
PI Propidium iodide 
PIDD p53-induced protein with a DD 
PKR Double-stranded RNA-activated protein kinase 
PMA Phorbol myristate acetate 
PMSF Phenylmethylsulphonylfluoride 
PS Phosphatidylserine  
PSR Phosphatidylserine receptor 
PTPC Permeability transition pore complex 
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RNAi RNA interference 
ROCK-1 Rho-associated coiled-coil forming kinase 1 
ROS Reactive oxygen species 
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SQTL Sesquiterpene lactones 
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TGF Transforming growth factor 
TLR2 / 4 Toll-like receptor 2 / 4 
TNF Tumour necrosis factor 
TNF-R1 Tumour necrosis factor receptor 1 
TRAIL TNF-related apoptosis–inducing ligand  
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III. INTRODUCTION 
1 BACKGROUND – NATURAL PRODUCTS IN CANCER 
THERAPY 
Cancer is the second-biggest cause of death in developed countries despite the 
global efforts and the major advances achieved in the last decades. Surgery is 
most frequently the first line of therapy. It may be used alone or in combination 
with radiotherapy, a valuable tool for the control of local tumours. However, 
more effective anticancer therapies are required for most patients. The use of 
drugs (chemotherapy) and/or other additional treatments as anti-angiogenic and 
immune therapies are needed to treat disseminated cancer and achieve 
eradication of the disease. 
 
The chemotherapy of cancer started with the discovery of nitrogen mustard 
sixty years ago but in spite of the successful advances the main problems 
observed at that time still exist: the acute and long-term toxicities and probability 
of relapses [1,2].  
 
A wide range of chemotherapeutic drugs induce death in malignant cells by 
inducing apoptosis [3,4] though other forms of programmed cell death (see III.5) 
seem to be involved in the killing of certain tumour cells [5]. Inactivation of 
apoptosis is one of the fundamental hallmarks of cancer and also the major 
contributor to drug resistance developed by many cancer cells [6]. Compounds 
employing novel mechanisms of action, different from conventional 
chemotherapeutic drugs, can certainly help to resensitise tumour cells to cancer 
therapy. In this respect, nature provides us with esoteric structures that may 
have unusual modes of action and help to combat chemoresistance.  
 
In fact, natural products or their structural relatives comprise about 50% of the 
drugs used for cancer chemotherapy. Plants, microorganisms and marine 
organisms have been screened by the NCI (National Cancer Institute, USA) 
since almost 50 years and have given us exceptional drugs and very promising 
antineoplastic agents (Table III.1 shows some examples). 
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Table III.1: Representative anticancer drugs from natural origin in development or clinical 
use (adopted from [7-9]). 
 
Drug (class) Source 
Etoposide, teniposide (Lignans) Podophyllum peltatum (plant) 
Vincristine, vinblastine (Vinca alkaloids) Catharanthus roseus (Vinca rosea) (plant) 
Paclitaxel, docetaxel (Taxanes) Taxus brevifolia, Taxus baccata (plant) 
Topotecan, irinotecan (Camptothecins) Camptotheca accuminata (plant) 
Combretastatin A-4 Combretum caffrum (plant) 
Geldanamycin, 17-AAG Streptomyces hygroscopicus 
(microorganism) 
Epothilones A-D Sorangium cellulosum (microorganism) 
Bleomycin Streptomyces verticillus (microorganism) 
Daunomycin, doxorubicin 
(Anthracyclines) 
Streptomyces sp. (microorganism) 
Bryostatin 1 Bugula neritina (marine organism) 
Aplidin™ Aplidium albicans (marine organism) 
Dolastatin 10 Dolabella auricularia (marine organism) 
Spongistatin 1 Hyrtios altum (marine organism) 
 
 
None of the compounds isolated from marine organisms has been accepted to 
commercialisation yet. However, several drugs as Aplidin™ and Bryostatin 1 
are in clinical development. 
 
The NCI introduced in 1990 a new programme in which extracts from plants, 
animals and microorganisms are screened against a rationally designed panel 
of 60 human tumour cell lines, derived from different solid human cancer types 
(colon, brain, lung, melanoma, ovary, kidney, breast, and prostate) and 
leukaemia. Interestingly, the growth-inhibitory patterns (GI50) of anticancer 
drugs against the cell lines correlate with their mechanism of action.  
 
 
2 CEPHALOSTATINS 
The familiy of cephalostatins has been isolated by Prof. G. R. Pettit from various 
collections of the South African marine tube worm Cephalodiscus gilchristi 
Ridewood (family Cephalodiscidae) (Figure III.1). Up to now 19 members of this 
family have been characterised [10-18], all of which have shown remarkable 
activity in the NCI-60 panel with differences in their overall toxicity.  
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Figure III.1: Cephalodiscus sp. (family Cephalodiscidae). 
Left panel, scanning electron microscopy micrograph of a zooid. Right panel, general view of a 
whole colony [19]. 
 
 
Cephalostatins possess a similar and unique growth-inhibitory fingerprint 
(Figure III.2), which suggests that they may employ a novel mechanism of 
action different from any other anticancer agent. The first studies destined to 
elucidate the mechanism of action of cephalostatin 1 support this notion [20]. 
Cephalostatin 2 potency is comparable to cephalostatin 1 (Figure III.3) and 
employs the same signalling pathways than cephalostatin 1 (research 
performed in our group by Anita Rudy). 
 
The main limitation of cephalostatins is their low yield (0.0008% w/w) in the 
worm. A total synthesis has been achieved [9,21], but it is not a suitable 
alternative to the isolation from C. gilchristi yet. The complexity and 
unprecedent nature of their structures makes synthesis a difficult and long 
process, not feasible for the future from an industrial and economic point of 
view.  
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Figure III.2: Fingerprint of growth inhibitory profile of cephalostatin 1 evaluated by the 
NCI-60 in vitro cancer screen (September 2005, [22]). 
The zero value represents the mean of all cell lines. Bars indicate the deviation of the mean 
data obtained from the individual cell line from the overall mean. Negative bars correspond to 
less sensitive cell lines and positive bars, to more sensitive. Average GI50 (growth inhibition of 
50%) of cephalostatin 1 was 1.8 nM. 
 
 
Due to this complexity, the structure of cephalostatin 1 (Figure III.3), the first 
isolated and the most potent member of the family was not reported until 1988. 
Cephalostatin 1 is 400-fold more active in vitro than paclitaxel and one of the 
most powerful cytostatics ever to be tested by the NCI with a mean GI50 of 1.8 
nM [9]. Structure-activity studies on cephalostatins and their analogues 
revealed that the Northern part (see Figure III.3) is not only the most common 
unit in the cephalostatin family but is also strongly associated with the most 
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potent antitumour activity. An increased hydroxylation in the Southern part 
results in a reduction in the human cancer cell growth inhibition [9]. 
 
 
 
Figure III.3: Chemical structure of cephalostatin 1 and 2. 
 
 
The biological activity of cephalostatin 1 is being evaluated by in vivo 
screenings in the NCI employing models of melanoma, in sarcoma, mammary 
carcinoma and P388 leukaemia in mice.  
 
 
3 SESQUITERPENE LACTONES 
Sesquiterpene lactones (SQTL) are secondary plant metabolites found 
predominantly in the sunflower family (Asteraceae). Since decades these 
compounds are recognised to have cytotoxic [23-27] as well as an anti-
inflammatory potential [28-33], accompanied by antibacterial and analgesic 
properties. In traditional medicine, preparations from flowers of Arnica montana 
(Figure III.4) are used externally to treat various inflammatory diseases.  
 
R
1: R = H,  Cephalostatin 1
2: R = OH, Cephalostatin 2
Southern
Northern
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Figure III.4: Illustration and photograph of Arnica montana. 
The leaves from A. montana form a flat rosette, from the center of which rises a flower stalk, 1 
to 2 feet high, bearing orange-yellow flowers. The rhizome is dark brown, cylindrical, usually 
curved (left panel, from [34,35]). Right panel, photograph of a flower [36]. 
 
 
SQTL of pseudoguaianolide type are the most potent compounds found in 
preparations of A. montana, with helenalin, dihydrohelenalin and their acetate 
and fatty acids esters as prominent representatives (Figure III.5). The most 
common structural feature of biologically active SQTL is an α-methylene-γ-
lactone. In addition or alternatively, other α,β-unsaturated carbonyl structures, 
such as α,β-unsaturated cylopentenones are found. These structural elements 
are thought to mediate the biological effects of SQTL by alkylating biological 
macromolecules, in particular enzymes with sulfhydryl groups [23,24,26,37]. 
 
 
 
Figure III.5: Sesquiterpene lactones from Arnica montana. 
Chemical structure of helenalin (A) and dihidrohelenalin acetate (B). 
A
O
O
O
H
OAc
O
O
O
H
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The anti-inflammatory activity of SQTL has been linked mainly to an inhibition of 
the activity of the transcription factor nuclear factor kappa B (NF-κB), although 
there is some controversy about the exact mechanism of inhibition [28,38,39]. 
Several studies have shown that SQTL with both kinds of α,β-unsaturated 
groups were the most active in in vivo and in vitro, but the α-methylene-γ-
lactone moiety seemed the most important property [31,33].  
 
The antitumoral activity of helenalin, possessing two α,β-unsaturated carbonyl 
structural elements (Figure III.5 A) was first reported in 1967. It proved to be the 
most active constituent of a collection of Helenium autumnale screened by the 
NCI in an in vivo assay employing the murine P388 lymphocytic leukaemia [7]. 
Toxic activities of SQTL have been explained by the covalent binding to 
sulfhydryl groups of biological molecules (such as endogenous glutathione) by 
Michael addition of their α,β-unsaturated carbonyl structures [23,37,40]. Early 
structure-activity relationships reported that the presence of the α-methylene-γ-
lactone group was essential for their cytotoxic activity and an α,β-unsaturated 
ester or cyclopentenone strengthened this property [24,25]. On the contrary, 
studies on helenalin derivatives have shown that the contribution of a 
cyclopentenone group to cytotoxicity is considerably higher than that of the 
methylene lactone group (summarized in [41]). In addition, a correlation 
between lipophilicity and cytotoxic activity could be shown [42]. 
 
However, the mode of cell death induced by SQTL and the signalling pathways 
involved were not investigated until recently. Our group reported that 
programmed cell death induced by helenalin differs considerably from that of 
classical chemotherapeutic drugs. Importantly, helenalin is capable to overcome 
mitochondrial apoptosis resistance mechanisms [43].  
 
 
4 AIM OF THE WORK 
The aim of the present work was to investigate mechanisms of action 
contributing to the biological activity of the natural compounds cephalostatin 1 
and selected sesquiterpene lactones, heading at identifying exceptional or 
unusual signalling. The project can be dislodged in two parts: 
 
A. Characterisation of cephalostatin 1-induced apoptosis: contribution of 
endoplasmic reticulum signalling pathways  
B. Investigation of whether the mode of cell death induced by sesquiterpene 
lactones with different reactive groups influences macrophage response 
and a putative anti-inflammatory effect 
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5 PROGRAMMED CELL DEATH, APOPTOSIS AND NECROSIS 
In multicellular organisms, programmed cell death (PCD) is an essential 
physiological process required for the maintenance of proper tissue 
homeostasis. PCD can be defined as a coordinated sequence of events based 
on cellular metabolism that leads to cell destruction and occurs at a specific 
point in development [44,45]. Dispensable or potentially dangerous cells are 
forced to die and are removed by phagocytes to avoid negative consequences 
for the organism such as inflammation or autoimmune responses. The most 
classical form of PCD is referred to as apoptosis, term first employed by Kerr et 
al. in 1972 [46] to describe a form of cell death in mammals distinctive to 
necrosis. Apoptosis is a genetically controlled event required to maintain the 
balance to mitosis and differentiation, with essential roles in embriogenesis and 
the homeostasis of the immune system, but also involved in diseases such as 
cancer, AIDS or neurodegenerative diseases. 
  
“Apoptosis” refers to a particular morphology characterised by cell shrinkage, 
internucleosomal cleavage of chromatin, blebbing of the plasma membrane and 
finally fragmentation of the cell into apoptotic bodies. These fragments are 
enclosed by an intact plasma membrane, avoiding leakage of intracellular 
contents into the surrounding tissue. A hallmark of apoptosis is the exposure of 
phosphatidylserine (PS) on the surface of apoptotic cells, which mediates their 
recognition and phagocytosis by macrophages. Caspases, a family of cysteine 
proteases, are specifically activated in apoptosis and mediate the series of 
characteristic morphological changes.  
 
Forms of PCD different than apoptosis have been extensively described [44,47-
50]. However, there is a lack of suitable names or classification of these modes 
of death. Some definitions are overlapping and dying cells may display a 
mixture of some morphological and/or molecular features associated to more 
than one of the types of PCD. According to morphological changes PCD can be 
classified into apoptosis, apoptosis-like PCD, necrosis-like PCD or autophagy 
(Table III.2) [47]. Biochemically, apoptosis (caspase-dependent) can be 
differentiated from death controlled by other proteases (caspase-independent 
cell death) [45]. Now it is accepted that all these forms of cell death exist in vivo 
and can occur under physiologic circumstances, but may be triggered by 
chemotherapeutic drugs as well [50-52]. In fact, a single stimulus may initiate 
overlapping death pathways depending on conditions such as the intracellular 
levels of ATP, nitrative/oxidative stress [53] or caspase inhibition. 
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Table III.2: Classification of PCD according to the morphology of the dying cell (adapted 
from [47,50,51]). 
 
MODE OF DEATH CHARACTERISTICS 
Apoptosis            
(type I cell death) 
• Chromatin condensation into compact figures (stage II) 
• Internucleosomal DNA fragmentation 
• Cytoplasm condensation 
• Activation of caspases 
• Phosphatidylserine exposure 
• Zeiosis and formation of apoptotic bodies 
• Phagocytosis of dying cell 
Apoptosis-like PCD 
 
 
• Chromatin condensation less compact than in 
apoptosis (stage I) 
• Caspase-dependent or –independent 
• Display of phagocytosis-recognition molecules before 
lysis of the plasma membrane 
• Induced by AIF (apoptosis inducing factor), 
endonuclease G, cathepsins, other proteases 
Necrosis-like PCD • Absence of chromatin condensation or chromatin 
clustering to form loose speckles 
• Usually caspase-independent 
• Externalisation of PS might occur before lysis 
• Result of the interception of active cellular processes 
by oxygen-radical scavengers, Bcl-2, protease 
inhibitors or inhibition of autophagosome formation 
Autophagy  
(type II cell death) 
• Caspase-independent 
• Formation of lysosome-derived cytosolic vacuoles 
containing organelles and cytoplasm.  
• Can be also classified as necrotic-like PCD. 
 
 
Necrosis is the conceptual counterpart to PCD (Figure III.6). It is an accidental, 
passive and uncontrolled mode of cell death that occurs after exposure to high 
concentrations of detergents, oxidants, ionophores or high intensities of 
pathologic insult (hyperthermia, hypoxia, ischemia, direct cell trauma, etc.). 
Necrosis is characterised by cellular swelling, absence of zeiosis (membrane 
blebbing), partial degradation of DNA in randomly sized fragments, disruption of 
organelles and lysis of the plasma membrane, leading to release of the 
potentially inflammatory cellular contents. Necrosis typically affects groups of 
contiguous cells and provokes a substantial inflammatory response.  
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Figure III.6: Schematic representation of apoptotic and necrotic cell death (A) and 
electron micrographs of a necrotic and an apoptotic cell (B, from [54]).  
Necrosis is characterised by swelling of the cytoplasm and organelles, followed by a rupture of 
plasma membrane and release of the cellular contents (left). On the contrary, apoptotic death 
(right) is characterised by condensation of the nucleus and the cell followed by fragmentation of 
the cell into apoptotic bodies with intact membranes, which are rapidly removed by 
macrophages (phagocytosis). Apoptotic cells that have not been removed by phagocytes may 
lose their integrity and proceed to secondary or apoptotic necrosis. 
 
 
6 SIGNAL TRANSDUCTION IN APOPTOSIS 
Cell death with apoptotic morphology can be triggered by several stimuli, 
including intracellular stress and receptor-mediated signalling. These signals 
activate an evolutionarily conserved and highly regulated intracellular machinery 
of execution where caspases play a pivotal role. 
 
 
NECROSIS
B
NECROSIS APOPTOSIS
Secondary necrosis
Phagocytosis
A
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6.1 CASPASES 
Early pioneering work in the molecular mechanism mediating apoptosis was 
developed in the worm Caenorrhabditis elegans, where it was observed that 
apoptosis was determined by 3 genes, including an inhibitor of apoptosis (ced-
9), an executor of apoptosis (ced-3) and an activator of apoptosis (ced-4). The 
general structure of this death sequence is evolutionarily conserved from 
nematodes to humans [55]. Identification of interleukin-1β-converting enzyme 
(ICE, now known as caspase-1) as the mammalian protein related to CED-3 led 
to the discovery of a whole family of proteases critically involved in apoptosis 
and today called caspases (cysteinyl-aspartate-cleaving proteases). Apart from 
caspases, other proteases can lead to the characteristic apoptotic morphology, 
including other cysteine proteases as calpains, cathepsins (lysosomal 
proteases) or serine proteases [47]. They contribute to the action of caspases 
or mediate caspase-independent cell death, and are often mutually activated by 
caspases in an amplification signal of cell death. 
 
 
6.1.1 Classification and structure 
To date, 15 mammalian caspases have been identified, of which there are 11 in 
humans. Caspases are zymogens (inactive enzyme precursors) that consist of 
an N-terminal prodomain of variable length followed by a large subunit of about 
20 KDa (p20) and a small subunit of about 10 KDa (p10) (Figure III.7). The p20 
and p10 subunits are separated by a small linker sequence. Depending on the 
structure of the prodomain and their function, caspases are typically divided into 
3 major groups [56]. Caspases with large prodomains (>90 residues) are 
classified by their phylogenetic relationship in inflammatory caspases (caspase-
1, -4, -5 and -13) and apoptotic initiator caspases (caspase-2, -8, -9, -10 and -
12). Caspases with short prodomains (20-30 residues) belong to the group of 
effector caspases (caspase-3, -6 and -7).  
 
The large prodomain of procaspases contain structural motifs that belong to the 
death domain (DD) superfamily. The death effector domain (DED) and the 
caspase recruitment domain (CARD) are responsible for the recruitment of 
initiator caspases into death- or inflammation-inducing signalling complexes, 
where they are activated. Procaspase-8 and -10 possess 2 tandem DEDs in 
their prodomain and the CARD is found in procaspase-1, -2, -4, -5, -9, -12 and -
13 [57]. 
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Figure III.7: Caspase structure.  
Procaspase-8 and -10 carry two repeats of the DED in their long prodomain, whereas other 
initiator caspases contain a CARD domain. All effector caspases have short prodomains (red). 
Prodomains are followed by the large subunit (~20 KDa), a linker region (grey) and the small 
subunit (~10 KDa). 
 
 
Except procaspase-9 and probably some other initiator caspases, all zymogens 
require proteolytic activation [58,59]. Mature caspases are “homodimers of 
heterodimers” [60] formed by association of two monomers, with each monomer 
comprising the large (p20 or α-) and the small (p10 or β-) subunits (Figure III.8). 
Each tetramer contains two active sites, positioned at opposite ends of the 
molecule and comprising amino acid residues from the p20 and p10 subunits. 
 
 
 
Figure III.8: Schematic representation of the proteolytic activation of caspases [59].  
Activation proceeds by cleavage of the N-terminal domain at Asp119, Asp296 and Asp316 (all 
caspase-1 numbering convention) leading to a large (α) and a small (β) subunit. The activity and 
specificity detemining residues (R179, H237, C285 and R341) are brought into the necessary 
structural arrangement for catalysis. Cys285 is the catalytic nucleophile. The active caspase is a 
tetramer of two heterodimers, each comprising a large and a small subunit and an active site. 
DED Large subunit (p20) Small subunit (p10)DEDH2N - - COOH
CARD Small subunit (p10)Large subunit (p20)H2N - - COOH
Small subunit (p10)Large subunit (p20)H2N - - COOH
Procaspase-8, -10 (initiator)
Procaspase-1, -2, -4, -5, -9, -12, -13 (initiator)
Procaspase-3, -6, -7 (effector)
Small subunit (β)Large subunit (α)H2N - - COOH
Prodomain D119
D296
D316 R341R179 H237 C285
Active site
R179 H237 C285 R341
Active caspase
Proteolysis
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6.1.2 Substrate cleavage 
Caspases are specific cysteine proteases that recognise four amino acids 
(except for caspase-2, five) named P4-P3-P2-P1 and cleave C-terminal to P1, 
which in most cases is an Asp residue [61]. Interestingly, P3 corresponds to Glu 
for all known mammalian caspases, leading to a general recognition sequence 
X-Glu-X-Asp. The cleavage site between the large and small subunits for 
initiator caspases carries its own tetrapeptide recognition motif, which is 
consistent with the model proposing that initiator caspases are autoactivated. 
 
To date, more than 280 caspase targets are identified [62]. Many structural and 
regulatory proteins are inactivated by caspases, while other substrates can be 
activated to ensure proper induction of cell death. Proteolysis of certain 
components leads to the morphological changes of cell death. Cleavage of 
ICAD (inhibitor of caspase-activated DNase) by caspase-3 liberates the active 
CAD (caspase-activated DNase) nuclease that mediates apoptotic DNA 
fragmentation while cleavage of PARP [poly (ADP-ribose) polymerase] inhibits 
DNA repair. The cleavage of gelsolin and the kinases ROCK-1 (Rho-associated 
coiled-coil forming kinase 1) and PAK2 [p21 (CDKN1A)-activated kinase 2] has 
been implicated in membrane blebbing. Destruction of nuclear matrix proteins 
and cytoskeletal proteins (actin, nuclear lamin) results in lost of the cellular 
architecture. Activation of Bid by caspase-8 is an example of the amplification of 
a death signal. Moreover, cell-protective mechanisms as c-FLIP (cellular FLICE-
inhibitory protein), Bcl-2, Bcl-xL, Akt or NF-κB are turned off by caspase 
cleavage.  
 
 
6.1.3 Mechanism of caspase activation and regulation 
All caspases are produced as single-chain inactive proenzymes located in 
cytosol or cellular compartments and must be tightly regulated to prevent 
spontaneous cell death. Caspases are subject to transcriptional regulation, 
post-translational modifications and are eliminated by ubiquitination and 
degradation by the proteasome system.  
 
The activation of caspases proceeds by limited proteolysis and removal of the 
N-terminal prodomain and the linker peptide within the protease domain. 
Effector caspases are activated by initiator caspases through cleavage at 
specific internal Asp residues that separate the large and small subunits. As a 
consequence, a conformational change occurs and the catalytic activity of the 
effector caspase is enhanced by several orders of magnitude [59].  
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Effector caspases are responsible for the proteolytic cleavage of a broad 
spectrum of cellular targets, leading ultimately to cell demise. 
 
Activation of initiator caspases occurs upon recruitment to large 
macromolecular activation complexes and is explained by the induced proximity 
and proximity-induced dimerisation model [63]. Apoptotic and inflammatory 
caspases are recruited and brought into close proximity by virtue of their long 
DED or CARD domains. The dimerisation of inactive monomers is sufficient to 
trigger the activation and processing of procaspases. Up to now, complexes 
have been described for the activation of procaspase-8 and -10 (DISC), 
procaspase-9 (apoptosome), procaspase-2 (PIDDosome) [64] and procaspase-
1 and -5 (inflammasome) [65,66]. 
 
Endogenous caspase inhibitors inhibit either the activation of caspases or the 
proteolytic effect of activated caspases. c-FLIP proteins are inhibitors of the 
extrinsic pathway of apoptosis by blocking activation of procaspase-8 at the 
death-inducing signalling complex (DISC). The enzymatic activity of mature 
caspases is inhibited by the IAP (inhibitor of apoptosis) protein family [67]. To 
date eight distinct mammalian IAPs have been identified (Figure III.9). The BIR 
(baculoviral IAP repeat) domain is the functional unit in IAPs, responsible for the 
binding to caspases. XIAP (X-linked inhibitor of apoptosis), c-IAP1 (cellular 
inhibitor of apoptosis 1), c-IAP2 (cellular inhibitor of apoptosis 2) and NAIP 
(neuronal apoptosis inhibitory protein) have three of such sequences. XIAP, the 
most efficient of the family, specifically inhibits active caspase-3, -7 and -9. 
Survivin controls cell division and inhibits apoptosis selectively in cancer cells. 
Down-regulation of surviving has emerged as a promising approach for the 
sensitisation of tumour cells to chemotherapy [68]. 
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Figure III.9: IAPs in mammals (adapted from [67]). 
Members of the mammalian IAP family and their domain structure. A conserved linker peptide 
that precedes the BIR2 domain of XIAP, c-IAP1 or c-IAP2 is responsible for inhibiting caspases-
3 and -7. Only the BIR3 domain of XIAP can potently inhibit caspase-9 by interacting with the 
small subunit. Mammalian IAPs are controlled by binding of Smac and Omi/HtrA2 (see III.6.3.1). 
 
 
Other natural inhibitors of caspases are viral proteins responsible for the 
survival of infected mammalian cells. CrmA (cytokine response modifier A) is a 
serpin that inhibits the activity of caspase-1 and -8 and the baculoviral p35 
protein is a pan-caspase inhibitor [69]. 
 
 
6.2 THE EXTRINSIC PATHWAY 
In mammalian cells, the apoptotic response is initiated through either the 
intrinsic pathway (see III.6.3) or the extrinsic pathway, depending on the origin 
of the death stimuli [6,55,67]. The extrinsic pathway is mediated by death 
receptors on the cell surface and is of particular importance in multicellular 
systems where signalling is crucial, such as the immune system. Death 
receptors are members of the TNF (tumour-necrosis factor) receptor 
superfamily and comprise a subfamily that is characterised by an intracellular 
death domain and an extracellular ligand-binding domain. Prominent 
representatives are Fas/CD95, TNF-R1 (tumour-necrosis factor receptor-1), 
DR4/TRAIL-R1 (death receptor-4/TNF-related apoptosis–inducing ligand 
receptor-1) or DR5/TRAIL-R2. The “decoy receptors” constitute a negative 
regulatory mechanism of the extrinsic pathway. These receptors, such as 
soluble CD95 (sCD95) bind the death ligands but cannot propagate 
downstream signals due to non-functional or absent death domains [6]. 
Caspase-3, -7 Caspase-9
Bruce/Apollon
ILP2
ML-IAP/Livin
XIAP
Survivin
NAIP
c-IAP1
c-IAP2
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The extrinsic pathway (Figure III.10) is activated by the binding of an 
extracellular death ligand, such as Fas ligand (FasL), to its death receptor, such 
as Fas. Binding leads to the formation of a minimally homotrimeric ligand-
receptor complex that recruits an intracellular adaptor protein, such as FADD 
(Fas-associated death domain), and the inactive proforms of caspase-8 or 
caspase-10, forming the death-inducing signalling complex (DISC). Formation 
of the DISC leads to the activation and cleavage of the initiator caspase-8, 
which in turn cleaves and activates downstream effector caspases (caspase-3, -
6 and -7) [6]. The DISC complex formation downstream of other death receptors 
(DR4/5, TNF-R1) is similar to the Fas pathway.  
 
 
 
Figure III.10: The extrinsic apoptotic pathway. 
Binding of death ligands (FasL, in this example) to their preassembled receptor (as a trimer) 
results in the recruitment of the adaptor protein FADD and procaspase-8, forming the death-
inducing signalling complex (DISC). FADD contains a death domain (DD), which enables the 
association with the intracellular part of the death receptor and a death effector domain (DED), 
which binds procaspase-8. In the DISC, procaspase-8 is autolytically cleaved and activates 
effector caspases. Active caspase-8 can also cleave Bid to amplify the apoptotic signal through 
mitochondria. 
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In some cells (known as type I cells) the amount of active caspase-8 formed is 
sufficient to initiate apoptosis directly, but in other cells (type II) the amount is 
too small and requires amplification of the death signal through mitochondria to 
generate sufficient effector caspase activity. This cross-talk is mediated through 
the caspase-8-mediated cleavage of Bid, which then translocates to 
mitochondria and triggers the release of pro-apoptotic proteins (see III.6.3.1). 
 
 
6.3 INTRINSIC PATHWAYS 
6.3.1 Mitochondria 
Work over the past few years has revealed that, apart from being the cell’s 
powerhouse, mitochondria is a crucial organelle regulating and mediating 
apoptotic cell death. In response to many apoptotic stimuli, such as 
chemotherapeutic agents, toxins or cellular stress, mitochondrial membrane 
integrity is disrupted, process known as mitochondrial membrane 
permeabilisation (MMP). As a consequence, an arsenal of pro-apoptotic 
proteins exclusively confined to mitochondria under physiological conditions are 
released from mitochondria into the cytoplasm and initiate or promote apoptotic 
pathways (Figure III.11). Some stimuli, as bilirubin, β-amyloid or bacterial toxins 
can induce MMP directly. Chemotherapeutic drugs induce MMP by 
mechanisms including generation of reactive oxygen species (ROS), increase 
of mitochondrial Ca2+ uptake or translocation of pro-apoptotic Bcl-2 proteins 
and/or inhibition of anti-apoptotic family members (see the Bcl-2 family) [70].  
 
Apoptogenic proteins released from the intermembranal space include 
cytochrome c, Smac/DIABLO (second mitochondria-derived activator of 
caspases/direct IAP-binding protein with low pI), AIF (apoptosis-inducing 
factor), EndoG (endonuclease G) and Omi/HtrA2 (high-temperature-
requirement protein A2).  
 
The most investigated of these proteins is cytochrome c, which binds to and 
activates the protein Apaf-1 (apoptotic-protease-activating factor-1) in the 
cytoplasm. The binding of cytochrome c to Apaf-1 induces a conformational 
change that allows Apaf-1 to bind to ATP/dATP and recruit procaspase-9 to 
form the apoptosome. The high local concentration of procaspase-9 promotes 
its activation and self-processing and acts as the initiator of a caspase cascade 
leading to cell death. 
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Smac/DIABLO interacts with multiple inhibitor of apoptosis proteins (IAPs) and 
removes IAP-mediated inhibition of active initiator and effector caspases. A 
Smac dimer binds the BIR2 domain of XIAP and allows caspase-3 activation. In 
the monomeric form, Smac binds the BIR3 domain of XIAP and relieves 
inhibition of processed caspase-9. Omi/HtrA2 contains an IAP-binding 
tetrapeptide motif and a serine protease domain and induces caspase-
independent cell death. The serine protease domain is absolutely essential to 
the cell killing activity whereas the N-terminal IAP-binding motif appears less 
critical [61]. AIF translocates to the nucleus and triggers apoptotic-like death 
characterised by caspase-independent chromatin condensation and the 
formation of large DNA fragments. Endonuclease G also translocates to the 
nucleus, where it catalyses both high molecular weight DNA cleavage and 
oligonucleosomal DNA fragmentation [71]. 
 
 
 
Figure III.11: The mitochondrial apoptotic pathway. 
Many apoptotic stimuli induce mitochondrial membrane permeabilisation (MMP) and release of 
apoptogenic factors from mitochondria. Cytochrome c (cyt c) binds and activates Apaf-1, which 
in turn recruits procaspase-9 to the apoptosome leading to auto-activation of caspase-9. Then, 
caspase-9 activates downstream effector caspases. Smac/DIABLO relieves the inhibition of 
active initiator and effector caspases by the IAPs. AIF, Omi/HtrA2 and endonuclease G initiate 
own death pathways. Anti-apoptotic Bcl-2 proteins inhibit the release of mitochondrial proteins 
whereas the pro-apoptotic members contribute to MMP. 
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The bcl-2 family 
 
The intrinsic pathway of apoptosis is critically regulated by the Bcl-2 family, an 
evolutionarily conserved group of proteins including pro-apoptotic as well as 
anti-apoptotic members [55,72]. The founding member is Bcl-2, first identified 
as a protooncogene involved in human follicular B cell lymphoma (hence the 
name bcl) and homologue to the C. elegans ced-9 gene [55]. These proteins 
have been classified into three functional groups (Figure III.12). Members of the 
first group, such as Bcl-2 and Bcl-xL, possess anti-apoptotic activity and are 
characterised by four short, conserved Bcl-2 homology (BH) domains (BH1-
BH4). They also possess a C-terminal hydrophobic tail, which anchors the 
proteins to organelles as mitochondria and the endoplasmic reticulum. Group II 
consists of Bcl-2 proteins with pro-apoptotic activity as Bax and Bak, with an 
overall structure similar to the first group. Group III is formed by a large and 
diverse collection of proteins whose common feature is the only presence of the 
BH3 domain and are also known as “BH3-only” proteins (Bid, Bik, Bim, Bad, 
among others).  
  
 
 
Figure III.12: Bcl-2 family members (adapted from [72]). 
The group I include anti-apoptotic proteins, characterised by four conserved Bcl-2 homology 
domains (BH1-BH4) and a hydrophobic domain (TM) responsible for the localisation to 
membranes. Group II proteins are pro-apoptotic and lack the BH4 domain. Group III consists of 
the pro-apoptotic “BH3-only” proteins. 
 
 
The multidomain pro-apoptotic members Bax and Bak are crucially involved in 
the induction of MMP and release of mitochondrial proteins. Upon receipt of a 
death signal inactive Bax and/or Bak experience a conformational change, 
oligomerise and insert into the mitochondrial membrane forming protein-
permeable channels.  Intermembrane mitochondrial proteins as cytochrome c 
are released through these channels. Another model proposes that Bax and 
Bak interact with and regulate the permeability of the permeability transition 
pore complex (PTPC), formed by the adenine nucleotide translocator (ANT, 
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inner membrane), the voltage-dependent anion channel (VDAC, outer 
membrane) and other proteins [72].  
 
The BH3-only members serve as “sensors” that selectively respond to specific 
death and survival signals. For example, cleavage of Bid by caspase-8 occurs 
after the activation of death receptors and Bad is switched on and off by its 
phosphorylation in response to survival factors. Activation of BH3-only 
molecules results in the activation of Bax, Bak and formation of channels. On 
the contrary, Bcl-2 and Bcl-xL bind and sequester BH3-only proteins, preventing 
Bax and Bak activation and the release of pro-apoptotic mitochondrial proteins. 
 
 
6.3.2 Endoplasmic reticulum 
The endoplasmic reticulum (ER) is the principal site of synthesis and folding of 
proteins [73,74] destined for secretion, the cell membrane, Golgi apparatus and 
lysosomes and a site of biosynthesis for steroids, cholesterol and other lipids. 
The second essential function of the ER is the storage and signalling of calcium 
(Ca2+). 
 
Chaperone proteins, a high Ca2+ concentration and an oxidative environment 
within the ER are required to fulfil these functions efficiently [75,76]. Properly 
folded proteins exit from the ER and progress down the secretory pathway to 
the Golgi complex. Any alterations in the ER environment can disrupt ER 
function, resulting in what has been referred to as “ER stress” [75,77-80]. The 
two major causes leading to ER stress are an alteration of Ca2+ homeostasis 
and the accumulation of unfolded or misfolded proteins. Thus, ER stress can be 
induced by calcium depletion from the ER lumen, inhibition of protein 
glycosylation, reduction of disulfide bonds, expression of mutated proteins in the 
ER or impairment of protein transport to the Golgi, among others. In order to 
overcome ER stress, this organelle has a specific signalling pathway globally 
called the “ER stress response” pathway.  
 
The ER responds with activation of the unfolded protein response (UPR) signal 
transduction pathway, the ER-overload response (EOR) and the ER-associated 
degradation (ERAD) to survive the stress. These pathways lead to a reduction 
in the amount of newly synthesised proteins, an increased degradation of 
misfolded proteins and an augmentation of the protein folding capacity of the 
ER. However, if the damage is too strong or prolonged, apoptosis is initiated to 
protect the organism from the damaged cell.  
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Figure III.13: The unfolded protein response (UPR) pathway.  
The UPR is activated by the accumulation of unfolded proteins in the ER. The transmembrane 
proteins IRE1, PERK and ATF6 act as sensors and induce the transcription factors XBP-1, 
p50ATF6 and ATF4, which in turn stimulate the transcription of their target genes. Target genes 
of the UPR share a consensus sequence in their promoters, the ER stress response element 
(ERSE), and code for chaperones and other proteins involved in protein folding as BiP/GRP78, 
GRP94, calreticulin or PDI (protein disulfide isomerase). Phosphorylation of eIF2α by PERK 
leads to an attenuation of general protein synthesis. 
 
 
The UPR (Figure III.13) is initiated by the activation of three ER transmembrane 
proteins: IRE1 (inositol requiring-1), ATF6 (activating transcription factor-6) and 
PERK (PKR-like ER-localised eIF2α kinase). These proteins are normally kept 
in an inactive state through an association between their N-terminal luminal 
domains and the chaperone BiP/GRP78 (binding protein/glucose-regulated 
protein of 78 kDa). Under accumulation of unfolded proteins in the ER, BiP 
dissociates from IRE1, PERK and ATF6 to bind unfolded proteins. IRE1 and 
PERK undergo homooligomerisation and autophosphorylation within their 
serine/threonine kinase domains. IRE1 contains a C-terminal endonuclease 
domain that excises a short sequence from the mRNA of the X-Box binding 
protein (XBP-1), generating an active bZIP transcription factor that stimulates 
transcription of ER chaperones and other folding enzymes. PERK 
phosphorylates the translation initiation factor eIF2α, leading to an attenuation 
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of general translational initiation and protein synthesis but to a stimulation of the 
translation of the mRNA of the transcription factor ATF4. ATF6 translocates 
from the ER to the Golgi, where it is processed to generate an N-terminal 
cytosolic domain, p50ATF6, which translocates to the nucleus and induces UPR 
target genes including BiP and XBP1.  
 
The EOR is triggered by accumulation of membrane proteins in the ER. It is 
believed that Ca2+ release from ER and sequent production of reactive oxygen 
intermediates activates NF-κB, a transcription factor mediator of anti-apoptotic 
responses. The ERAD pathway eliminates misfolded proteins in the ER by the 
ubiquitin-proteasome system [81,82].  
 
When these stress modulators are unable to rescue cells, at least three 
pathways can induce apoptosis (Figure III.14). The cytosolic domain of 
activated IRE1 recruits the adaptor molecule TRAF2 (TNF receptor-associated 
factor 2) and activates the apoptosis signal-regulating kinase 1 (ASK1)/c-Jun N-
terminal kinase (JNK) cascade [79]. In addition, the transcription factors 
activated by the UPR, but most notably ATF4, increase the transcription of 
CHOP (C/EBP homologous protein), a transcription factor that induces cell 
cycle arrest and apoptosis by modulation of Bcl-2 and many other proteins 
[82,83]. Furthermore, caspases participate in ER-triggered apoptosis [80]. 
Caspase-12 (a murine caspase) aggregates at the ER membrane surface 
through the complex IRE1-TRAF2, resulting in its cleavage and activation, 
followed by activation of caspase-9 independent of cytochrome c and Apaf-1 
[80,84,85]. Caspase-7 can translocate to the ER surface upon ER stress and 
participate in caspase-12 activation [86]. In humans, caspase-4 has been 
proposed to play a role as ER stress-specific caspase similarly to caspase-12 
[87], and also caspase-2 can be activated by ER stress [88,89]. Caspase-8 
cleavage of the transmembrane protein BAP31 (B cell receptor associated 
protein 31) generates a p20 fragment that probably induces a pro-apoptotic 
Ca2+ flux between the ER and mitochondria [75,77].  
 
On the other hand, an increase in cytosolic free Ca2+ as the primary mechanism 
causing ER stress or as a consequence of the ER dysfunction can activate 
many proteins involved in cell death pathways [90-92]. For instance, the Ca2+-
activated protein phosphatase calcineurin dephosphorylates the BH3-only 
protein BAD, promoting mitochondrial targeting of BAD and apoptosis [93].  
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Calpains are a family of cysteine proteases that require Ca2+ for their activity 
[94-96]. An increasing number of cellular proteins are dually susceptible to 
cleavage by calpain and caspases, especially in neuronal death. The activation 
of calpains can facilitate or inhibit apoptotic cell death and switch to necrosis 
depending on the cellular context [92,97,98]. Notably, caspase-12 has been 
reported to be activated upon cleavage by calpain [99].  
 
 
 
Figure III.14: ER apoptotic pathways. 
ER stress-activated IRE1 recruits TRAF2 and ASK1 to the ER membrane surface, leading to 
activation of ASK1 and its downstream kinase JNK (A). The initiator caspase-12 and probably 
caspase-4 can also aggregate at the ER through TRAF2, resulting in the activation of caspase-
12/4 (B). In addition, the UPR-activated transcription factors ATF4, XBP-1 and p50ATF6 
activate the pro-apoptotic transcription factor CHOP (C). Ca2+ released from the ER lumen can 
activate the cysteine protease calpain, which may activate caspase-12/4 or induce cell death on 
its own (D). 
 
 
Besides their role in mitochondria, Bcl-2 family members participate in the 
regulation of apoptosis at the ER. Bcl-2, Bcl-xL, Bax, Bak and some BH3-only 
proteins can localise to the ER membrane. Bax, Bak and Bcl-2 exert a critical 
control of the Ca2+ homeostasis in the ER and subsequent cross-talk to 
mitochondria. Bcl-2 reduces the quantity of Ca2+ released after a pro-apoptotic 
stimulus arrives by increasing the leak of Ca2+ under resting conditions, thus 
lowering mitochondrial Ca2+ uptake [90,100,101]. The pro-apoptotic proteins 
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Bax and Bak exert the contrary effect and, in fact, are required for the induction 
of apoptosis by some apoptotic stimuli whose primary target is not the ER 
[102,103]. Furthermore, the interaction of the BH3-only protein Bim with Bcl-xL 
has been reported to induce caspase-12 activation and apoptosis [104]. 
 
Caspase-4 and caspase-2 
 
Caspase-4 was first described in 1995 as a novel protein with protease and 
apoptotic activity exhibiting 50% sequence identity with caspase-1. It was 
classified in the inflammatory caspase family, proteases involved in the 
processing of pro-inflammatory cytokines as IL-1 (interleukin 1) and IL-18. Many 
studies have demonstrated that caspase-4 is necessary in Fas-, TRAIL (TNF-
related apoptosis–inducing ligand)- and INF (interferon)-induced apoptosis 
[105-109]. But most importantly, caspase-4 has been proposed to be the human 
homologue and fulfil the same function than mouse caspase-12. Caspase-4 
was recently shown to mediate apoptosis induced specifically by ER stress and 
amyloid β treatment [87]. Interestingly, a physiological role for caspase-4 in 
apoptosis has been lately described [110]. During spontaneous plasma cell 
death, ER stress induces caspase-4 activation upstream of mitochondria that 
leads to caspase-3 activation and apoptosis. 
 
Even though caspase-2 was the second mammalian caspase identified, its 
exact role in the regulation of cell death is controversial and relatively unknown, 
in part due to its different function dependent on cell type and stimulus. 
Caspase-2 contains a CARD domain, as other initiator caspases, and shares 
sequence homology with caspase-1, -4, -5 and -9. Caspase-2 can act as 
initiator caspase (cleavage of itself and golgin-160) but has characteristics of 
effector caspase (e.g. cleavage of αII-spectrin). It is localised predominantly to 
the Golgi complex and the nucleus, but also in mitochondria and cytosol [111]. 
Caspase-2 is activated in response to DNA damage, where it acts as the only 
initiator caspase, and it appears necessary for apoptosis triggered by UV 
(ultraviolet) irradiation, trophic factor withdrawal [112,113], cytokine deprivation 
or administration of TNF and TRAIL. Importantly, caspase-2 has been also 
implicated in neuronal death induced by β-amyloid [114] and recently in ER 
stress [88,89].  
 
 
6.3.3 Pathways originated in other organelles 
Besides mitochondria and the endoplasmic reticulum, other organelles have 
been demonstrated to trigger, or at least to participate in, apoptotic and non-
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apoptotic cell death [70]. Examples are the activation of p53 in the nucleus or 
the role of lysosomes in autophagic and in cathepsins-mediated cell death. 
 
The Golgi apparatus plays an essential role in membrane traffic and is situated 
in an ideal position to sense and integrate information about the state of the cell. 
Even though its role has not been deeply investigated so far, some studies 
evidence a potential and specific role in cell death. The Golgi complex contains 
several apoptosis-signalling proteins: caspase-2, death receptors (TNF-R1, 
Fas), beclin (protein involved in autophagy) and GD3 synthase, which converts 
ceramide into the mitochondria-targeting GD3 ganglioside [70]. Moreover, 
recent reports demonstrate that the calpain/calpastatin network is associated 
with the cytosolic surface of the Golgi apparatus and ER membranes and 
calpains can be activated at the interface between these organelles [115,116]. 
Accordingly, both the Golgi apparatus and the endoplasmic reticulum contribute 
to the rise in cytosolic Ca2+ observed upon agonist stimulation [117]. The role of 
caspase-2 is particularly interesting. After delivery of a pro-apoptotic signal, 
caspase-2 is locally activated at the Golgi complex and cleaves golgin-160 at a 
unique site not susceptible to cleavage by other caspases. This initial event is 
entirely responsible for the disintegration of the Golgi complex [118].  
 
 
7 ELIMINATION OF APOPTOTIC CELLS 
7.1 PHAGOCYTOSIS 
7.1.1 Importance 
Extensive studies over the last decades have provided deeper insights in the 
characteristics and signalling pathways of apoptosis, but only recently apoptosis 
research focused also on the importance of self debris clearance. Phagocytosis 
of dying cells constitutes the last step of programmed cell death in vivo and 
should occur before cells undergo severe damage and spill their contents into 
surrounding tissues. Dead cells are continuously generated but are immediately 
removed from the organism by neighbouring cells or professional phagocytes, 
mainly macrophages, to avoid tissue damage and inflammatory or autoimmune 
responses. 
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7.1.2  “Eat-me” signals on the apoptotic cell 
During the apoptotic process cells mark themselves for the recognition and 
engulfment by phagocytes. The surface of apoptotic cells exhibits molecules 
that are absent in normal cells and existing molecules are modified in sugar 
chains or by oxidation processes [119,120]. 
 
The most prominent “eat-me” signal is the phospholipid phosphatidylserine 
(PS), which is externalised by essentially all apoptotic cells during apoptosis. In 
a resting cell, PS is normally confined to the inner leaflet of the membrane 
bilayer by two mechanisms. First, an aminophospholipid translocase, i.e. a 
Mg2+-ATPase inhibited by Ca2+, transfers PS from the external to the inner 
layer. Second, PS is bound to proteins of the membrane-associated 
cytoskeleton. PS translocation requires the concomitant inhibition of the 
aminophospholipid translocase and activation of a plasma membrane 
phospholipid scramblase [121-123]. Activation of the scramblase requires 
phosphorylation processes and Ca2+, whereas the translocase is inactivated 
probably due to the decrease in ATP and increase in Ca2+ often associated with 
the apoptotic process. PS exposure has been linked to caspase activation 
[47,121] but there are also reports that PS externalisation occurs independent 
of caspases [124,125] and even in necrotic cells [126].  
 
The modification of membrane structures with carbohydrate chains has not 
been very extensively studied but is suggested to be another important signal in 
apoptotic cells. ICAM-3 (intercellular adhesion molecule-3), a highly 
glycosylated protein expressed in leukocytes, is somehow modified during 
apoptosis. Another example is the CD43 glycoprotein, which undergoes a 
transient capping with sialylpolylactosaminyl sugar chains at early stages of 
apoptosis [127,128]. Oxidation of proteins and lipids at the apoptotic cell surface 
is also important for engulfment. Phosphatidylserine oxidation is required for its 
externalisation [129-131] and for efficient phagocytosis [120]. 
 
 
7.1.3 Interaction phagocyte-target cell and phagocytosis 
The engulfment of apoptotic cells is explained by the “tether and tickle” two step 
model. In a first step, recognition molecules on the phagocytic cell bind to 
structures on the apoptotic cell to tether it to the surface of the phagocyte. 
Following, the structures of the phagocyte participating in tethering and/or 
additional receptors are engaged to enclose the target cell and initiate uptake. 
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In the past years, a vast array of receptors and factors that participate in the 
recognition and engulfment of apoptotic cells in mammals have been identified 
[119,120,132-137]. Even though there are still obscure points and some 
controversy, there is agreement about the critical role of PS in cell removal. A 
receptor specific for PS was identified [138] and called phosphatidylserine 
receptor (PSR). Engagement of the PSR leads to macropinocytosis and uptake 
of tethered apoptotic cells. Numerous in vitro and in vivo experiments have 
demonstrated that the PSR is essential for cell uptake and for the clearance of 
apoptotic cells in the early stages of mammalian organogenesis [139]. However, 
it requires the collaboration of other receptors for the first step of cell tethering. 
Members of the scavenger receptor family, integrins (αVβ3 and αVβ5), lectins and 
CD14 are considered tethering receptors [140,141]. 
 
One of the systems best characterised after the PSR is the recognition by the 
vitronectin receptor (αVβ3). Non-activated macrophages recognise an unknown 
ligand on apoptotic cells through a complex formed by αVβ3, CD36 and secreted 
thrombospondin, whereas activated macrophages form a tripartite PS/MFG-
E8/αVβ3. MFG-E8 [milk fat globule epidermal growth factor (EGF) factor 8] is a 
soluble glycoprotein secreted by activated macrophages that acts as a bridge 
between aminophospholipids (such as PS) on the apoptotic cell and the 
integrins αVβ3 or αVβ5 on the macrophage [142,143]. Other receptors in the 
macrophage are the receptor tyrosine kinase Mer [144], β2GP1 (β2 glycoprotein 
1) receptor, CD14, lectins, annexin I and II and scavenger receptors, among 
others. Scavenger receptors include CD36 [145], CD68, LOX1 (lectin-like 
oxLDL-receptor 1, that recognises oxidised sites on the apoptotic cell) and the 
scavenger receptors A and B (SR-A, SR-B). 
 
Adding a level of complexity, several bridging molecules linking specific 
receptors on the phagocyte to ligands on the dying cell appear to increase the 
efficiency of uptake. In many cases, these are known PS-binding proteins, such 
as the serum proteins β2 glycoprotein 1 (β2GP1) and protein S, the gene product 
of Gas-6 (growth-arrest-specific 6), annexin I, thrombospondin and the milk fat 
globule protein MFG-E8. β2GP1 and protein S receptors are not been identified 
yet, whereas Gas-6 is a ligand for the receptor tyrosine kinase Mer. Annexin I 
may facilitate the recognition of PS by the PSR [146]. 
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Figure III.15: Simplified model for the phagocytic synapse. 
Phosphatidylserine (PS) on the surface of apoptotic cells is recognised by the tyrosine kinase 
receptors Mer and β2 glycoprotein 1 (β2GP1) receptor, the phosphatidylserine receptor (PSR) 
scavenger receptors and some integrins. The vitronectin receptor (αVβ3) recognises apoptotic 
cells through the bridging molecules milk fat globule epidermal growth factor (EGF) factor 8 
(MFG-E8) and thrombospondin (TSP). Some members of the innate immunity, as collectins, 
bridge the apoptotic cell to the calreticulin-CD91 receptor. Sugar chains and intercellular 
adhesion molecule-3 (ICAM-3) on the apoptotic cell are recognised by lectins and CD14. 
 
 
Recognition molecules of the innate immune system play a pivotal role in the 
clearance of apoptotic cells [147]. This group includes soluble proteins such as 
collectins, C-reactive protein (CRP), complement proteins (C3b/bi) and the 
membrane-bound receptors calreticulin-CD91, Toll-like receptors and 
complement receptors 3 and 4 (CR3, CR4) [148]. The collectin family is a group 
of serum opsonins that includes mannose-binding lectin (MBL), surfactant 
proteins A and D (SP-A, SP-D) and the complement component C1q. These 
molecules are especially effective at recognising components of late apoptotic 
cells, necrotic cells and cell debris, and bind to ligands different than PS 
exposed late in the apoptotic process. Collectins seem to be the mechanism of 
removal of dying cells that have not been engulfed by macrophages in the early 
apoptosis phase. The receptor to collectins corresponds to cell-surface 
calreticulin, which together with its partner signalling molecule CD91 initiates 
macropinocytosis of dead cells [149,150].  
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One of the requirements for proper phagocytosis is the polymerisation and 
reorganisation of the actin cytoskeleton underneath bound particles. Binding of 
apoptotic cells induces actin polimerisation and protein phosphorylation at 
nascent phagocytic cups, crucial for the formation of membrane extensions 
around, and engulfment of the target particle [151]. The intracellular signalling in 
the phagocytosis of apoptotic cells may depend on the receptor involved. In 
mammals, the small GTPases of the Rho family Rac and Cdc42 (cell division 
cycle 42) are required for the organisation of actin filaments leading to uptake of 
apoptotic cells [120,141].  
 
 
7.1.4 Inhibition of phagocytosis 
In general, removal of apoptotic corpses is a beneficial process for the 
organism. However, too much phagocytosis can produce undesirable results, 
as the production of ROS and tissue injury. Molecules displayed on the target 
cell and macrophage participate in a negative regulation of phagocytosis.  
 
Normal cells present molecules that promote detachment from phagocytes or 
that inhibit phagocytic activity, the so-called “don’t eat-me” signals. They are lost 
by apoptotic cells and allow macrophages to discriminate between viable and 
apoptotic cells. CD31 (PECAM-1, platelet-endothelial cell adhesion molecule-1) 
is a demonstrated “don’t eat-me” signal. The encounter of a viable cell with a 
phagocyte via the homophilic interaction of CD31 on both cell surfaces leads to 
the viable cell’s active repulsion from the phagocyte. Upon induction of 
apoptosis, the inside-out signalling of CD31 is somehow disabled and the 
apoptotic cell is not able to detach [152]. Moreover, a range of inhibitory 
receptors on the macrophage attenuate activation signals initiated by other 
receptors. Inhibitory receptors contain immuno-receptor tyrosine-based 
inhibitory motifs (ITIMs), which recruit phosphatases that in turn transduce 
inhibitory signals [120]. 
 
 
7.2 CYTOKINE RESPONSE AND BIOLOGICAL CONSEQUENCES 
Macrophages do not simply engulf and degrade dying cells acting as 
scavengers, but also respond actively modulating immune responses. In 
general, monocytes and macrophages react to apoptotic cells releasing anti-
inflammatory cytokines as IL-10, TGF-β1 (transforming growth factor β1), PGE2 
(prostaglandin E2) and PAF (platelet activating factor) and down-regulating the 
production of pro-inflammatory factors including TNF-α (tumour necrosis factor-
α), IL-1β, IL-12, IL-8, GM-CSF (granulocyte macrophage-colony stimulating 
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factor), INF-γ (interferon-γ) and eicosanoids [TXB2 (thromboxane B2) and LTC4 
(leukotriene C4) [119,153-155], leading to an overall anti-inflammatory and 
immunosuppressive response.  
 
It has been proposed that, in fact, TGF-β is the main cytokine responsible for all 
the anti-inflammatory effects of apoptotic cells, by modulating the others at the 
level of gene transcription or protein translation [156]. It is explained by a 
mechanism involving TGF-β activation of ERK (extracellular signal-regulated 
kinase), which in turn up-regulates MKP-1 (MAPK phosphatase-1), thereby 
inactivating the kinase p38 MAPK (p38 mitogen-activated protein kinase) [157]. 
In vivo, TGF-β secretion follows a biphasic response: early increase 
corresponding to release of preformed TGF-β and a late increase 
corresponding to de novo protein synthesis [153]. 
 
Phosphatidylserine exposed on apoptotic cells and its major counterpart, the 
PSR, have been implicated as the major players in the anti-inflammatory effect. 
In vitro and in vivo studies support this notion. Specific stimulation of the PSR 
mimics the effect of apoptotic cells, increasing TGF-β and reducing TNF-α 
release [138]. But phagocyte receptors other than PSR can also mediate the 
immunosuppressive effects of apoptotic cells. Ligation of the vitronectin 
receptor αVβ3-CD36 by apoptotic lymphocytes has been reported to mediate an 
increase in IL-10 and decrease in TNF-α, IL-1β and IL-12 [154]. A recent study 
clearly demonstrates that the tripartite PS/MFG-E8/αVβ3 is required for the 
inhibitory signal of the phagocytosis of apoptotic B cells in the germinal centres 
of the spleen and lymph nodes [142,143]. The kinase domain of the Mer 
receptor has shown ability to down-regulate the production of cytokines such as 
TNF-α after the ligation of PS on apoptotic cells via gas-6 [158].  
 
Necrotic or lysed cells are also efficiently removed and can expose PS on their 
membranes, but their uptake is normally pro-inflammatory. Even though they 
can be recognised by the PSR, the anti-inflammatory effect is overridden by 
other mechanisms. Necrotic cells release proteins that stimulate macrophage 
production of pro-inflammatory mediators, as HMGB-1 (high-mobility group box 
chromosomal protein-1), heat shock proteins [137] and double-stranded DNA. 
HMGB-1 is recognised by TLR2 and TLR4 (toll-like receptor-2 and -4), acting 
similarly to LPS [159]. The effect may also be due to the blocking of PS by 
cytoplasmic proteins as annexins [140] or cleavage of the PSR by proteases 
contained in cell lysates such as neutrophil elastases [160,161].  
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However, a body of investigations demonstrates that it is not that simple. 
Apoptotic cells have elicited pro-inflammatory responses in several studies 
[162-165]. The uptake mediated by some molecules of the innate immunity 
such as the receptor calreticulin-CD91 is pro-inflammatory [147]. Under some 
conditions, apoptotic debris can be opsonised with antibodies and recognised 
by macrophages via Fc receptors that trigger pro-inflammatory responses in the 
phagocyte [166]. In addition, necrotic cells are not necessarily pro-inflammatory. 
The membranes of either necrotic or apoptotic cells are recognised through PS 
and are an anti-inflammatory stimulus [126,161,167].  
 
 
 
Figure III.16: Suppression of inflammation by macrophages ingesting apoptotic cells. 
Macrophages that have engulfed apoptotic cells contribute to an anti-inflammatory effect by 
several mechanisms. Uptake avoids the leakage of potentially immunogenic contents from 
dying cells and induces an active suppression of inflammation through an increase of anti-
inflammatory cytokines and a down-regulation of pro-inflammatory. Phagocytosis triggers 
release of the death-inducing ligand FasL by macrophages, resulting in the apoptosis of 
bystander cells. 
 
 
The recognition and engulfment of apoptotic cells by professional phagocytes 
plays an active and necessary role in the resolution of inflammation (Figure 
III.16). In inflammatory sites, neutrophils need to be removed prior to their lysis, 
as their contents would otherwise expel into the extracellular milieu and 
perpetuate inflammation. A primary mechanism is the modulation of the 
macrophage production of anti- and pro-inflammatory cytokines [153-155]. 
Uptake of apoptotic cells promotes an increased survival and decreased 
proliferation of macrophages, which may aid the macrophage in its role as 
scavenger during resolution of inflammation [168]. Furthermore, macrophages 
are not only scavengers of apoptotic debris, but can induce apoptosis actively. 
Deficiencies in the apoptosis of inflammatory cells or in the removal of dead 
cells are involved in the development of autoimmune diseases as cystic fibrosis 
[160], rheumatoid arthritis [169] or systemic lupus erythematosus (SLE) [170]. 
 
 
Prevention of leakage of contents from dying cells
Induction of apoptosis (FasL)
Suppression of inflammation
▪ TGF-β↑, PGE2↑, IL-10↑
▪ TNF-α↓, IL-1β↓, IL-8↓, IL-12↓
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7.3 ROLES OF APOPTOTIC CELL CLEARANCE IN DISEASE 
Autoimmune diseases can result from impairment of apoptotic cell clearance or 
due to defective signalling in the anti-inflammatory response that apoptotic cells 
elicit. Apoptotic cells are a rich source of autoantigens that can drive 
autoimmune responses.  
 
Deficiencies of the complement component C1q are linked with the 
development of autoimmune disorders as SLE [170]. Mutations in the Mer gene 
seem to be associated with retinitis pigmentosa. MFG-E8 deficient mice 
develop high titres of autoantibodies and consequent glomerulonephritis [143]. 
Importantly, defects in apoptotic cell clearance has been observed in the 
airways of patients with cystic fibrosis, characterised by accumulation of 
inflammatory cells into the airways and release of neutrophil elastases that 
cleave the PSR [160]. An in vivo study has demonstrated the beneficial effects 
of apoptotic cells [153]. The instillation of apoptotic cells into LPS-stimulated 
lungs induced a reduction in the pro-inflammatory chemokine levels and in the 
infiltration of inflammatory cells in the bronchoalveolar lavage fluid. The 
beneficial effects were attributed to the secretion of TGF-β by macrophages 
after ligation of the PSR. 
 
On the contrary, the beneficial consequences of apoptotic cells uptake are 
turned into negative in circumstances where suppression of inflammation or 
immunity is harmful, as in infectious diseases, sepsis and cancer. The uptake of 
apoptotic cells by macrophages infected with Trypanosoma cruzi, an 
intracellular parasite, can enhance parasite growth through macrophage 
production of TGF-β and PGE2 [171]. In an in vivo mouse sepsis model, 
adoptive transfer of apoptotic cells worsened the survival of mice whereas 
necrotic cells improved survival via modulation of INF-γ [172,173]. Tumour cells 
killed by chemotherapy treatment are normally apoptotic and expose PS (some 
of them as malignant melanoma cells even when they are viable), provoking a 
tolerance of the organism to tumour cells that attenuates immune reactions 
against tumours and favours the growth of cancer. A study demonstrates that 
the release of the anti-inflammatory cytokine IL-10 is negative in renal cell 
carcinoma [174]. Furthermore, the phagocytosis of apoptotic tumour cells 
contributes to genetic instability and diversity within tumours [175].  
 
The modulation of the process of programmed cell clearance may yield novel 
strategies for therapeutic intervention, especially in autoimmune diseases and 
cancer.  
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IV. MATERIALS AND METHODS 
1 MATERIALS 
1.1 COMPOUNDS 
Cephalostatin 1 and cephalostatin 2, isolated as described in [10,11], were 
obtained from Prof. G. R. Pettit (Cancer Research Institute, Arizona State 
University, Tempe, USA).  
 
Sesquiterpene lactones were isolated as described previously: 11α,13-
dihydrohelenalin acetate (DHA) was isolated from flower heads of Arnica 
montana [176], 7-hydroxycostunolide (HC) was isolated from Podachaenium 
eminens [177] and 4β,15-epoxymiller-9Z-enolide (EM) was isolated from Milleria 
quinqueflora [178]. They were kindly provided by Prof. Irmgard Merfort 
(Department of Pharmaceutical Biology and Biotechnology, University of 
Freiburg, Freiburg, Germany). 
 
 
1.2 BIOCHEMICALS, INHIBITORS, DYES AND CELL CULTURE 
REAGENTS 
Carboxy-H2DCFDA Molecular Probes, Eugene, OR, USA 
CCFSE Molecular Probes, Eugene, OR, USA 
Complete™  Roche, Mannheim, Germany 
DMEM  PAN Biotech, Aidenbach, Germany 
Etoposide   Calbiochem, Schwalbach, Germany 
FCS gold PAN Biotech, Aidenbach, Germany 
FITC-VAD-fmk Promega, Heidelberg, Germany 
Fura-2, AM  Biotrend, Cologne, Germany 
G418 sulfate PAA Laboratories, Cölbe, Germany 
Hoechst 33342 Sigma, Taufkirchen, Germany 
MTT Sigma, Taufkirchen, Germany 
PKH26 Sigma, Taufkirchen, Germany 
PMA Sigma, Taufkirchen, Germany 
Probenecid Sigma, Taufkirchen, Germany 
Propidium iodide Sigma, Taufkirchen, Germany 
Pyruvate  Merck, Darmstadt, Germany 
RPMI 1640  PAN Biotech, Aidenbach, Germany 
SP600125  Calbiochem, Schwalbach, Germany 
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Staurosporine Calbiochem, Schwalbach, Germany 
Thapsigargin Sigma, Taufkirchen, Germany 
TNF-α  Sigma, Taufkirchen, Germany 
Tunicamycin Sigma, Taufkirchen, Germany 
zLEVD-fmk MBL, Woburn, Massachusetts, USA 
zVAD-fmk  Calbiochem, Schwalbach, Germany 
zVDVAD-fmk MBL, Woburn, Massachusetts, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 TECHNICAL EQUIPMENT 
Vi-CELL™ (Beckman Coulter) Cell viability analyser 
FACSCalibur (Becton Dickinson) Flow cytometer 
Axiovert 25 (Zeiss) Inverted microscope 
Axiovert 200 (Zeiss) Inverted microscope 
LSM 510 Meta (Zeiss) Confocal laser scanning microscope
Sunrise™ (Tecan) Microplate absorbance reader 
SpectraFluor Plus™ (Tecan)  Plate-reading multifunction 
photometer 
Curix 60 (Agfa)  Tabletop film processor 
Lambda Bio 20 (Perkin Elmer) Photometer 
RF-1502 spectrofluorophotometer 
(Shimadzu) 
Spectrofluorophotometer 
Thermoshake THO 500 (Gerhardt) Incubator shaker 
Nucleofector™ II (Amaxa) Electroporation device 
PBS (pH 7.4) 
NaCl                                         7.20 g 
Na2HPO4                                         1.48 g 
KH2PO4                                         0.43 g 
H2O                                  ad 1,000 ml 
Trypsin/EDTA (T/E)   
Trypsin                                  0.50 g 
EDTA                                  0.20 g 
PBS                           ad 1,000 ml 
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2 CELL CULTURE 
2.1 CELL LINES 
The human leukemia Jurkat T cells (J16) (kindly provided by Prof. Dr. P.H. 
Krammer and Dr. H. Walczak, Heidelberg, Germany) as well as Jurkat T cells 
stably expressing an inactive form of ASK1 (ASK1-DN, clones A2-1 and A2-3 
[179]) (kindly provided by Prof. M. Lienhard Schmitz, Giessen, Germany) were 
cultured in RPMI 1640 containing 2 mM L-glutamine (PAN Biotech, Aidenbach, 
Germany) supplemented with 10% foetal calf serum (FCS) (PAA Laboratories, 
Cölbe, Germany) and 1% pyruvate (Merck, Darmstadt, Germany). Caspase-9-
deficient Jurkat cells (courtesy of Prof. Klaus Schulze-Osthoff, Düsseldorf, 
Germany) were cultured in the medium described above containing heat-
inactivated FCS. Medium of transfected cells was supplemented with 1 mg/ml 
G418 (PAA Laboratories, Cölbe, Germany) every fifth passage for antibiotic 
selection. Cells exposed to G418 were not used for experiments. 
 
As an additional model for the study of apoptosis the human HeLa cervix 
carcinoma cell line was employed. HeLa cells were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany) and cultured in DMEM (PAN Biotech, Aidenbach, Germany) 
supplemented with 10% FCS (PAA Laboratories, Cölbe, Germany). 
 
The human monocytic leukemia cell line THP-1, usually employed in 
phagocytosis assays after differentiation into macrophages, was obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany). Cells were cultured in RPMI 1640 medium (PAN 
Biotech, Aidenbach, Germany) supplemented with 10% FCS (PAA 
Laboratories, Cölbe, Germany). 
 
 
2.2 CULTURE AND SPLITTING 
Jurkat cells were split three times a week (to a concentration of 1 x 105 cells/ml 
but 0.8 x 105 cells/ml before weekends) in order to maintain them under a 
concentration of 1 x 106 cells/ml and thus reduce the probability of mutations. 
Cells were not used after passage number twenty for the same reason. THP-1 
cells were cultured exactly as Jurkat cells. 
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The HeLa carcinoma cell line growths in monolayer adhered to plastic surfaces. 
Cells were split when reaching 85-90% confluency. Cells were shortly washed 
with PBS and detached by incubation with a solution of trypsin/EDTA at 37°C. 
The process was stopped as soon as cells detached by addition of medium. 
The cell suspension was centrifuged (180 x g, 10 min, 25°C) and resuspended 
in fresh medium before transferring to culture flasks.  
 
All cell lines were cultured in tissue culture flasks at 37°C in a humidified 
atmosphere and 5% CO2. Cell concentration and viability was determined in the 
Vi-CELL™ cell viability analyser (Beckman Coulter, Krefeld, Germany). 
 
 
2.3 SEEDING FOR EXPERIMENTS 
Jurkat cells were seeded approximately 16 h before experiments (alternatively, 
at a higher cell concentration 2-3 h before). The cell suspension was 
centrifuged (180 x g, 10 min, 25°C), resuspended in prewarmed medium, and 
analysed in the Vi-CELL™ cell viability analyser. The desired cell density was 
adjusted by addition of the required volume of medium. Except for the MTT and 
caspase-9 activity assays (96-well), cells were seeded in 24-well tissue culture 
plates. 
 
HeLa cells were detached and centrifuged as described in IV.2.2. The cell 
suspension was analysed in the Vi-CELL™ and concentration was adjusted. 
Cells were seeded in 12-well tissue culture plates 8-16 h before experiments.  
 
 
2.4 FREEZING AND THAWING 
Cryogenic preservation of cell lines is necessary to maintain reserves of cells. 
Frozen cells can be stored almost indefinitely in liquid nitrogen. Some 
advantages of this process are that cells are protected from microbial 
contamination, genetic and morphological changes are avoided and 
experiments can be conducted using cells of similar passage number, 
increasing reproducibility.  
 
Cells are frozen in a special medium (freezing medium, Table V.1) that contains 
a higher percentage of serum than culture medium and 10% (v/v) of DMSO as a 
cryoprotector. Some cell lines such as THP-1 cells are more sensitive to DMSO 
and are stored in freezing medium containing a high concentration of serum. 
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After centrifugation (180 x g, 10 min, 4°C) cells were resuspended in the 
appropriate freezing medium at a concentration of 2 x 106 cells/ml. The cell 
suspension was transferred to cryovials (1.5 ml) and frozen overnight at -20°C. 
Cells were then kept at -80°C and if desired, transferred to liquid nitrogen         
(-196°C) after two days for long-term storage. 
 
 
Table IV.1: Freezing medium. 
 
 Jurkat THP-1 HeLa 
RPMI 1640 70 % 45 % - 
DMEM - - 80 % 
FCS gold 20 % 45 % 10 % 
DMSO 10 % 10 % 10 % 
 
 
Cells were thawed in a water bath (37°C), diluted 1:10 with medium and 
centrifuged (200 x g, 5 min) to remove dead cells and DMSO. Cells were 
resuspended in fresh medium and cultured for at least five days before 
conducting any experiment. 
 
 
3 FLOW CYTOMETRY 
3.1 INTRODUCTION 
FACS buffer 
NaCl                  8.12 g 
KH2PO4                  0.26 g 
Na2HPO4                  2.35 g 
KCl                  0.28 g 
Na2EDTA                  0.36 g 
LiCl                  0.43 g 
Na-azide                  0.20 g 
H2O           ad 1,000 ml, pH 7.37 
 
 
Flow cytometry is a method that allows for the analysis of various properties of 
single cells or particles suspended in a fluid. This technology is ideally suited for 
the rapid, reliable and accurate quantitative analysis of selected physical 
properties of cells of interest, even (or especially) when these form a small 
population within a mixture of cell types. Flow cytometers can be used for the 
analysis of cell cycle, viability, apoptosis, calcium influx, membrane potential or 
amounts of surface receptors or intracellular proteins.  
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In the flow chamber (Figure IV.1) the suspension of single cells emerges from 
the sample needle into a surrounding sheath fluid liquid that is moving with a 
greater velocity. The resulting acceleration at the orifice forces the particles to 
travel one by one in the central portion of the fluid jet that emerges from the flow 
chamber. This principle is called hydrodynamic focusing.  
 
 
 
Figure IV.1: Close up of the flow chamber (adapted from [180]).  
 
 
The cells flow past the detector point and are illuminated by a focused laser 
beam. The illuminating light is scattered and simultaneously, if particles have 
been previously stained with a fluorescent dye capable of absorbing the 
illuminating light, fluorescence emission occurs. Scattered light and emitted 
fluorescence is collected and sent to different detectors by using optical filters. 
The relative size and granularity of a cell influence the way in which light is 
scattered as the cell passes through the laser beam. Low angle scattered light 
depends on cell size and is recorded as a parameter called forward scatter 
(FSC). Similarly, cell granularity and surface convolutions scatter light at higher 
angles. For convenience the signal is measured orthogonal to the stream and is 
referred to as side scatter (SSC). Fluorescence (FL) measurements are also 
made in the orthogonal direction with detectors appropriate to the specific 
emission spectrum of the fluorochrome used (Table IV.2).  
 
 
Table IV.2: Emission wavelength and detectors. 
 
Fluorochrome                                      λem Detector 
Propidium iodide 617 nm FL2 
CCFSE 525 nm FL1 
Carboxy-H2DCFDA (oxidized dye) 525 nm FL1 
 
Sample Sheath fluid
Sample 
needle
Hydrodynamic
focusing
zone
Laser 
beam
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All measurements were performed on a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany) (Figure IV.2). Cells are illuminated by a 488 nm argon-
ion laser. Scattered light and emitted fluorescence are filtered and the last is 
measured with several detectors: FL1 (530 nm), FL2 (585 nm), FL3 (650 nm) or 
FL4 (optional, in this case FL3 detects >670 nm). 
 
 
 
Figure IV.2: Optical bench diagram of the FACSCalibur benchtop flow cytometer (from 
[181]). 
 
 
3.2 DETERMINATION OF CELL VIABILITY (PI EXCLUSION ASSAY) 
Propidium iodide (PI) is a red fluorescent dye which binds to DNA and RNA by 
intercalating between the bases. Its absorption and emission wavelengths are 
535 and 617 nm respectively when bound to nucleic acids. Cells with an intact 
membrane are impermeable to PI and do not take it up when incubated in a 
solution of this dye. On the contrary, dead or damaged cells (late apoptotic or 
necrotic) that have lost membrane integrity are stained and can be quantified by 
flow cytometry.  
 
5 x 105 untreated, stimulated with SQTL/etoposide or necrotic Jurkat cells were 
harvested by centrifugation (600 x g, 10 min, 4°C) and washed once with 
phosphate buffered saline (PBS).  
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Pellets were resuspended in 500 µl of a PI solution (1 µg/ml in PBS) and 
incubated for 10 min at room temperature in the dark. Probes were stored 
shortly on ice and analysed by flow cytometry using a FACSCalibur. 
Fluorescence intensity of cells was recorded with the fluorescence channel 2 
(FL2, λem 585 nm). Cells from 0 to 101 (histogram plot, logarithmic scale) were 
regarded as viable while cells with a fluorescence ranging from 101 to ~104 
were considered dead. 
 
 
3.3 QUANTIFICATION OF DNA FRAGMENTATION BY PI STAINING 
(NICOLETTI METHOD) 
During the apoptotic process endogenous endonucleases become activated 
and cause the fragmentation of nuclear DNA into oligonucleosomal-size 
fragments. Thus an easy and widely used assay to quantify apoptotic cell death 
is the counting of nuclei with a subdiploid DNA content after staining with PI. 
The method described by Nicoletti et al. [182] is one of the most widely used for 
the quantification of apoptosis because of its rapidness and simplicity. Cells are 
permeabilised in a hypotonic buffer that contains PI and red fluorescence is 
measured by flow cytometry.  
 
The whole DNA content of cells is stained independently from their viability or 
membrane integrity. Most cells of normal untreated cell populations are in Go/G1 
phase with 2n DNA content and emit a homogenous fluorescence after binding 
of PI to DNA. Cells in G2/M phase (DNA content of 4n) peak at higher 
fluorescence intensity and cells in S phase appear between the Go/G1 and G2/M 
peaks. DNA fragments of apoptotic cells respectively apoptotic bodies have a 
lower fluorescence and thus appear “left” to the Go/G1 peak in the FL2 
histogram.  
 
7 x 105 Jurkat cells/ml (500 µl, 24-well plate) or 2 x 105 HeLa cells were left 
untreated or stimulated with the required substances. In some experiments, 
caspase inhibitors were added 1 h before stimulation at a concentration of 20 
µM. After different incubation times cells were harvested by centrifugation (600 
x g, 10 min, 4°C) and washed once with PBS. Cells were incubated in a 
hypotonic buffer containing PI [hypotonic fluorochrome solution (HFS) buffer] 
overnight at 4°C and analysed by flow cytometry on a FACSCalibur. The 
logarithmic mode of FL2 was recorded and the instruments settings were 
adjusted in each experiment by assigning a fluorescence intensity of 103 to the 
Go/G1 peak. Events to the left of the “G1-peak” containing hypodiploid DNA 
were quantified as apoptotic cells.  
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Propidium iodide was added under light protection just before use. 
 
 
3.4 MEASUREMENT OF ROS GENERATION 
The fluorogenic probe carboxy-2′,7′-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA) is commonly used for measuring the production of reactive 
oxygen species (ROS) in both flow cytometric and spectrofluorometric systems, 
mainly due to its simplicity, high sensitivity, and low cost relative to traditional 
approaches to the measurement of ROS.  
 
Carboxy-H2DCFDA is a nonfluorescent compound capable of crossing the 
plasma membrane to enter the cell, where cellular esterases hydrolyse its 
acetyl moieties to produce 2′,7′-dichlorodihydrofluorescein (H2DCF) which is 
trapped in the cells. The de-acetylated form of the probe is then susceptible to 
oxidation, generating a fluorescent product, 2′,7′-dichlorofluorescein (DCF). 
Accumulation of DCF indicates the production of redox-active substances. 
 
Jurkat cells were centrifuged (180 x g, 10 min, 25°C), washed once in PBS and 
resuspended at 106 cells/ml in PBS containing 0.1% bovine serum albumine 
(BSA). Carboxy-H2DCFDA was added to a final concentration of 5 µM, and cells 
were incubated for 30 min at 37°C in the dark. Cells were subsequently washed 
once with 0.1% BSA-PBS solution, resuspended in fresh medium (without 
phenol red) at a concentration of 8 x 105 cells/ml and transferred to FACS 
tubes. Cells were left untreated or stimulated with cephalostatin-1 (1 µM) or 
staurosporine (0.5 µM) as a positive control, placed into a water bath (37°C) 
and measured at different points of time by flow cytometry. Fluorescence 
intensity of cells was recorded with the fluorescence channel 1 (FL1, λem 530 
nm) and analysed employing histogram plots.  
 
 
 
HFS  
Propidium iodide                               50 µg 
Sodium citrate                                0.1 % (w/v) 
Triton X-100                               0.1 % (v/v) 
PBS                                 ad 1 ml 
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4 ANALYSIS OF OTHER CELL DEATH FEATURES 
In addition to the quantification of DNA fragmentation (Nicoletti) other features 
of SQTL-induced cell death were investigated (appearance of small granular 
cells, visualisation of apoptotic nuclei after staining with Hoechst 33342, 
translocation of phosphatidylserine to the cell surface and total caspase activity) 
as well as overall cytotoxicity (MTT assay) as described in [183]. 
 
Late apoptotic and necrotic cells usually lose membrane integrity as a result of 
the deterioration of cellular function. Plasma membrane rupture can be 
analysed by quantifying the activity of lactate dehydrogenase (LDH), a cytosolic 
enzyme, in the culture supernatant of treated cells. This assay is based on the 
conversion of pyruvate to lactate. This reaction is catalysed by LDH and 
accompanied by an oxidation of NADH/H+ to NAD+. The activity of LDH is 
proportional to the decrease of NADH/H+ measured [184]. 
 
 
Phosphate buffer                                          
Adequate volumes of KH2PO4 (6.80 g/l) and K2HPO4 (8.74 g/l) solutions were 
mixed until a pH of 7.5 was achieved. Subsequently 66 mg of pyruvate were 
added to 1 l of this buffer. The final solution can be stored for 14 days at 4°C. 
 
NADH solution (stability 7 days)                            
NADH-Na2                         10 mg 
NaHCO3 (0.5 % in H2O)                           1 ml 
 
 
5 x 105 Jurkat cells/ml (1 ml, 24-well plate) were left untreated or stimulated for 
24 h with sesquiterpene lactones (DHA 40 µM, HC 20 µM, EM 5 µM) or as 
control with etoposide (25 µg/ml). Cells were centrifuged (600 x g, 10 min, 4°C) 
and supernatants were recovered in new tubes. 600 µl of supernatant were 
mixed with 400 µl of phosphate buffer before addition of 10 µl of NADH solution. 
Absorbance was recorded with a Lambda Bio 20 photometer (Perkin Elmer, 
Überlingen, Germany) for 1 min and enzyme concentration was calculated 
based on the decrease in absorbance due to the conversion of NADH (ε365nm = 
3.34 mM-1 cm-1) to NAD+. 
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5 MICROSCOPY 
5.1 LIGHT MICROSCOPY 
The characteristic morphological changes of apoptosis as well as other forms of 
programmed cell death, such as shrinking, swelling or formation of apoptotic 
bodies can be easily detected by light microscopy. 
 
7 x 105 cells/ml (500 µl, 24-well plate) were left untreated or stimulated with the 
required substances for different periods of time. Cells were viewed with a Zeiss 
Axiovert 25 microscope (Zeiss, Oberkochen, Germany) at 200 x magnification 
and pictures were taken with a connected reflex camera. 
 
 
5.2 CONFOCAL LASER SCANNING MICROSCOPY  
Confocal microscopes are increasingly used in life sciences due to the many 
advantages they offer. Among them, the fact that extremely high-quality images 
are obtained with a maximum resolution, three-dimensional information of thick 
specimens can be obtained and colocalisations of signals from different 
fluorochromes can be reliably studied.  
 
Confocal can be defined as “having the same focus”: the final image has the 
same focus as the point of focus in the object. A confocal microscope is able to 
filter out the out-of-focus light from above and below the point of focus in the 
object.  
 
For the visualisation of phagocytosis of Jurkat cells by THP-1-derived 
macrophages an LSM 510 Meta (Zeiss, Oberkochen, Germany) was used. 
Figure IV.3 represents schematically the beam path of this confocal laser 
scanning microscope. The excitation light is reflected by a main dichroic 
beamsplitter and focused into the specimen by the objective. The focused 
excitation light is scanned through the specimen point by point. The light 
returned or the fluorescent radiation emitted by the specimen is collected by the 
objective and focused on to a confocal pinhole which allows only the in-focus 
portion of the light to be imaged. Light passing through the image pinhole is 
detected by a photodetector while out-of-focus interference is rejected.  
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Figure IV.3. LSM 510 Meta beam path (adapted from [185]). 
 
 
6 LUMINOMETRIC CASPASE-9 ACTIVITY ASSAY 
Activation of caspases is usually demonstrated by the appearance of smaller 
processed fragments by Western Blot. However, cleavage of caspases does 
not always correlate with caspase activation and some initiator caspases can be 
active before or without catalytic processing [58,186]. Thus caspase activity is 
often quantified by the use of fluorescent or luminescent-labelled specific 
peptide substrates.  
 
Caspase-9 activity was measured using the Caspase-Glo™ 9 Assay from 
Promega GmbH (Mannheim, Germany) following manufacturer’s protocol. This 
assay system employs a proluminogenic substrate (z-LEHD-aminoluciferin) 
containing the LEHD sequence, which has been shown to be selectively 
recognised by caspase-9. After cleavage of the substrate by caspase-9 
aminoluciferin is recognised by luciferase and a luminescent signal (light) is 
produced. Luminescence is proportional to the amount of caspase-9 activity.  
 
Laser source
Collimator
Specimen
Focal plane
Z-motor
Objective
Scanning
mirrors
Main dichroic
beamsplitter
Detector
Emission filter
Confocal
pinhole
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5 x 105 cells/ml (100 µl, 96-well plate) were left untreated or treated with 1 µl 
DMSO (solvent) or cephalostatin 1 for 4 h with or without preaddition of 
caspase-4 or -2 inhibitors (20 µM, added 1 h before stimulation). After 
stimulation 100 µl of Caspase-Glo™ 9 Reagent was added to each well and 
gently mixed. Luminescence was measured immediately in a plate-reading 
multifunction photometer (SPECTRAFluor PLUS, Tecan, Crailsheim, Germany) 
using Xfluor 4 software and every 10 min for 2 hours. Background 
luminescence corresponding to the culture medium was subtracted from 
experimental values. The 100 % of caspase-9 activity was assigned arbitrarily 
to the luminescence corresponding to untreated cells. 
 
 
7 WESTERN BLOT 
Western Blot (WB) is a method extensively used by investigators to identify 
specific proteins present in different protein mixtures (usually samples prepared 
from cell lysates). Proteins are first separated by electrophoresis, then 
transferred (“blotted”) to membranes and finally visualised by immunodetection. 
 
 
7.1 PREPARATION OF SAMPLES 
 
 
Lysis buffer for BiP, CHOP and caspases                                       
  30 mM Tris-HCl, pH 7.5 
150 mM NaCl     
    2 mM EDTA 
       1 % Triton X-100 
              Complete™ 
Lysis buffer for phosphorylated proteins (p-JNK, p-eIF2α)              
  20 mM Tris-Base  
137 mM NaCl 
    2 mM Na4P2O7 
    2 mM EDTA 
  20 mM C3H7Na2O6P (Na glycerolphosphate) 
  10 mM NaF 
    2 mM Na3VO4 
    1 mM PMSF 
       1 % Triton-X 100 
     10 % Glycerol 
              Complete™ 
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7 x 105 Jurkat cells/ml (1 ml, 24-well plate) or 4 x 105 HeLa cells/ml (500 µl, 12-
well plate) were left untreated or stimulated with cephalostatin 1 (1 µM), 
cephalostatin 2 (50 nM) or the respective positive controls. In some 
experiments, caspase-4 and -2 inhibitors (20 µM) were added 1 h before 
stimulation or the JNK inhibitor SP600125 (10 µM) was added 30 min before. 
After the required incubation times cells were harvested (HeLa cells were 
detached as described in IV.2.2) by centrifugation (1,500 x rpm, 10 min, 4°C) 
and washed once with cold PBS. Pellets were resuspended in the appropriate 
lysis buffer (100 µl for three wells) and incubated on ice for 30 min or stored 
overnight at -80°C. Lysates were homogenized with an ultrasonic device and 
centrifuged at 10,000 x g, 4°C for 10 min. Supernatants were transferred to new 
tubes and protein concentration was determined by the Bradford method as 
described in IV.7.2. Lysates were diluted 1 : 5 with 5 x sample buffer with the 
exception of the analysis of ASK1, where a 3 x sample buffer containing 
bromophenol blue was used (dilution 1 : 3). Protein solutions were digested at 
95°C for 5 min and stored at -20°C or used immediately for WB analysis.  
 
PMSF, Na3VO4 and Complete™ were added to the lysis buffers immediately 
before use.  
 
Sample buffer (5 x) 
3.125 M Tris-HCl, pH 6.8                     100 µl 
Glycerol                     500 µl 
SDS 20 %                     250 µl 
DTT 16 %                     125 µl 
Pyronin Y 5 %                         5 µl 
H2O             ad 1,000 µl 
Lysis buffer for p-ASK1  (modified RIPA buffer, from BioSource)            
  10 mM Tris, pH 7.4 
100 mM NaCl 
    1 mM EDTA 
    1 mM EGTA 
    1 mM NaF 
  20 mM Na4P2O7 
    2 mM Na3VO4 
    1 mM PMSF 
    0.1 % SDS 
    0.5 % Sodium deoxycholate 
       1 % Triton-X 100 
     10 % Glycerol 
              Complete™ 
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Sample buffer for ASK1 (3 x)             
0.5 M Tris-HCl, pH 6.8                   375 µl 
SDS                      60 mg 
Glycerol                   300 µl 
Bromophenol blue                  0.15 mg 
H2O           ad 1,000 µl 
 
 
 
7.2 PROTEIN QUANTIFICATION 
The concentration of proteins in a sample can be quantified by different 
methods. The method developed by Bradford [187] employs the dye Coomassie 
Brilliant Blue G-250. After binding to proteins, the absorption maximum of this 
dye shifts from 465 to 595 nm. Probes are incubated with a reagent solution 
and absorbance is typically measured at 595 nm. 
 
10 µl of a calibration curve containing increasing concentrations of BSA in H2O 
and 10 µl of dilutions 1 : 10 of the cell lysates in H2O were incubated with 190 µl 
of Bradford solution (Bio-Rad, Munich, Germany, diluted 1 : 5 in H2O) in 
enzyme linked immunosorbent assay (ELISA) plates for 5-10 min and 
absorbance of samples at 592 nm was measured in a microplate absorbance 
reader (Sunrise™, Tecan, Crailsheim, Germany). Before electrophoresis, the 
required volumes of 1 x sample buffer were added to the protein solutions in 
order to achieve the same protein concentration in all samples.  
 
 
7.3 SDS-PAGE 
Equal amounts of the protein samples described above were separated by 
discontinuous SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according 
to Laemmli [188]. 
 
Proteins are denatured in order to ensure reproducibility of the technique. 
Sodium dodecyl sulfate (SDS) is an anionic detergent which binds to the 
hydrophobic parts of protein molecules in aqueous solutions. The negative 
charges on SDS destroy most of the secondary and tertiary structure of 
proteins. Moreover the reducing agent dithiothreitol (DTT) included in the 
sample buffer cleaves disulfide bonds inside the proteins. Denatured and 
negatively charged proteins are strongly attracted and migrate toward the 
anode in an electric field. The final separation of proteins is dependent almost 
entirely on the differences in molecular weight of polypeptides. Molecular weight 
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of proteins is estimated by comparison with commercial solutions containing 
mixtures of prestained proteins of known molecular weight, as the marker Bio-
Rad All Blue® (Bio-Rad, Munich, Germany). 
 
 
Stacking gel 
PAA solution 30 %          1.7 ml 
1.25 M Tris-HCl , pH 6.8            1 ml 
SDS 10 %        100 µl 
H2O            7 ml 
TEMED          20 µl 
APS        100 µl 
 
Separating gel (10 %)                                          
PAA solution 30 %             5 ml 
1.5 M Tris-HCl , pH 8.8       3.75 ml 
SDS 10 %        150 µl 
H2O         6.1 ml 
TEMED          15 µl 
APS          75 µl 
 
 
In a discontinuous electrophoresis system the solid support (gel) is formed by 
two layers. Proteins are applied into the stacking gel (upper layer) where they 
are compressed in order to have thin bands and correspondingly better 
resolution. Proteins begin to separate when they reach the separating gel (lower 
layer). The concentration of acrylamide of the separating gel was adjusted for 
an optimal protein separation depending on the molecular weight of the proteins 
to be analysed (Table IV.3). For gel preparation a stock solution of acrylamide 
30 % / bis-acrylamide 0.8 % (Rotiphorese™ Gel 30, Roth, Karlsruhe, Germany) 
was used. 
 
 
Table IV.3: Separating gel concentrations. 
 
                            Protein                                        Acrylamide concentration 
p-ASK1, ASK1     7.5 % 
p-JNK, JNK, p-eIF2α, caspase-9, ubiquitin      10 % 
BiP, CHOP, caspase-4, caspase-2      12 % 
 
 
 
IV Materials and methods 
 
58 
Electrophoresis was performed using a vertical Mini Protean III system (Bio-
Rad, Munich, Germany) connected to a power supply (Biometra, Göttingen, 
Germany). Electrophoresis was run at 100 V for 21 min for stacking of proteins 
and at 200 V for 38-40 min for the separation of proteins.  
 
 
 
 
 
 
 
 
 
7.4 WESTERN BLOTTING AND DETECTION 
After separation of the protein mixtures by electrophoresis, proteins are 
transferred onto blotting membranes which bind them with a high affinity. The 
blotting process concentrates proteins and thus increases sensitivity of the 
subsequent detection of proteins by binding to specific antibodies and 
visualisation by chemiluminescence. 
 
The Western Blot was carried out by the tank blotting technique using freshly 
prepared tank buffer (1 x). Nitrocellulose membranes (Hybond™-ECL™, 
Amersham Biosciences, Freiburg, Germany) were activated by soaking in tank 
buffer for at least 15 minutes. Transfer sandwiches were assembled in a box 
containing tank buffer by putting first the black piece of the plastic (cathode 
side), then a wetted pad, a soaked blotting paper, the gel followed by the 
membrane, a second blotting paper and pad and finally the sandwich was 
closed with the white piece of the sandwich (anode side). Sandwiches were 
mounted in a transfer device (Mini Trans-Blot®, Bio-Rad, Munich, Germany), the 
cubette was filled up with buffer and transfer was performed at 100 V for 80 min 
or at 23 V overnight, with magnetic stirring. 
Electrophoresis buffer                                            
Tris base                                    3 g 
Glycine                                 14.4 g 
SDS                                    1 g 
H2O                        ad 1,000 ml 
Tank buffer (5 x)                               
Tris base                        15.2 g  
Glycine                          72.9 g 
H2O                 ad 1,000 ml 
Tank buffer (1 x)                               
Tank buffer (5 x)               200 ml  
Methanol                 200 ml 
H2O       ad 1,000 ml 
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After transfer, membranes were blocked in 5 % non-fat dry milk in Tris-buffered 
saline with Tween (TBS-T) for 1 h at room temperature. After a short washing in 
TBS-T, membranes were incubated in the respective primary antibody solutions 
(see Table IV.4) in 5 % BSA in TBS-T overnight at 4°C with gently shaking. 
After four wash steps in TBS-T for 5-10 minutes each, membranes were shaken 
in appropriate dilutions of secondary antibodies conjugated to horseradish 
peroxidase (see Table IV.5) in 1 % non-fat dry milk in TBS-T for 1 h at room 
temperature. Before development of the blot membranes were washed again as 
described above. 
 
Protein bands of interest were visualised using the ECL Plus™ Western Blotting 
detection reagent (Amersham Biosciences, Freiburg, Germany). Membranes 
were exposed to X-ray film for the appropriate time periods and subsequently 
developed in a tabletop film processor (Curix 60, Agfa, Cologne, Germany).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TBS-T                                        
Tris base                                            3 g 
NaCl                                         11.1 g 
Tween 20                                            1 ml 
H2O                                ad 1,000 ml
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Table IV.4: Primary antibodies. 
 
Antigen Isotype Dilution Provider 
ASK1 Rabbit 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
p-ASK1 (Thr845) Rabbit 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
BiP / GRP78 Mouse IgG2a 1 : 250 BD Biosciences, 
Heidelberg, Germany 
Caspase-2 Mouse IgG1 1 : 1000 BD Biosciences, 
Heidelberg, Germany 
Caspase-4 Mouse IgG1 1 : 1000 MBL, Woburn, USA 
Caspase-9 Rabbit 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
CHOP / GADD153 Rabbit 1 : 250 Sigma-Aldrich, 
Taufkirchen, Germany 
p-eIF2α (Ser51) Rabbit 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
JNK Rabbit 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
p-JNK 
(Thr183/Tyr185) 
Mouse IgG1 1 : 2000 Cell Signaling, Frankfurt, 
Germany 
Ubiquitin Mouse IgG1 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
 
 
Table IV.5: Secondary antibodies. 
 
Antibody Dilution Provider 
Goat anti-mouse IgG1 : HRP 1 : 1000 Biozol, Eching, Germany 
Goat anti-mouse IgG : HRP 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
Goat anti-rabbit : HRP 1 : 10,000 Dianova, Hamburg, Germany 
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7.5 MEMBRANE STRIPPING 
After carrying out a WB experiment membranes can be re-used for the 
detection of different proteins. Bound antibodies resulting from the previous 
experiment must be removed to avoid cross reactions and mistaken results. For 
this purpose, membranes were washed after development (4 x 5 min) and 
incubated in stripping buffer for 30 min at 50°C on a shaking platform. 
Afterwards membranes were thoroughly washed (6 x 5 min) to remove any 
remnants of stripping buffer and developed with ECL Plus™ solution to confirm 
stripping effectiveness. After another washing step membranes were blocked 
and incubated with primary and secondary antibodies as described in IV.7.4. 
 
 
 
 
 
 
 
 
2-mercaptoethanol was added to the stripping buffer immediately before use.  
 
 
7.6 STAINING OF GELS AND MEMBRANES 
Equal protein loading and blotting of samples was checked by staining of gels 
as well as membranes after WB experiments. A commonly used stain for 
detecting proteins in polyacrylamide gels is Coomassie blue, which penetrates 
the gel and sticks permanently to the proteins. Excess dye is washed out by 
'destaining'. Ponceau S was used to stain reversibly proteins on nitrocellulose 
membranes.  
 
After transfer gels were stained with Coomassie blue solution for 20 min at 
room temperature on a shaking platform. Next gels were washed several times 
in destaining solution until the proteins appeared as blue bands against a clear 
background.  
 
 
 
 
 
 
Stripping buffer 
Tris-HCl pH 6.8                                     62.5 mM 
SDS                                                           2 % 
2-mercaptoethanol                                 100 mM 
Coomassie staining solution                                  
Coomassie blue                                    3 g 
Glacial acetic acid                                100 ml 
Ethanol                                450 ml 
H2O                        ad 1,000 ml 
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Moreover blotting membranes were stained after development by immersion in 
Ponceau staining solution (0.2 % Ponceau S in 5% acetic acid) and agitation for 
5 minutes on a shaking platform. Membranes were washed in H2O until the 
background disappeared. 
 
 
8 MEASUREMENT OF Ca2+ 
Changes in intracellular calcium levels can be analysed with a range of ion-
sensitive indicators, whose light emission reflects the local concentration of the 
ion. Fura-2 is a calcium indicator often used in the esterified form Fura-2 
acetoxymethyl ester (fura-2-AM). The acetoxymethyl ester group increases 
uptake of the dye and is hydrolysed by cytoplasmic esterases to regenerate and 
trap the dye in cytosol. Fura-2 free of Ca2+ emits fluorescence upon excitation at 
380 nm but after binding to Ca2+ experiences a shift to 340 nm in its excitation 
wavelength. Therefore, the ratio of fluorescence intensity obtained by excitation 
at 340 nm to the intensity obtained by excitation at 380 nm provides an accurate 
measurement of the free Ca2+ concentration. If the technical equipment only 
allows for the excitation with a single wavelength at any time, a measurement of 
the fluorescence emitted after excitation at 340 nm is an acceptable indicator of 
the free ion concentration. 
 
 
Hepes buffer, pH 7.40            
 125 mM NaCl 
     3 mM KCl 
1.25 mM NaH2PO4 x H2O 
  2.5 mM CaCl2 x 2H2O 
  1.5 mM MgCl2 x 6H2O 
   10 mM Glucose 
   10 mM HEPES 
 
 
Variations in cytosolic calcium were studied in Jurkat and HeLa cells. For this 
purpose, Jurkat cells were centrifuged (180 x g, 10 min, 25°C), washed once 
with Hepes buffer and resuspended at 2 x 106 cells/ml in Hepes buffer 
containing 0.1% BSA and supplemented with 2.5 mM probenecid (Sigma-
Coomassie destaining solution                            
Glacial acetic acid                                100 ml 
Ethanol                             333.3 ml 
H2O                        ad 1,000 ml 
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Aldrich, Taufkirchen, Germany) to avoid Fura-2 leakage. Fura-2-AM was added 
to a final concentration of 1 µM and the cell suspension was incubated for 45 
min at 37°C. After two washing steps with Hepes buffer-0.1% BSA, cells were 
resuspended in Hepes buffer supplemented with 2.5 mM probenecid at 106 
cells/ml. The cell suspension was then transferred to a 10 mm square quartz 
cell polished on four sides and temperature was kept at 37°C by placing the cell 
in a cell holder equipped with a magnetic stirrer and connected to a constant-
temperature water circulating device. After 2-3 min cells were stimulated with 
cephalostatin 1, thapsigargin or solvent (DMSO). Cytosolic Fura-2 fluorescence 
was assayed on a Shimadzu RF-1502 spectrofluorophotometer (Shimadzu, 
Duisburg, Germany) at an emission wavelength of 510 nm and an excitation 
wavelength of 340 nm. Changes in intracellular calcium concentration were 
registered with the PC-1501 software (Shimadzu, Duisburg, Germany). 
 
For the analysis of Ca2+ release in HeLa cells, 6 x 105 cells were plated onto 42 
mm glass round coverslips and allowed to adhere for 40 h. Cells were then 
washed two times with 5 ml Hepes buffer and loaded by incubation in 1 ml of 
Hepes buffer containing 5 µM Fura-2-AM for 1 h at 37°C. Loaded cells were 
washed twice with Hepes buffer and kept in 2 ml buffer until experiments were 
done. Coverslips containing loaded cells were mounted into a coverslip holder, 
buffer was then washed away and replaced with 1 ml of fresh Hepes buffer. The 
coverslip holder was placed on the stage of a Zeiss Axiovert 200 inverted 
microscope (Zeiss, Oberkochen, Germany) equipped with a Polychrome V 
monochromator and an IMAGO-QE camera (TILL Photonics GmbH, Gräfelfing, 
Germany). Chamber temperature was maintained to 37°C by placing the 
coverslip holder on a heating insert P (Zeiss, Oberkochen, Germany). Cells 
were stimulated by addition of 100 µl of Hepes buffer (control) or buffer 
containing the adequate concentration of cephalostatin 2 and thapsigargin. 
Excitation wavelengths were alternately selected at 340 nm and 380 nm and 
fluorescence filtered at 440 nm (LP filter) was recorded. Images were acquired 
and analysed with TILLvisION Software 4.0.1.2 (TILL Photonics GmbH, 
Gräfelfing, Germany). Areas of interest corresponding to single cells and to the 
whole field of vision were selected, the background was subtracted and the 
average intensity of each area over the course of the experiment was recorded. 
Data were expressed as the ratio of fluorescence emitted by excitation at 340 
and 380 nm and curves representing the change in fluorescence over the 
course of the experiment were created.  
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9 CASPASE-4 siRNA 
RNA interference (RNAi) has emerged as a powerful method for sequence-
specific inhibition of gene function. Down-regulation of the gene of interest can 
be achieved by introduction of double-stranded short interfering RNAs (siRNAs) 
into the cells or by producing the silencing RNA within the cells employing 
expression vectors [189].  
 
The psiRNA-h7SKneo G1 expression vector system (Figure IV.4, InvivoGen, 
San Diego California, USA) was used to decrease expression of caspase-4. 
The human 7SK promoter provides a continuous expression of short hairpin 
RNAs (shRNAs) containing a 19-21 double-stranded stem that is identical in 
sequence to the target mRNA. The two strands of the stem are connected by a 
short loop which is removed in vivo by Dicer to generate siRNAs. The Neo gene 
encodes an aminoglycoside 3’-phosphotransferase that confers resistance to 
the antibiotics kanamycin in bacteria and G418 in mammalian cells, enabling 
the continuous selection of the cells that have uptaken the plasmid. The EM7-
alpha-peptide enables the white/blue selection of bacteria colonies. 
 
 
 
Figure IV.4. psiRNA-h7SKneo G1 vector (from [190]). 
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9.1 INSERT DESIGN AND CLONING INTO psiRNA-h7SKneo G1 
VECTOR 
For the specific targeting of caspase-4 two different oligonucleotides (see Table 
VI.6) were designed and obtained from Biomers, Ulm, Germany. Sequences 
encoded respective short hairpin RNAs with a 21 nt complementary region 
separated by a small loop of 7 nt and flanked by 5’- and 3’- overhangs required 
for cloning by Bbs I. Target sequences had been described in [87] and 
designated as caspase-4a and caspase-4b.  
 
DNA oligonucleotides were diluted in nuclease-free H2O to a concentration of 
25 µM and hybridised by incubation of the annealing solutions (2 µl forward 
oligo, 2 µl reverse oligo, 6 µl 0.5 M NaCl, 20 µl H2O) for 2 minutes at 80°C in a 
heating block. The annealed oligos were slowly cooled by switching off the 
heater and waiting until the temperature was about 35°C. Afterwards solutions 
were stored at -20°C. 
 
 
Table IV.6: Insert oligonucleotides containing siRNA sequences. 
 
 
 
The psiRNA-h7SKneo G1 plasmid was dissolved in nuclease-free H2O to a 
concentration of 1 µg/ml. The vector was linearised by incubation with the Bbs I 
restriction enzyme (New England Biolabs, Frankfurt, Germany). For this 
purpose an appropriate solution was prepared (10 µl plasmid, 2 µl 10 x Bbs I 
buffer, 1 µl Bbs I, 7 µl H2O) and incubated for 2 h at 37°C in a water bath [191]. 
The large fragment (2945 bp) was eluted using a 0.7% agarose gel and the 
fragment containing the linearised plasmid was cut using a scalpel. DNA was 
extracted using a QIAquick® gel extraction kit (QIAGEN, Hilden, Germany) and 
diluted to obtain a solution 0.1 µg/µl. 
Caspase-4a  
Forward 5'-acctcAAGTGGCCTCTTCACAGTCATtcaagagATGACTGT 
GAAGAGGCCACTTtt-3' 
Reverse 5'-caaaaaAAGTGGCCTCTTCACAGTCATctcttgaATGACTGT 
GAAGAGGCCACTTg-3´ 
Caspase-4b  
Forward 5'-acctcAAGATTTCCTCACTGGTGTTTccaagagAAACACCA 
GTGAGGAAATCTTtt-3' 
Reverse 5'-caaaaaAAGATTTCCTCACTGGTGTTTctcttggAAACACCA 
GTGAGGAAATCTTg-3´ 
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Subsequently ligation solutions were assembled (15 µl H2O, 2 µl 10 x ligation 
buffer, 1 µl annealed insert, 1 µl linearised vector, 1 µl T4 DNA ligase) and 
incubated at 27°C for 2 hours to obtain the recombinant vectors containing 
caspase-4a and caspase-4b inserts.  
 
 
9.2 TRANSFORMATION OF LyoComp GT116 
E.coli strain GT116, provided as lyophilized competent cells called LyoComp 
GT116 (Invivogen, San Diego California, USA) were reconstituted following 
manufacturer’s protocol. 10 µl of the ligation product (see IV.9.1) were 
incubated with 100 µl of bacteria in ice for 30 min. Then bacteria were incubated 
at 42°C for 30 seconds and placed back in ice for 1-2 min. 900 µl of room 
temperature lysogeny broth (LB) medium (Gibco/Invitrogen, Karlsruhe, 
Germany) were added to each tube and bacteria were incubated in a water bath 
at 37°C for 90 min.  
 
200 µl of bacteria suspension were spread onto kanamycin (Calbiochem, 
Schwalbach, Germany)-agar plates [191] containing IPTG (20 µl, solution 100 
mM, Calbiochem, Schwalbach, Germany) and X-Gal (30 µl, solution 50 mg/ml, 
Calbiochem, Schwalbach, Germany). Plates were incubated at 37°C overnight.  
 
 
LB agar-kanamycin 
Lennox L Broth Base              20 g 
Agar              15 g 
Kanamycin 100 mg/ml              1 ml 
H2O   ad 1,000 ml 
 
LB medium-kanamycin 
Lennox L Broth Base                20 g 
Kanamycin 100 mg/ml                  1 ml 
H2O       ad 1,000 ml 
 
Kanamycin was added to LB medium freshly before use. 
 
 
9.3 MINI PREPARATION OF PLASMIDS  
Five white colonies each of bacteria transformed with recombinant vectors were 
picked and inoculated in 2 ml of LB medium containing 100 µg/ml of kanamycin. 
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Bacteria were grown under agitation at 200 rpm in an orbital incubator shaker 
(Thermoshake THO 500, Gerhardt, Königswinter, Germany) for 10-12 h at 
37°C. Thereafter plasmid DNA was isolated using a QIAprep® Miniprep kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s protocol and 
dissolved in nuclease-free H2O. Presence of plasmids was confirmed by 
running probes in 1% agarose gels. 
 
Liquid bacteria cultures can be stored for a long time in glycerol stocks. These 
were prepared by mixing 775 µl of an overnight bacteria culture with 225 µl of 
80% glycerol and frozen at -80°C [191]. 
 
 
9.4 SEQUENCING OF THE siRNA INSERT 
The presence as well as the sequences of the siRNA inserts within 2 clones 
containing the recombinant plasmids were confirmed (Medigenomics GmbH, 
Martinsried, Germany) using the sequencing primers provided in the kit (OL559 
and OL408) before maxi preparation and transfection in Jurkat cells. 
 
 
9.5 MAXI PREPARATION OF PLASMIDS 
2 ml of transformed bacteria containing unaltered inserts were added to 600 ml 
of LB medium-kanamycin and cultures were grown overnight as described in 
IV.9.3. Plasmids containing caspase-4a and caspase-4b inserts were obtained 
employing an EndoFree® Plasmid Maxi Kit (QIAGEN, Hilden, Germany) 
following manufacturer’s instructions and dissolved in nuclease- and endotoxin-
free H2O. Purified plasmids were directly used for transfection. 
 
 
9.6 AMPLIFICATION OF psiRNA-h7SKneo AND psiRNA-h7SKnScr 
VECTORS 
The psiRNA-h7SKneo (empty vector) and psiRNA-h7SKnScr (containing the 
scramble sequence 5’-GCATATGTGCGTACCTAGCAT-3’) plasmids provided in 
the kit were used as controls in the siRNA experiments. In order to obtain 
enough quantities of these plasmids, competent E.coli DH5α bacteria were 
transformed [191] and grown on kanamycin-agar plates.  
 
Several colonies were picked and grown in LB medium-kanamycin. Mini 
preparations were performed as described above and presence of plasmids 
was checked by running probes in 1% agarose gels.  
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Maxi preparations of the colonies containing the plasmid of interest were used 
to obtain purified DNA, which was likewise dissolved in nuclease- and 
endotoxin-free H2O and directly used for transfection. 
 
 
9.7 TRANSFECTION AND SELECTION OF JURKAT CELLS  
Jurkat T cells (clone J16) were transfected by electroporation with the 
Nucleofector™ II device (Amaxa, Cologne, Germany) employing the Cell Line 
Nucleofector™ Kit V. For each transfection, 4 x 106 Jurkat cells from passages 
four to seven in exponential growing phase were centrifuged for 10 min at 200 x 
g and resuspended in 100 µl of room temperature Nucleofector™ Solution V. 
The cell suspension was mixed with 3 µg of psiRNA-h7SKneo, 3 µg of psiRNA-
h7SKnScr or 3-4 µg of a 1:1 mixture of the caspase-4a and caspase-4b shRNA 
constructs. The mixture of cells and DNA was transferred to an amaxa certified 
cuvette and transfection was performed using the program C19. 500 µl of pre-
warmed culture medium were added to the cuvette and cells were immediately 
seeded in 12-well plates and further cultured or used for experiments 24 h after 
transfection. 
 
Control cell lines expressing psiRNA-h7SKneo and psiRNA-h7SKnScr were 
obtained by addition of 1 mg/ml G418 to the culture medium 2 days after 
transfection and selection for 4 weeks. It was not possible to obtain cell lines 
with a long-term down-regulation of caspase-4. 
 
 
9.8 EFFECT OF CASPASE-4 SILENCING IN CASPASE-9 ACTIVATION 
AND APOPTOSIS 
To study the influence of caspase-4 down-regulation in apoptosis, 3 µg of 
shRNA-generating plasmids (caspase-4a and caspase-4b 1:1) were transfected 
into Jurkat cells as described above. Cells were incubated at 37°C for 24 h, 
seeded in 24-well plates and stimulated with cephalostatin 1 for 16 h. DNA 
fragmentation was quantified by flow cytometry (see IV.3.3).  
 
To investigate caspase-9 activation in cells with silenced caspase-4 expression, 
Jurkat cells were transfected with 4 µg of shRNA constructs (caspase-4a and 
caspase-4b 1:1) and 1 mg/ml G418 was added to the culture medium 2 days 
thereafter. 48 h later, cells were seeded in G418-free medium and stimulated 
for the required times. Cell lysates were prepared and caspase-9 protein was 
analysed by Western Blot as described in IV.7. 
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In both cases cells stably expressing psiRNA-h7SKneo and psiRNA-h7SKnScr 
vectors were used as controls. Efficiency of RNAi in transfected cells was 
checked for each experiment by Western Blot analysis using antibodies against 
caspase-4.  
 
 
10 PHAGOCYTOSIS ASSAY AND CYTOKINE RELEASE 
10.1 EVALUATION OF PHAGOCYTOSIS 
Phagocytosis of Jurkat cells was investigated employing a co-culture model with 
human macrophages and flow cytometric analysis. For this purpose, THP-1 
cells were differentiated to macrophages and Jurkat cells were fluorescently 
labelled (green) before the induction of cell death. Figure IV.5 represents 
schematically the co-culture model employed. 
 
 
 
Figure IV.5: Schematic illustration of the phagocytosis co-culture model. 
 
 
THP-1 cells were centrifuged (180 x g, 10 min, 25°C), washed twice with PBS 
and resuspended at a concentration of 5 x 105 cells/ml in 10% FCS-RPMI 
containing 160 nM phorbol myristate acetate (PMA). Cells were seeded (1 ml, 
24-well plate) and incubated for 72 h at 37°C [162]. PMA-treated THP-1 cells 
were washed with PBS three times and maintained in 10% FCS-RPMI until the 
phagocytosis assay. PMA is an activator of protein kinase C widely used to 
induce differentiation of several cell lines. 
 
Jurkat cells were labelled with 5-(and-6)-carboxy-2’,7’-dichlorofluorescein 
diacetate, succinimydil ester (CCFSE), a non-toxic cell-permeable fluorescent 
dye that binds covalently to the amine groups of proteins.  
 
 
3.5 h
37 °C
THP-1
Jurkat
- cell size (FSC-H)
- green fluorescence (FL1-H)
green
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Cells were centrifuged (180 x g, 10 min, 25°C), washed once with PBS and 
resuspended at 106 cells/ml in PBS containing 0.1% BSA. CCFSE was added 
to a final concentration of 10 µM and the cell suspension was incubated for 10 
min at 37°C (protocol adapted from [192]). After a washing step with 0.1% BSA-
PBS solution, cells were resuspended in fresh medium and seeded at 5 x 105 
cells/ml in 24-well tissue culture plates for the induction of apoptosis / PCD or at 
106 cells/ml in tissue culture dishes for the induction of necrosis. Fluorescent 
labeled Jurkat cells were left untreated or treated with DHA (40 µM), HC (20 
µM), EM (5 µM) or etoposide (1.5 µM) for 4 h at 37°C. Subsequently cells were 
pooled, centrifuged (600 x g, 10 min, 25°C), washed once with PBS and 
resuspended in 10% FCS-RPMI at 106 cells/ml. Necrosis was induced by 
incubation of cells for 15 min at 55°C [126]. 
 
Target cells (SQTL-, etoposide-treated, necrotic or untreated Jurkats) were 
added to the differentiated THP-1 cells at a ratio of 2:1 and culture plates were 
incubated for 3.5 h at 37°C. Wells were then gently washed three times with 
cold PBS to remove uningested cells. Adherent cells were recovered by 
trypsinisation and analysed by flow cytometry. The fluorescence intensity (FL1) 
as well as scatter parameters of macrophages were acquired. For the 
quantification of phagocytosis a region including macrophages was set up and 
the mean size (linear mode) and fluorescence (logarithmic mode) of gated cells 
was recorded. Moreover a dot plot representing FSC versus FL1 was used to 
calculate the percentage of macrophages that had acquired green fluorescence 
[126,162].  
 
 
10.2 CYTOKINE QUANTIFICATION  
The possible influence of the removal of apoptotic cells in the cytokine secretion 
pattern of co-culture macrophages was investigated by quantifying tumor 
necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) in 
cell culture supernatants.  
 
THP-1 cells were differentiated to macrophages at a density of 1 x 105 cells/ml 
(200 µl, 96-well plates) as described in IV.10.1. Macrophages were stimulated 
with 0.1 µg/ml lipopolysaccharide (LPS) (E. coli) for 3 h and washed with 
prewarmed PBS after this incubation time. Jurkat cells were stimulated with 
SQTL/etoposide or incubated for 30 min at 55°C (necrosis) and prepared for 
phagocytosis as described above. Untreated, apoptotic or necrotic cells were 
given to macrophages at a ratio of 10:1. Culture supernatants were collected in 
ice after 3.5 and 18 h of co-culture, centrifuged (1,000 x g, 10 min, 4°C) to 
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eliminate particulates and stored at –80°C before quantification of cytokines 
[126,155]. 
 
TNF-α and TGF-β concentrations in the supernatants were quantified by means 
of ELISA techniques at the Department of Biochemical Pharmacology, 
University of Konstanz (Konstanz, Germany). TNF-α was determined by self-
made ELISA using TNF-α Antibodies von Pierce – Endogen (Biot. Prod. Nr.: M 
302B, Coat. Prod. Nr.: M 303) and TGF-β using the human TGF-β1 DuoSet® 
ELISA kit from R&D Systems. TNF-α concentrations were normalised to the 
value corresponding to LPS-stimulated macrophages which did not receive 
Jurkat cells. For TGF-β analysis, TGF-β concentration found in culture medium 
was subtracted from experimental values. 
 
 
10.3 ANALYSIS OF PHAGOCYTOSIS BY CONFOCAL MICROSCOPY  
In order to visualise and confirm phagocytosis, confocal microscopy 
experiments were carried out. For this purpose, macrophages were stained with 
the red fluorescent substance PKH26 before co-culture with CCFSE-stained 
Jurkat cells. 
 
THP-1 cells were differentiated in 24-well plates with glass coverslips as 
described in IV.10.1. Macrophages were fluorescently labelled with PKH26 by 
adapting the manufacturer’s instructions. Cells were washed once with RPMI 
1640 and incubated with 200 µl of staining solution (2 µM PKH26 in diluent B, 
freshly prepared) per well for 3 min at room temperature. The staining reaction 
was stopped by addition of 200 µl of FCS. One minute later, 400 µl of complete 
medium were added and cells were finally washed 3 times with RPMI or 
medium. Labelled cells were kept in medium until addition of target cells.  
 
Jurkat cells were labelled with the fluorescent marker CCFSE and cell death 
(apoptosis or necrosis) was induced as described in IV.10.1. After 3.5 h of co-
culture at a ratio 2:1, uningested Jurkat cells were removed by several 
washings with cold PBS. Samples were fixed with 1 ml of 4 % para-
formaldehyde in PBS for 10 min at room temperature and washed three times 
with PBS. Glass coverslips were then covered with a droplet of fluorescent 
mounting medium (DakoCytomation GmbH, Hamburg, Germany) and mounted 
on a microscope slide. Probes were allowed to solidify for at least 2 h.  
 
Dual-channel fluorescence and transmitted light images were taken by the 
confocal microscope LSM 510 Meta (Zeiss, Oberkochen, Germany). PKH26 
fluorescence was obtained by excitation with the HeNe1 laser (543 nm) and 
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detection with a 560 nm LP filter. Simultaneously, the argon laser (488 nm) was 
used to excite samples and emitted light recorded with a 505-530 BP filter 
corresponded to CCFSE fluorescence.  
To perform three-dimensional analysis of the samples, a set of dual-channel z-
stack images of each macrophage of interest was captured. Thickness of slices 
ranged between 10 and 15 µM. Three-dimensional projections of the z-stacks 
were created with the microscope software and rotated to observe localisation 
of engulfed cells. 
 
 
11 STATISTICS 
All experiments were performed at least three times. Results are expressed as 
mean value ± SEM. Statistical analysis was performed with GraphPad PRISM™ 
version 3.03 for Windows (GraphPad Software, San Diego, California, USA). 
Statistical comparisons were made by one-way ANOVA with Bonferroni or 
Dunnett multiple comparison post-test or by unpaired two-tailed Student’s t test. 
P values < 0.05 were considered significant. 
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V. RESULTS 
A. CEPHALOSTATIN 1 
1 IMPORTANCE OF CASPASE-9 IN CEPHALOSTATIN 1-
INDUCED APOPTOSIS 
Our group has previously shown that the experimental chemotherapeutic agent 
cephalostatin 1 induces apoptosis in Jurkat T cells without cytochrome c 
release and apoptosome formation or requirement of active caspase-8 but 
involving activation of caspase-9 [20]. To clarify the role of this caspase in 
cephalostatin 1-induced apoptosis, a Jurkat cell line deficient in caspase-9 was 
used and compared to normal Jurkat T cells. Interestingly, apoptosis induced by 
cephalostatin 1 was almost completely inhibited in caspase-9-deficient cells 
(Figure V.1) pointing to a crucial role of this caspase. As expected, mutant cells 
did not show any signs of apoptosis in response to etoposide, a drug that 
induces apoptosis through the intrinsic mitochondrial pathway and used as 
positive control. These data asked for clarifying the mechanism underlying the 
apoptosome-independent activation of caspase-9 by cephalostatin and 
subsequent apoptosis.  
 
 
Figure V.1: Caspase-9 is essential for cephalostatin 1-induced apoptosis. 
Parental Jurkat cells (S-Jurkat) and Jurkat cells lacking caspase-9 (Casp.9-/-) were left 
untreated (CO) or treated for 24 hours with cephalostatin 1 (CPH; 1 µM) or etoposide (ETO; 2 
µM). Apoptotic cells were quantified by flow cytometry as described in “Materials and Methods” 
(upper panel). Protein extracts from S-Jurkat and caspase-9-/- cells were prepared and 
caspase-9 protein levels were analysed by Western Blot (lower panel). Equal protein loading 
was controlled by staining membranes with Ponceau S (a representative fragment of the 
stained membrane is shown). Bars, the mean ± SEM of three independent experiments 
performed in triplicate. ***, P < 0.001 (unpaired two-tailed t test). 
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2 SIGNAL TRANSDUCTION IN CEPHALOSTATIN-INDUCED 
ENDOPLASMIC RETICULUM (ER) STRESS AND APOPTOSIS 
2.1 CEPHALOSTATIN INDUCES ER STRESS 
2.1.1 Influence on ER stress markers 
In search of the initial event leading to caspase-9 activation and apoptosis, it 
was sought to investigate whether cephalostatin 1 induces an ER stress 
response which could lead to an apoptosome-independent activation of 
caspase-9. A cytochrome c and Apaf-1-independent but ER-dependent 
activation of caspase-9 has been described [84,85]. In addition, the cellular 
morphological changes caused by cephalostatin 1 treatment supported the 
theory of induction of ER stress. These include the enlargement of ER 
membranes and the appearance of ER-derived vesicles in the cytoplasm [193].  
 
First, it was studied whether the expression of an ER stress sensor 
(BiP/GRP78) and an ER stress-induced cell death modulator 
(CHOP/GADD153) were affected by cephalostatin 1. As shown in Figure V.2 
cephalostatin 1 (1 µM) increases expression of the ER chaperone BiP/GRP78 
and the transcription factor CHOP/GADD153 as does the known ER stress-
inducer tunicamycin. The increase of BiP showed a biphasic pattern, with an 
early increase (30 min-1 h) followed by a plateau and a second strong elevation 
after 16-24 h. CHOP protein level increased rapidly (15 min-1 h) and decreased 
slowly thereafter. The α-subunit of eukaryotic translation initiation factor-2 
(eIF2α) is phosphorylated by the kinase PERK in response to ER stress leading 
to an attenuation of translational initiation and protein synthesis and activation 
of pathways leading to cell death or survival [75]. Indeed, cephalostatin 1 
induced a very early and strong eIF2α phosphorylation as the known ER stress-
inducer thapsigargin (Figure V.2) further supporting the assumption of ER 
stress induction by cephalostatin. 
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Figure V.2: Cephalostatin 1 induces ER stress in Jurkat leukemia T cells. 
Cells were either left untreated (CO), treated with cephalostatin 1 (CPH; 1 µM) or as a positive 
control with tunicamycin (TM; 1 µg/ml) or thapsigargin (TG; 3 µM, 2h) for the indicated times. 
Western Blot analysis was performed as described in “Materials and Methods” using antibodies 
against BiP, CHOP and the phosphorylated form of eIF2α. One representative blot out of three 
is shown. Equal protein loading was controlled by staining membranes with Ponceau S (a 
representative fragment of the stained membrane is shown).  
 
 
Cephalostatin 2 shows a similar cytotoxicity profile and induces apoptosis via 
mechanisms common to cephalostatin 1 (experiments performed by Anita 
Rudy). To find out whether ER stress is a phenomenon restricted to Jurkat cells 
or could be a general mechanism involved in apoptosis, HeLa cells were treated 
with cephalostatin 2 (50 nM) and the expression of ER stress markers was 
investigated. As shown in Figure V.3, BiP, CHOP and eIF2α phosphorylation 
were early induced by cephalostatin 2 treatment, suggesting that ER stress may 
be a general initial event in cephalostatin-induced cellular effects. 
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Figure V.3: ER stress is observed in HeLa carcinoma cells treated with cephalostatin 2.  
HeLa cells were left untreated (CO) or treated with cephalostatin 2 (CPH; 50 nM) for the 
indicated times. Cell lysates were prepared as described in “Materials and Methods” and 
analysed by Western Blot for the expression of BiP, CHOP and p-eIF2α. One representative 
Western blot is shown. Protein loading was controlled by staining with Ponceau S. 
 
 
2.1.2 Cephalostatin does not induce Ca2+ release into cytosol 
ER stress can be induced, among many other mechanisms, by alterations in 
calcium homeostasis [75,92,194]. Moreover, an early (1 h) and notable 
cleavage of µ-calpain, a Ca2+-dependent cysteine protease, to its active form 
upon cephalostatin 1 treatment has been observed [193]. Thus, possible 
variations in intracellular Ca2+ concentration were measured to find out whether 
an increase in cytosolic free Ca2+ could be responsible for the induction of ER 
stress by cephalostatin. 
 
First, the Fura-2 fluorescence of Jurkat cells treated with cephalostatin 1 (1 µM) 
or as a positive control with thapsigargin (3 µM), an inhibitor of the endoplasmic 
reticulum Ca2+ ATPase that induces Ca2+ leakage into the cytosol, was 
recorded. Unexpectedly, cephalostatin 1 did not increase the intracellular free 
Ca2+ concentration, showing no effect or a slight reduction in Fura-2 
fluorescence (Figure V.4). Very similar results were obtained when the dye 
Calcium Green-1, with different spectral properties, was used (data not shown). 
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Figure V.4: Cephalostatin 1 does not induce Ca2+ release into cytosol. 
Jurkat cells were loaded with 1 µM Fura-2-AM as described in “Materials and Methods”. 
Subsequently, cell suspensions were either left untreated (CO) or exposed to solvent (DMSO), 
1 µM cephalostatin 1 (CPH) (A) or as a positive control with 3 µM thapsigargin (TG) (B) and 
Fura-2 fluorescence was monitored with a spectrofluorophotometer. Cells were excited at 340 
nm and fluorescence emitted at 510 nm, corresponding to the portion of Fura-2 bound to free 
Ca2+, was recorded and results of one representative experiment are here represented. 
Experiments were performed three times with similar results.  
 
 
To confirm these observations, HeLa cells were treated with cephalostatin 2 
(50-500 nM) or thapsigargin (3 µM) and changes in intracellular Ca2+ were 
followed. Cephalostatin-treated cells behaved as control cells even at 
concentrations 10-fold higher than the normally used whereas thapsigargin 
induced a prominent increase in Ca2+ concentration (Figure V.5). 
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Figure V.5: HeLa cells do not increase intracellular Ca2+ concentration in response to 
cephalostatin treatment.  
Fura-2 preloaded HeLa cells were placed on a Zeiss Axiovert 200 inverted microscope and 
sequential images were taken. Cells were stimulated by addition of Hepes buffer (control) or 
buffer containing adequate pre-dilutions of cephalostatin 2 (CPH; final concentration 500 nM) or 
thapsigargin (TG; final concentration 3 µM). Excitation wavelengths were alternately selected at 
340 nm and 380 nm and fluorescence filtered at 440 nm was recorded. Curves represent the 
change in the ratio of fluorescence emitted by excitation at 340 and 380 nm over the course of 
the experiment. The figure shows one representative experiment. 
 
 
2.1.3 ROS production is not increased by cephalostatin 1 treatment 
It has been recently described that ROS production can be associated with 
induction of ER stress [195,196]. In search of the mechanism responsible for 
triggering ER stress, the possibility that cephalostatin 1 might influence ROS 
levels was studied. 
 
Figure V.6 provides clear evidence that cephalostatin 1 does not increase ROS 
levels whereas the positive control staurosporine induces a significant 
production of ROS.  
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Figure V.6: ROS levels are not increased upon cephalostatin 1 treatment. 
Jurkat cells were pre-loaded with carboxy-H2DCFDA as described in “Materials and Methods” 
and left untreated (CO) or exposed to 1 µM cephalostatin 1 (CPH) or 500 nM staurosporine 
(STA). At indicated time points, the intracellular fluorescence was quantified by flow cytometry. 
Bars, the mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01 
(Anova/Dunnett’s test). 
 
 
2.1.4 Ubiquitinated proteins accumulate upon cephalostatin 1 treatment 
Neither an intracellular increase in calcium levels nor the production of ROS 
were induced by cephalostatin. Thus, another mechanism should be 
responsible for the induction of ER stress. Proteasome inhibitors, such as 
bortezomib, have been described to cause accumulation of ubiquitinated 
proteins, leading to ER stress and apoptosis [196-199]. As a first approach, it 
was investigated whether proteins targeted to degradation by ubiquitin 
accumulated in cells treated with cephalostatin.  
 
Interestingly, cephalostatin 1 treatment leads to a time-dependent increase of 
ubiquitinated proteins (Figure V.7). A slight increase in the ubiquitination of 
small proteins (<25 KDa) could be seen as soon as after 15 min of stimulation. 
A global ubiquitination of cellular proteins was clear after 1 h and increased 
further in the course of time. This result suggests that the primary mechanism of 
cephalostatin-induced ER stress could be an accumulation of ubiquitinated 
proteins provoked by an inhibition of proteasomal protein degradation. 
 
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
0 min 15 min 30 min 1 h 2 h
Time
R
O
S 
ge
ne
ra
tio
n
(fl
uo
re
sc
en
ce
in
cr
ea
se
, x
-fo
ld
)
CO
CPH
STA
** *
**
R
O
S 
ge
ne
ra
tio
n
(fl
uo
re
sc
en
ce
in
cr
ea
se
, x
-fo
ld
)
V Results 
81 
 
Figure V.7: Accumulation of ubiquitin-containing proteins upon cephalostatin 1 
treatment. 
Jurkat cells were either left untreated (CO) or treated with cephalostatin 1 (CPH; 1 µM) for the 
indicated times. Cell lysates were analysed by Western Blot using an antibody directed against 
ubiquitin. One representative blot out of three is shown. Equal protein loading was controlled by 
staining membranes with Ponceau S (a representative fragment of the stained membrane is 
shown). 
 
 
2.2 INVOLVEMENT OF THE ASK1/JNK SIGNALLING PATHWAY  
2.2.1 Activation of ASK1 and JNK 
The ASK1 and the downstream JNK cascade are known to be activated under 
conditions of ER stress-induced apoptosis [75]. As observed in Figure V.8, both 
kinases were activated very early upon cephalostatin 1 treatment. 
Phosphorylation of ASK1 at Thr845, which is correlated with ASK1 activity, was 
observed after only 15 minutes and maintained up to at least 2 h of treatment. 
Its downstream kinase JNK was also already phosphorylated after 15 minutes 
and the intensity of phosphorylation increased further in the course of time.  
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Figure V.8: Activation of ASK1 and JNK by cephalostatin 1. 
Jurkat T cells were left untreated (CO) or stimulated with cephalostatin 1 (CPH; 1 µM) or with 
thapsigargin (TG; 3 µM) for the indicated times (p-JNK/JNK: stimulation with TG for 2 h). 
Western Blot experiments were performed using antibodies against the active phosphorylated 
forms of ASK1 (Thr845) (A) and JNK (Thr183/Tyr185) (B). Membranes were stripped and 
reprobed with antibodies recognising the total level of the proteins (A, B). One representative 
Western Blot out of three is shown. 
 
 
2.2.2 Importance of ASK1 in cephalostatin 1-induced apoptosis 
To evaluate the role of the ASK1/JNK pathway in cephalostatin 1-induced 
apoptosis, two Jurkat clones expressing a dominant negative ASK1 (ASK1-DN) 
[179] were employed. In both clones of ASK1-DN cells (A2-1, A2-3), a 
significant reduction of cephalostatin 1 (1 µM, 24 h)-induced apoptosis was 
observed compared to control cells (Jurkat J16 clone) (Figure V.9 A). TNF-α (10 
nM, 24 h) was used as positive control since TNF-induced apoptosis depends 
on the activation of ASK1 [200]. To verify the reduction of ASK1 activity of the 
ASK1-DN clones, Jurkat J16 and A2-3 clones were treated with cephalostatin 1 
or TNF-α and investigated for JNK phosphorylation by Western Blot. As 
expected, JNK phosphorylation was impaired in A2-3 cells in both cases 
compared to control J16 cells (Figure V.9 B). These data show that the 
ASK1/JNK cascade is involved in cephalostatin 1-induced apoptosis. 
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Figure V.9: The ASK1/JNK pathway is important for cephalostatin 1-induced apoptosis. 
A: Jurkat T cells (Jurkat J16) and Jurkat ASK1-DN cells (clone A2-1, clone A2-3) were treated 
for 24 hours with cephalostatin 1 (CPH; 1 µM) or human tumor necrosis factor-alpha (TNF; 10 
nM) and apoptotic cells were quantified by flow cytometry as described in “Materials and 
Methods”. Insert, the indicated cells were lysed and equal amounts of protein were separated 
by SDS-PAGE and further analysed by Western blot using anti-ASK1 antibodies. The lower 
arrow points to the endogenous and overexpressed ASK1 proteins, while the upper band 
detects a nonspecific (n.s.) band.  B: Jurkat cells and ASK1-DN clone A2-3 were investigated 
for the activation of JNK after treatment with cephalostatin 1 (CPH; 1 µM) and tumor necrosis 
factor-alpha (TNF; 10 nM). After treatment for 30 minutes, cell lysates were prepared and the 
phosphorylated form of JNK was detected using Western Blot analysis. Equal protein loading 
was controlled by staining membranes with Ponceau S. All experiments were performed three 
times with consistent results. Bars, the mean ± SEM of three independent experiments 
performed in triplicate. *, P < 0.05; **, P < 0.01 (unpaired two-tailed t test). 
 
 
2.3 ROLE OF CASPASES IN CEPHALOSTATIN 1-INDUCED ER 
APOPTOTIC PATHWAY 
In addition to transcription factors as CHOP and kinases as ASK1/JNK, 
caspases are important mediators of ER stress-induced apoptosis (see 
III.6.3.2). It has been shown that murine caspase-12, which is capable of 
activating caspase-9 independently of apoptosome formation [85], is early 
activated by cephalostatin 1 [193]. However, functional caspase-12 is lacking in 
humans due to a frame shift mutation and a premature stop codon [201] and its 
actual role in apoptosis is controversial. Caspase-4 has been recently proposed 
as the human homologue of caspase-12 and seems to be activated exclusively 
by situations that alter ER functionality [87,110].  
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Caspase-2 is one of the best conserved caspase across species and has 
features of both initiator and effector caspases. However, assigning a distinct 
function to this protease has been difficult [111]. Recently evidence is given that 
in addition to caspase-12/-4 caspase-2 plays a role as an apical caspase in 
some models of ER stress-induced apoptosis [88,89].  
 
 
2.3.1 Cephalostatin 1-induced activation of caspase-4 is necessary for 
apoptosis  
It was hypothesised that caspase-4 might be the initiator of a cephalostatin 1-
induced specific ER caspase cascade. Indeed, cephalostatin 1 as well as the 
well-known ER stress inducers tunicamycin and thapsigargin activate caspase-
4 time-dependently (Figure V.10). Even though cleavage products of caspase-4 
were difficult to detect in Jurkat cells, a strong reduction of the proform could be 
observed after 4 h of cephalostatin 1 treatment suggesting that caspase-4 might 
act as an apical caspase. Processing of procaspase-4 occurred similarly in 
tunicamycin- and thapsigargin-treated cells supporting the hypothesis that ER 
stress activates caspase-4 in Jurkat cells.  
 
 
 
Figure V.10: Caspase-4 activation by cephalostatin 1. 
Jurkat cells were either left untreated (CO) or treated with cephalostatin 1 (CPH; 1 µM), 
tunicamycin (TM; 1 µg/ml) or thapsigargin (TG; 3 µM) for the indicated times. Processing of 
procaspase-4 was examined by Western Blot. Representative Western Blots of three 
independent experiments are shown. 
 
 
To elucidate if caspase-4 plays a critical role in cephalostatin 1-induced 
apoptosis, the specific caspase-4 inhibitor zLEVD-fmk was used. Blockage of 
caspase-4 proteolytic activity led to a marked inhibition of cephalostatin 1-
induced DNA fragmentation, demonstrating a crucial role of caspase-4 in the 
apoptotic pathway of cephalostatin 1 (Figure V.11 A). Caspase-4 contribution to 
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tunicamycin and thapsigargin-induced apoptosis was similar to that seen for 
cephalostatin 1 further supporting its role in ER stress-induced apoptosis.  
 
Tetrapeptidic caspase inhibitors are not completely specific blockers of a 
particular caspase but usually inhibit caspases of the same subfamily [202]. 
Therefore, to further prove the involvement of caspase-4 in cephalostatin 1-
induced apoptosis, expression of caspase-4 was inhibited by RNA interference. 
Two expression constructs (caspase-4a and caspase-4b, see IV.9) coding for 
two different siRNA sequences directed against all three caspase-4 isoforms 
were prepared and cells were transfected with a mixture of both constructs. As 
observed in Figure V.11 B, the expression of caspase-4 was strongly 
downregulated 24 h after transfection. Cell lines containing the empty vector or 
vector coding for a scramble hairpin sequence were established and employed 
as controls. DNA fragmentation induced by cephalostatin 1 treatment was 
significantly reduced (~ 50%) in cells transfected with siRNA plasmids in fact 
being consistent with the results obtained using the caspase-4 inhibitor zLEVD-
fmk. 
 
 
 
Figure V.11: Caspase-4 is necessary for apoptosis. 
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A: Jurkat cells were left untreated (CO), preincubated with the caspase-4 inhibitor zLEVD-fmk 
(20 µM, 1 h) and then treated with cephalostatin 1 (CPH; 1 µM), or stimulated with cephalostatin 
1 (1 µM) alone for the indicated times. Tunicamycin (TM; 1 µg/ml, 24 h) or thapsigargin (TG; 3 
µM, 24 h) were used as control substances inducing ER stress. Apoptotic cells were quantified 
by flow cytometry. B: Jurkat cells were transfected with empty vector (Neo), vector containing a 
scramble sequence (Scramble) or a mixture of two vectors encoding respective caspase-4 
siRNA sequences (siRNA) as described in “Materials and Methods” and treated with 
cephalostatin 1 for 16 h. Apoptotic cells were quantified by flow cytometry. A significant 
decrease in apoptosis compared to vector as well as scramble sequence was observed (upper 
panel). Bottom panel shows reduction of caspase-4 protein level in cells transfected with siRNA 
plasmids. All experiments were carried out three times in triplicate. Bars, the mean ± SEM of 
three independent experiments performed in triplicate. *, P < 0.05; ** P < 0.01; ***, P < 0.001 
(unpaired two-tailed t test). 
 
 
In order to extend the knowledge about the role of caspase-4 to other cell types 
HeLa cells, which undergo ER stress in response to cephalostatin treatment 
(see Figure V.3), were pre-treated with the caspase-4 inhibitor zLEVD-fmk and 
subsequently with cephalostatin 2. Figure V.12 shows that apoptosis takes 
place in a caspase-4-dependent manner since DNA fragmentation was reduced 
in HeLa cells pre-treated with zLEVD-fmk. Together, these results demonstrate 
that caspase-4 is a central caspase in cephalostatin-induced apoptosis. 
 
 
 
Figure V.12 : Caspase-4 is involved in apoptosis in HeLa cells. 
HeLa cells were left untreated (CO), preincubated with the caspase-4 inhibitor zLEVD-fmk (20 
µM, 1 h) and then treated with cephalostatin 2 (CPH; 50 nM), or stimulated with cephalostatin 2 
(50 nM) alone for the indicated times. Apoptotic cells were quantified by flow cytometry as 
described in “Materials and Methods”. Bars, the mean ± SEM of three independent experiments 
performed in triplicate. *, P < 0.05; ns, not significant (unpaired two-tailed t test). 
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2.3.2 Caspase-2 participation in apoptosis 
The second point of interest was whether caspase-2 was involved in 
cephalostatin 1-induced apoptosis. Indeed, treatment of Jurkat cells with 
cephalostatin 1 leads to activation of caspase-2 as demonstrated by the 
appearance of the caspase-2 cleavage product p31 after 4 h of incubation 
(Figure V.13 A). Thapsigargin was used as positive control [89]. 
  
In order to prove whether caspase-2 is involved in apoptosis, inhibitor studies 
were performed. The caspase-2 inhibitor zVDVAD-fmk reduced DNA 
fragmentation induced by cephalostatin 1 and thapsigargin to a similar extent 
(Figure V.13 B), indicating that caspase-2 contributes to cephalostatin 1-
mediated apoptosis. 
 
 
 
Figure V.13 : Cephalostatin 1 activates caspase-2. 
A: Jurkat cells were either left untreated (CO) or treated with cephalostatin 1 (CPH; 1 µM) or 
thapsigargin (TG; 3 µM) for the indicated times. The p31 cleavage product of procaspase-2 was 
examined by Western Blot. B: Cells were left untreated (CO), preincubated with the caspase-2 
inhibitor zVDVAD-fmk (20 µM, 1 h) and then treated with cephalostatin 1 (1 µM), or stimulated 
with cephalostatin 1 (1 µM) for 24 h. Thapsigargin (3 µM, 24 h) was used as a positive control. 
All experiments were carried out three times with consistent results. Bars, the mean ± SEM of 
three independent experiments performed in triplicate. *, P < 0.05; **, P < 0.01 (unpaired two-
tailed t test). 
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2.3.3 Caspase-4 and caspase-2 are activated upstream of caspase-9 
The strong processing of caspase-4 as early as 4 h after stimulation supported 
the notion that caspase-4 could function as an initiator caspase in the apoptotic 
pathway of cephalostatin 1. Caspase-2 has been reported to act as an initial 
caspase [64,203], but also to be activated downstream of caspase-9 [204]. To 
investigate whether caspase-4 and/or caspase-2 act as initiator caspases in 
cephalostatin-induced apoptosis, it was taken advantage of the caspase-9-
deficient (Casp.9-/-) Jurkat cell line.   
 
First, it was examined whether caspase-4 and caspase-2 are processed in 
caspase-9-deficient cells or if, on the contrary, activation of these proteases is 
an event occurring downstream of activated caspase-9. The results depicted in 
Figure V. 14 deliver evidence supporting the first hypothesis. Procaspase-4 was 
cleaved strongly and time-dependently in caspase-9 deficient cells upon 
cephalostatin 1 treatment (Figure 14 A) but not by thapsigargin or tunicamycin, 
substances that in contrast to cephalostatin 1 induce cytochrome c release and 
apoptosome formation. Processing of the caspase-2 proform was observed 
upon cephalostatin 1 as well as thapsigargin but not after tunicamycin treatment 
(Figure V.14 B), supporting the notion that caspase-2 activation is dependent on 
the apoptotic stimulus [111].  
 
In addition, pre-treatment of Casp.9-/- cells with the specific caspase-4 inhibitor 
zLEVD-fmk or the caspase-2 inhibitor zVDVAD-fmk was not able to reduce the 
residual DNA fragmentation induced by cephalostatin 1 (Figure V.14 C). This 
fact supports the hypothesis that caspase-4 and -2 are activated upstream of 
caspase-9 and require the presence of caspase-9 to induce apoptosis.  
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Figure V.14: Caspase-4 and caspase-2 are activated upstream of caspase-9 in 
cephalostatin 1-induced apoptosis. 
A: Jurkat cells lacking caspase-9 were either left untreated (CO) or treated with cephalostatin 1 
(CPH; 1 µM), thapsigargin (TG; 3 µM) or tunicamycin (TM; 1 µg/ml) for the indicated times. Cell 
lysates were prepared and processing of procaspase-4 was examined by Western Blot. B: 
Caspase-9-/- Jurkats were incubated for the indicated times with cephalostatin 1 (CPH; 1 µM) or 
with the known ER stress inductors thapsigargin (TG; 3 µM) or tunicamycin (TM; 1 µg/ml) and 
caspase-2 activation was investigated by Western Blot. C: Caspase-9-/- cells were left 
untreated (CO) or treated for 24 hours with etoposide (ETO; 2 µM) or cephalostatin 1 (CPH; 1 
µM) with or without preincubation with the caspase-4 inhibitor zLEVD-fmk or the caspase-2 
inhibitor zVDVAD-fmk (20 µM, 1 h). Apoptotic cells were quantified by flow cytometry. All 
experiments were carried out three times with consistent results. Bars, the mean ± SEM of three 
independent experiments performed in triplicate. 
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2.3.4 Caspase-4 and caspase-2 are required for caspase-9 activation 
and apoptosis 
To verify the notion that caspase-4 and caspase-2 act as initiator caspases in 
cephalostatin 1-induced apoptosis the impact of the inhibition of these caspases 
on caspase-9 activation and apoptosis was investigated. 
 
Biochemical and genetic inhibition experiments were used to study possible 
consequences of the inhibition of these caspases in the initial as well as late 
activation of caspase-9. As represented in Figure V.15 A, activation of caspase-
9 was measured already 4 h following treatment with cephalostatin 1 and 
employment of specific caspase-4 and -2 inhibitors (zLEVD-fmk and zVDVAD-
fmk, respectively, or a combination of both) completely inhibited the catalytic 
activity of caspase-9.  
 
To confirm these data, activation of caspase-9 in the execution phase of 
apoptosis (16-24 h) was studied by Western Blot. Inhibition of active caspase-4 
resulted in a marked reduction in the cleavage of caspase-9 whereas 
employment of the caspase-2 inhibitor led to a less pronounced inhibition of the 
appearance of caspase-9 active fragments (Figure V.15 B). These results 
correlate with the individual contribution of each caspase to apoptosis (Figure 
V.11 and V.13 B).  
 
Additional evidence for the upstream role of caspase-4 is shown in Figure V.15 
C. Jurkat cells with a completely reduced caspase-4 expression were generated 
by siRNA techniques, stimulated with cephalostatin 1 for 16 and 24 h and 
caspase-9 activation was analysed by Western Blot and compared to cell lines 
expressing the empty vector or vector containing a scramble sequence. 
Caspase-4 siRNA treated cells showed a marked inhibition of the activation of 
caspase-9 in response to cephalostatin 1. Reduction of caspase-4 expression 
also inhibited the activation of caspase-9 by thapsigargin and tunicamycin, 
pointing to a general involvement of caspase-4 in caspase-9 activation upon 
induction of ER stress. 
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Figure V.15:  Caspase-4 and caspase-2 are required for cephalostatin 1-induced caspase-
9 activation. 
A: Jurkat T cells were either left untreated (CO), treated with cephalostatin 1 (CPH; 1 µM) or 
preincubated with the caspase-4 inhibitor zLEVD-fmk (20 µM, 1 h), the caspase-2 inhibitor 
zVDVAD-fmk (20 µM, 1 h) or a combination of both and then treated with cephalostatin 1 for 4 
h. Caspase-9 activity was measured by luminescence using the Caspase-Glo™ 9 Assay. B: 
Representative Western Blot showing the reduced processing of procaspase-9 into its 
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intermediates in response to cephalostatin 1 (CPH; 1 µM) treatment for 16 h when cells were 
pre-treated with specific caspase-4 or caspase-2 inhibitors. C: Decrease in caspase-9 activation 
by cephalostatin 1 after inhibition of caspase-4 expression by siRNA. Jurkat cells were 
transfected with a mixture of plasmids encoding siRNA sequences and selected with G418 for 
48 h as described in “Materials and Methods”. Empty vector (neo), scramble and caspase-4 
siRNA cells were seeded in G418-free medium and stimulated with cephalostatin 1 (CPH; 1 µM) 
for 16 and 24 h. Cell lysates were prepared and caspase-9 activation was analysed by Western 
Blot. Activation of caspase-9 by thapsigargin (TG; 3 µM) and tunicamycin (TM; 1 µg/ml) was 
also investigated. As a control, caspase-4 protein level in cell lysates from neo, scramble and 
caspase-4 siRNA cells was analysed by Western Blot. One Western Blot representative out of 
three is shown. Equal protein loading was controlled by staining membranes with Ponceau S (a 
representative fragment of the stained membrane is shown). Bars, the mean ± SEM of three 
independent experiments performed in triplicate. *, P < 0.05; **, P < 0.01 (ANOVA/Bonferroni’s 
test). 
 
 
Finally, the effect of the simultaneous inhibition of both initiator caspases was 
investigated. Figure V.16 shows that the reduction in DNA fragmentation after 
blockage of both caspases was additive and in fact, very similarly to the 
absence of caspase-9 (see Figure V.1).  
 
 
 
Figure V.16: Caspase-4 and -2 activation are essential for cephalostatin 1-induced 
apoptosis.  
Cells were left untreated (CO), preincubated with a combination of  zLEVD-fmk (20 µM, 1 h) and 
zVDVAD-fmk (20 µM, 1 h) and then treated with cephalostatin 1 (1 µM), or stimulated with 
cephalostatin 1 alone for 24 h. Apoptotic cells were quantified  by flow cytometry. Bars, the 
mean ± SEM of three independent experiments performed in triplicate. ***, P < 0.001 (unpaired 
two-tailed t test). 
 
 
In summary, these data demonstrate an initial and essential role of caspase-4 
and caspase -2 in cephalostatin 1-induced apoptotic signalling. Engagement of 
these caspases is followed by an activation of caspase-9 that leads to 
apoptosis. 
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2.4 ASK1/JNK AND CASPASE-4 PATHWAYS ACT INDEPENDENTLY  
The ASK1 kinase has been described to be activated in case of ER stress and 
induce a sustained activation of JNK that leads to apoptosis [79,200,205]. 
Activation occurs via TRAF2, an adaptor protein that couples IRE1 activation in 
ER stress to cytosolic signalling. On the other hand caspase-12, the murine 
homologue of caspase-4, has been proposed to be activated via a similar 
mechanism. Caspase-12 forms a complex with IRE1 and TRAF2 and is 
activated, as other initiator caspases, by an autocatalytic mechanism [206]. 
Interestingly, a cross-talk between these two pathways has been very recently 
described [197]. The authors show that the proteasome inhibitor bortezomib 
induces ER stress and apoptosis by mechanisms involving JNK and caspase-4 
activation. Herein, JNK seemed to be responsible for caspase-4 activation since 
inhibition of JNK completely inhibited caspase-4 processing. 
 
However, cephalostatin 1-induced caspase-4 activation was neither affected by 
overexpression of ASK1-DN nor inhibition of JNK (Figure V.17). Examination of 
the processing of caspase-4 in ASK1-DN cells revealed a similar activation as 
compared to control cells. Furthermore, the JNK inhibitor SP600125 did not 
impair but even increased activation of caspase-4 upon cephalostatin 1 
treatment in Jurkat cells. Therefore, we assume that caspase-4 activation 
occurs at the ER membrane independently of the ASK1/JNK kinase pathway. 
 
 
Figure V.17: Neither ASK1 nor JNK are involved in caspase-4 activation. 
ASK1-DN cells (Jurkat A2-3) were treated with cephalostatin 1 (CPH; 1 µM) for the indicated 
times (A) and Jurkat cells (Jurkat J16) were left untreated or pretreated with the JNK inhibitor 
SP600125 (SP; 10 µM, 30 min preincubation) before stimulation with cephalostatin 1 (CPH; 1 
µM) as indicated (B). Cell lysates were prepared and processing of procaspase-4 was studied 
by Western Blot. One Western Blot representative out of three is shown. Protein loading was 
controlled by staining membranes with Ponceau S. 
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B. SESQUITERPENE LACTONES (SQTL) 
First, the morphological and biochemical features of programmed cell death 
(PCD) induced by SQTL bearing only one of the biologically active groups (α-
methylene-γ-lactone versus an α,β-unsaturated cyclopentenone) were 
characterised in order to examine the impact of these chemical moieties on cell 
death. The experiments displayed in V.B.1 (except V.B.1.3.1 and V.B.1.3.3) 
were performed by Prof. Verena M. Dirsch and Dulce Ferreira but are exhibited 
here for a proper understanding of the results presented in V.B.2.  
 
The objective of the second part was to investigate whether the mode of cell 
death induced by SQTL can be related to the response of human macrophages 
(phagocytosis and cytokine response). 
 
 
1 CHARACTERISTICS OF SQTL-INDUCED CELL DEATH 
1.1 CYTOTOXIC ACTIVITY 
Overall cytotoxicity of all three SQTL was assessed. For this purpose, Jurkat T 
cells were exposed to increasing concentrations of SQTL for 24 h and cell 
viability was determined by the MTT assay. Dose-response curves were 
created and the IC50 values calculated (Figure V.18). The values obtained are 
for DHA IC50: 45.8 µM (95% CI: 36.2-57.9 µM, n = 3), for HC IC50: 26.5 µM 
(95% CI: 21.6–32.4 µM, n = 3) and for EM IC50: 5 µM (95% CI: 3.5–7.1 µM, n = 
3). Thus, as expected, the cytotoxicity of compounds with one α,β-unsaturated 
carbonyl group such as DHA (α,β-unsubstituted cyclopentenone group) and HC 
(α-methylene-γ-lactone group) is lower than that of EM bearing in addition to an 
α-methylene-γ-lactone group further reactive centers. The α-methylene-γ-
lactone group seems to be more effective than the cyclopentenone group. 
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Figure V.18: Chemical structure and cytotoxic activity of the SQTL in study. 
A: Chemical structure of DHA (α,β-unsaturated cyclopentenone), HC (α-methylene-γ-lactone) 
and EM (α-methylene-γ-lactone and other reactive centers). B: Jurkat cells were stimulated with 
SQTL (concentrations as indicated) for 24 h. Impairment of cell viability was analysed by an 
MTT assay. Represented are the mean ± SEM of three independent experiments performed in 
triplicate. 
 
 
1.2 MORPHOLOGIC CHANGES OF THE NUCLEUS (DNA 
CONDENSATION AND FRAGMENTATION) 
One typical feature of classical apoptotic cell death is the fragmentation of DNA. 
Thus, an easy and widely used assay to quantify apoptotic cell death is the 
counting of nuclei with a subdiploid DNA content after staining with PI [182]. In 
order to examine whether the observed cytotoxicity is due to apoptosis dose-
response studies within the concentration ranges proven to be cytotoxic were 
performed using this method (Figure V.19 A). Surprisingly, only DHA treatment 
induced significant DNA fragmentation. HC and EM employed at concentrations 
even four times higher than the determined IC50 value for cytotoxicity did not 
lead to fragmented DNA. This observation was confirmed by staining nuclei with 
the fluorescent dye Hoechst 33342 (Figure V.19 B). HC (20 µM) and EM (5 
µM), however, led to a more condensed chromatin since Hoechst 33342-
stained nuclei of HC and EM-treated cells appeared much brighter than control 
nuclei. This chromatin condensation was apparent also after staining nuclei with 
PI followed by FACS analysis: although no typical “sub-G1 peak” was observed 
the G1, S and G2/M peak was shifted slightly to the left, possibly reflecting a 
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lower degree of PI staining due to changes in chromatin density (Figure V.19 A, 
inserts).  
 
 
Figure V.19: Induction of DNA fragmentation and condensation, respectively, by SQTL.  
A: Jurkat T cells were treated with the indicated compounds, 11α,13-dihydrohelenalin acetate 
(DHA), 7-hydroxycostunolide (HC) and 4β,15-epoxymiller-9Z-enolide (EM) at the indicated 
concentrations for 24 h. Cells were harvested and nuclei stained with PI as described under 
”Materials and Methods”. DNA fragmentation was quantified by counting nuclei with a sub-
diploid DNA content by flow cytometry. The inserts show an overlay of the G1,S and G2/M peaks 
obtained without treatment (CO; control) and after treatment with the highest concentration of 
HC (80 µM) and EM (20 µM), respectively. B: Jurkat T cells were left untreated (control) or 
treated with the SQTL DHA (40 µM), HC (20 µM) and EM (5 µM) for 24 h. Nuclei were stained 
with Hoechst 33342 and analysed by fluorescence microscopy. A representative picture out of 
three experiments is shown. Bars, the mean ± SEM of three independent experiments 
performed in duplicate. *, P < 0.05; ***, P < 0.001 (ANOVA/Dunnett’s test). 
 
 
These results show that only DHA, the SQTL with an α,β-unsaturated 
cyclopentenone group, was able to induce DNA fragmentation, but not those 
SQTL with an α-methylene-γ-lactone moiety or an α,β-unsaturated aldehyde 
group nearby of an unsaturated acyl moiety. An epoxide group as in the case of 
EM does not influence this outcome.  
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1.3 CHANGES IN CELL MORPHOLOGY, PHOSPHATIDYLSERINE 
EXPOSURE AND MEMBRANE INTEGRITY 
1.3.1 Light microscopic analysis of SQTL-treated cells 
During classical apoptosis cells undergo morphologic changes such as cell 
shrinkage and formation of apoptotic bodies, easy to detect performing a light 
microscopic analysis.  
 
SQTL treatment leads to prominent morphologic changes (Figure V.20). Cells 
treated with DHA showed classical apoptotic morphology, consisting of cell 
shrinkage and formation of apoptotic bodies. Interestingly, HC- and EM-treated 
cell populations contained cells of apoptotic morphology but also cells showing 
unusual morphologies. In some cells the cytoplasm was condensed at one 
region of the cell whereas plasma membrane was dilated but still closed. 
Moreover in samples stimulated with EM some cells were swollen, consistent 
with an atypical death style. 
 
 
 
Figure V.20: Light microscopic pictures of SQTL-treated Jurkat T cells. 
Pictures taken from untreated Jurkat T cells (Control) or cells treated for 24 h with 11α,13-
dihydrohelenalin acetate (DHA; 40 µM), 7-hydroxycostunolide (HC; 20 µM) or 4β,15-
epoxymiller-9Z-enolide (EM; 5 µM). Arrows show apoptotic cells (DHA) and “atypical” 
morphologies of programmed cell death (HC, EM). 
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1.3.2 Flow cytometric analysis of cell morphology, membrane 
permeability and translocation of phosphatidylserine 
Due to the conspicuous differences in nuclear morphology induced by DHA 
(DNA fragmentation) versus HC and EM (no DNA fragmentation) and the 
observation of atypical cell shapes, the morphological changes as well as the 
induction of apoptotic biochemical features by these compounds were further 
investigated by flow cytometry.  
 
Quantifying the appearance of small (shrunken) cells with a high granularity 
(typical apoptotic morphology) it was determined that all three compounds 
applied at the same concentration as used for Hoechst staining (Figure V.19 B) 
led to a comparable amount of cells with apoptotic morphology. The kinetic by 
which these compounds induce apoptotic morphology, however, was different 
(Figure V.21 A). Interestingly, HC inducing no DNA fragmentation, led very 
rapidly to small and granular cell morphology. However, cells treated with HC 
lost cell membrane integrity with a similar kinetic as after treatment with the 
other SQTL (Figure V.21 B).  
 
Externalization of phosphatidylserine (PS) represents the most important “eat 
me” signal to surrounding phagocytosing cells [140]. Comparing the extent and 
kinetic of PS translocation again it was found a striking behaviour for HC (Figure 
V.21 C). It induced a very rapid and strong PS translocation. In contrast, PS 
externalization induced by DHA occurred late (8 h) compared to the other 
compounds (4 h) and was weak. All compounds clearly induced PS 
translocation before cells lost membrane integrity.  
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Figure V.21: Temporal changes in cell morphology, membrane permeability and 
translocation of PS due to SQTL treatment.  
A: Jurkat T cells were treated with 11α,13-dihydrohelenalin acetate (DHA; 40 µM), 7-
hydroxycostunolide (HC; 20 µM) or 4β,15-epoxymiller-9Z-enolide (EM; 5 µM). The appearance 
of small granular cells was quantified by flow cytometry counting cells with a low FSC and high 
SSC. B: Cells were treated as in A and incubated with PI (1 µg/ml). Only cells staining positively 
with PI were counted by flow cytometry. C: Cells treated with SQTL as in A and B were labeled 
with Annexin V-FITC (0.5 µg/ml) and PI (1 µg/ml). Only Annexin V-FITC positive and PI 
negative cells were counted by flow cytometry. All data represent mean ± SEM of three 
independent experiments performed in duplicate. *, P < 0.05; ***, P < 0.001 (ANOVA/Dunnett’s 
test). 
 
 
1.3.3 Analysis of membrane integrity by measure of LDH activity 
In late phases of apoptotic and in necrotic cell death plasma membrane integrity 
is lost and intracellular constituents are released into the extracellular space. 
Membrane integrity can be also investigated by quantifying the LDH present in 
culture medium of treated cells compared to untreated cells.  
 
Measurement of LDH in Jurkat cell culture supernatants 24 h after addition of 
SQTL (Figure V.22) indicated that LDH levels in culture medium of HC-treated 
Jurkat cells were almost 5-fold higher than control whereas 2-fold in case of EM 
and only slightly increased in DHA-treated cells. This result suggests that HC-
treated cells undergo cell death very fast and are not able to maintain 
membrane integrity as long as DHA- or EM-treated cells. 
 
 
 
Figure V.22: LDH levels in culture medium of SQTL-treated Jurkat cells. 
Jurkat cells were either left untreated (CO) or incubated with SQTL for 24 h. Culture 
supernatants were recovered by centrifugation and LDH concentration was determined using a 
Lambda Bio 20 photometer as described in “Materials and Methods”. Bars represent the mean ± 
SEM of three independent experiments performed in triplicate. **, P < 0.01; ***, P < 0.001 
(ANOVA/Bonferroni’s test) vs. control. ###, P < 0.001 (ANOVA/Bonferroni’s test) vs. HC. 
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1.4 CASPASE ACTIVATION 
Caspases are pivotal executioners of apoptosis responsible for the induction of 
classic apoptotic morphological features (see III.6.1). Since HC and EM induced 
no classic form of apoptosis it was examined whether the three SQTL differ in 
their ability to activate caspases as the observed morphology (DNA 
fragmentation or changes in chromatin density) is dependent on active 
caspases.  
 
Total caspase activity was detected using the fluorescent in situ marker FITC-
VAD-fmk. According to the temporal onset of cell death (Figure V.21) cells were 
incubated for either 16 h (DHA, HC, EM) or 5 h for the positive control etoposide 
before addition of FITC-VAD-fmk and flow cytometric analysis. As shown in 
Figure V.23 A, all SQTL at effective cytotoxic concentrations led to caspase 
activation. Surprisingly, DHA induced only moderate caspase activity compared 
to HC and EM. This observation was not due to kinetic differences since DHA-
induced caspase activity did not further increase up to 20 and 24 h (data not 
shown).  
 
To examine whether cell death morphology is dependent on caspase activation 
Jurkat T cells were preincubated with the pan-caspase inhibitor zVAD-fmk and 
subsequently treated with SQTL for 24 h. Quantification of changes in nuclear 
morphology was performed by flow cytometry after PI staining. All nuclei 
appearing left of the G1 peak of control cells were counted. As shown in Figure 
V.23 B, changes in nuclear morphology induced by all three SQTL were 
significantly reduced by zVAD-fmk.  
 
 
 
Figure V.23: Caspases are activated and responsible for changes in nuclear morphology 
in response to SQTL treatment.  
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A: Jurkat T cells were either left untreated (CO) or treated with 11α,13-dihydrohelenalin acetate 
(DHA; 40 µM), 7-hydroxycostunolide (HC; 20 µM) or 4β,15-epoxymiller-9Z-enolide (EM, 5 µM) 
for 16 h. As a positive control etoposide (ET, 25 µg/ml, 5 h) was applied. Then FITC-VAD-fmk (5 
µM) was added, incubated for 20 min (37°C) and cells were analysed by flow cytometry. B: 
Jurkat cells were pretreated (+) or not (-) with the pan-caspase inhibitor zVAD-fmk (50 µM, 1 h), 
then exposed to SQTL and analysed by flow cytometry. Depicted are the mean ± SEM of the 
mean fluorescence intensity (n = 3, in duplicate). *, P < 0.05; ***, P < 0.001 (Anova/Dunnett’s 
test) (A); **, P < 0.01, ***, P < 0.001 (two-tailed unpaired student’s t test) (B). 
 
 
2 MACROPHAGE RESPONSE 
2.1 ANALYSIS OF PHAGOCYTOSIS BY FLOW CYTOMETRY 
The exposure of PS is the all-important and best studied cell surface marker 
involved in the removal of dying cells by macrophages [138,141,167,207]. The 
SQTL in study showed great differences in the extent and kinetic of PS 
translocation. Thus, the next objective was to investigate whether SQTL-treated 
Jurkat cells were differently phagocytosed by employing THP-1-derived 
macrophages. 
 
Several methods can be used for the investigation of phagocytosis: measure of 
LDH concentration in co-culture supernatants after the phagocytic process 
[174], counting by microscopy of the number of macrophages that have 
ingested stained target cells [138,145,155] or quantification of the increase in 
macrophages size [162] or fluorescence [149,162,208,209] by flow cytometry.  
 
 
2.1.1 Increase in macrophages cell size 
The first approach employed consisted of the analysis of the increase in THP-1 
cell size after co-culture with Jurkat cells. Target cells were stimulated with 
SQTL for 4 h before feeding because differences in the percentage of PS 
positive/PI negative cells were maximal for all three substances, whereas the 
percentage of PI positive cells was very similar at that time point (see Figure 
V.21).  
 
Time-course studies had shown that 3.5 h of co-culture delivered the higher 
increase in macrophages cell size (data not shown) and this was the incubation 
time used for all experiments. Interestingly, macrophages fed with HC-treated 
Jurkat cells experienced the higher increase in cell size (Figure V.24). This fact 
points to a correlation between the degree of PS exposed in the apoptotic cells 
and the efficiency of their removal by phagocytes. 
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Figure V.24: Quantification of the increase in THP-1-derived macrophages cell size after 
phagocytosis of Jurkat cells. 
Macrophages were cultured in medium alone (CO) or co-cultured with untreated (viable) or 
SQTL-treated (4 h) Jurkat cells for 3.5 h as described in “Materials and Methods”, followed by 
evaluation of cell size by flow cytometry. Bars represent the mean ± SEM of three independent 
experiments performed in triplicate. *, P < 0.05 (ANOVA/Bonferroni’s test) vs. viable Jurkat. #, P 
< 0.05 (ANOVA/Bonferroni’s test) vs. Jurkat HC. 
 
 
2.1.2 Quantification of phagocytosis by analysis of cell fluorescence 
(FL1) 
To confirm this result and exclude differences due to different kinetics in the 
phagocytosis of target cells, an additional procedure consisting of a fluorescent 
staining of Jurkat cells was developed.  
 
Target Jurkat cells were stained with the fluorescent marker CCFSE and then 
cell death was induced. At the concentrations used, the dye showed no toxicity 
and was retained by cells throughout the whole experiment (data not shown). 
Jurkat cells were left untreated, treated with SQTL (DHA, HC, EM) or etoposide 
(1.5 µM) for 4 h, or killed with heat (55°C, 15 min) to generate pathological cell 
death (necrosis). The efficient induction of cell death was checked for each 
experiment by PI exclusion assay after 24 h of treatment with SQTL/etoposide 
(data not shown). After co-culture for 3.5 h, macrophages were recovered and 
analysed by flow cytometry. As shown in Figure V.25, the mean green 
fluorescence of THP-1-derived macrophages as well as the number of green 
positive macrophages increased after co-culture, indicating uptake of target 
cells.  
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Figure V.25: Phagocytotic activity of differentiated THP-1 cells fed with SQTL-treated 
Jurkat cells.  
Jurkat T cells labeled covalently with the green fluorescent marker CCFSE were left untreated 
(viable) or treated with SQTL for 4 h and co-cultured with PMA-treated THP-1 cells 
(macrophages; Mφ) at a ratio 2:1 during 3.5 h. Adherent cells were recovered and analysed by 
flow cytometry. Representative histogram plots show the green fluorescence intensity (FL1-H) 
of macrophages. The experimental histograms are shaded in black, while the control profile is 
outlined. Dot plots show that the number of macrophages FL1 positive (upper quadrants) 
increased after co-culture with Jurkat cells. 
 
 
Phagocytosis was quantified on the basis of the increase in mean green 
fluorescence intensity of macrophages co-cultured with target cells referred to 
unfed macrophages (extent of phagocytosis, Figure V.26 A) or as the 
percentage of FL-1 positive macrophages (percent of phagocytosing 
macrophages, Figure V.26 B). Jurkat cells that had been treated with HC were 
phagocytosed, again, more efficiently than DHA- or EM-treated Jurkat cells. 
These cells were also better phagocytosed than etoposide-treated Jurkats 
(“classical” apoptosis) or heat-killed cells (necrosis) (Figure V.26 A). In 
accordance, HC-treated Jurkat stimulated most macrophages to phagocyte 
(Figure V.26 B). In fact, the results obtained with both approaches were very 
similar. 
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Figure V.26: Quantification of phagocytosis by differentiated THP-1 cells fed with SQTL-
treated Jurkat cells by flow cytometry. 
Experiments were performed as described in Figure V.25 and in “Materials and Methods”. 
Phagocytosis was quantified on the basis of the increase in mean green fluorescence intensity 
(FL1) of engulfing macrophages referred to macrophages alone (CO, control) (A), or as the 
percentage of FL1-positive macrophages (B). As control, phagocytosis of etoposide-treated 
Jurkat cells, (ET; 1.5 µM, 4 h) and heat-killed Jurkats (necrotic; 15 min at 55°C), was also 
quantified. Bars represent the mean ± SEM of three independent experiments performed in 
triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Anova/Bonferroni’s test) vs. viable Jurkat. 
 
 
3 CONFOCAL MICROSCOPY 
The phagocytosis of apoptotic (etoposide-treated), necrotic, SQTL-treated and 
untreated Jurkat cells was confirmed by confocal laser scanning microscopy. 
For this purpose, macrophages were stained with the red fluorescent substance 
PKH26 before co-culture with CCFSE-stained Jurkat cells. Fluorescence 
images were taken to detect target cells (green, 505-530 nm) and macrophages 
(red, >560 nm) as well as transmitted light images to show cell shapes. Figure 
V.27 shows the co-localisation of red and green fluorescence, displayed as 
yellow colour, in macrophages that have phagocytosed Jurkat cells.  
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Figure V.27: Representative pictures showing co-localisation of macrophages and target 
cells fluorescence. 
PKH26-stained macrophages (red) and CCFSE-stained Jurkat cells (green) were co-cultured for 
3.5 h and macrophages were fixed with formaldehyde. Preparations were analysed by confocal 
microscopy as described in “Materials and Methods” to obtain target cells (upper left), 
macrophages (upper right) or transmission (lower left) images. Lower right, merged confocal 
images of the three channels. 
 
 
To confirm that Jurkat cells were located inside macrophages and not just 
adhered to the surface of the cells, a stack of fluorescence images that 
traversed the z dimension of the samples were collected. Stacks of serial 
sections were projected and visualised in three dimensions (Figure V.28). 
These results clearly demonstrate that CCFSE-stained Jurkat cells are engulfed 
by THP-1-derived macrophages.  
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Figure V.28: 3D projections of macrophages that have engulfed Jurkat cells. 
After co-culture with Jurkat cells and sample preparation as described in “Materials and 
Methods”, macrophages were analysed by confocal microscopy. Z-stacks of the macrophages 
that showed a co-localisation with Jurkat cells were obtained and 3D projections were created. 
 
 
4 CYTOKINE RELEASE 
The removal of apoptotic cells by macrophages has been mostly related to anti-
inflammatory and immunosuppressive responses, associated with a reduction in 
the levels of pro-inflammatory cytokines such as TNF-α, IL-1β or IL-12 and/or 
the release of anti-inflammatory mediators as TGF-β or IL-10 [153-156] and 
indeed attributed to the interaction of macrophage and target cell through the 
phosphatidylserine receptor (PSR) [138,140,141]. Given that HC-treated Jurkat 
cells strongly exposed PS and were efficiently uptaken by macrophages, it was 
hypothesised that phagocytosis of SQTL-treated cells, at least in case of HC, 
could be mediated by the PSR and followed by a modulation of cytokine 
production by macrophages leading to an anti-inflammatory effect. 
 
To investigate this notion, an experiment analogue to the phagocytosis assay 
was performed. Culture supernatants were collected after 3.5 and 18 h of co-
culture and analysed for TNF-α and TGF-β concentration by ELISA (Figure 
V.29). To our surprise, HC-treated cells significantly increased TNF-α levels, but 
to a lesser extent than necrotic cells (Figure V.29 A). A similar tendency was 
observed for DHA and EM although differences were not significant. On the 
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other hand, TGF-β levels after 18 h of co-culture were nearly unaffected by the 
presence of SQTL- or etoposide-treated cells, but strongly reduced by necrotic 
cells (Figure V.29 B). Viable, necrotic or stimulated Jurkat cells did not release 
any detectable levels of cytokines (data not shown). Induction of cell death was 
verified for each experiment by PI exclusion assay of Jurkat cells after 24 h of 
treatment with SQTL/etoposide (data not shown). 
 
 
Figure V.29: Concentration of TNF-α and TGF-β in culture supernatants of THP-1 cells fed 
with SQTL-treated Jurkat cells.  
THP-1-derived macrophages were stimulated with 0.1 µg/ml LPS for 3 h before addition of 
Jurkat cells at a ratio of 10:1 followed by incubation for 3.5 and 18 h. For comparison, THP-1 
received untreated (viable), etoposide-treated (ET; 1.5 µM, 4 h) or heat-killed (necrotic) (30 min 
at 55°C) Jurkat cells. A: TNF-α was quantified by means of specific ELISA after 3.5 h of co-
culture. TNF-α was not detectable in supernatants of unstimulated macrophages (THP-1 
control). Data are expressed as TNF-α concentration (± SEM) relative to LPS-stimulated 
macrophages which are indicated as 100% (n = 3, in triplicate). The 100% TNF-α production of 
LPS-stimulated macrophages corresponds to a mean value of 146 pg/ml. B: Supernatants were 
recovered after 18 h of co-culture and TGF-β concentration was quantified by ELISA. Bars 
represent the TGF-β concentration (± SEM) relative to LPS-stimulated macrophages which are 
indicated as 100% (n = 3, in triplicate). TGF-β contained in culture medium was subtracted from 
the experimental values. *, P < 0.05; *** P, < 0.001 (Anova/Bonferroni’s test) vs. viable Jurkat 
(A); * P < 0.05 (two-tailed unpaired t test) vs. viable Jurkat (B). 
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VI. DISCUSSION 
A. CEPHALOSTATIN 1 
A wide range of chemotherapeutic drugs employed in cancer therapy induce 
apoptosis, most of them by mechanisms involving death receptors and 
mitochondrial pathways [3,4]. Unfortunately, tumour cells often develop 
chemoresistences due to defects or mutations in these pathways [6], leading to 
therapy failure. Hence, novel mechanisms of action are required to resensitise 
cancer cells to chemotherapy. In this respect, cephalostatins are promising 
substances. It had been previously described that cephalostatin 1 induces 
apoptosis in a CD95-, caspase-8- and apoptosome-independent manner [20]. It 
was sought to further characterise the apoptotic pathways employed by 
cephalostatin 1, since they could represent novel targets for the development of 
new cancer chemotherapeutic strategies. 
 
 
1 REQUIREMENT OF CASPASE-9 
Intriguingly, caspase-9 was activated and found essential for cephalostatin 1-
induced apoptosis despite the absence of an apoptosome. Thus, caspase-9 can 
be the central caspase in apoptosome-independent apoptosis. Up to now 
apoptosome-independent apoptotic cell death has been described in the 
literature before [210,211], but in these cases apoptosis occurred also 
independently of caspase-9 activation.  
 
In search of the mechanism(s) responsible for apoptosome-independent 
caspase-9 activation and apoptosis, it was hypothesised that cephalostatin 1 
may target the endoplasmic reticulum (ER) and induce apoptosis by triggering 
ER-specific pathways.  
 
 
2 INDUCTION OF ER STRESS 
The role of ER stress in tumour development and therapy is unclear at present, 
although supposedly ER stress response is important for regulating the balance 
between tumour cell death and its growth as well as for the sensitivity to 
chemotherapeutic agents [212]. Up to now only a few chemotherapeutic drugs 
including cisplatin [197,213] and proteasome inhibitors [196-198] have been 
reported to induce ER stress and ER-related apoptotic pathways. ER stress 
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pathways linked to apoptosis have been reported in pathological states such as 
ischemia-reperfusion injury and diabetes as well as in neurodegenerative 
diseases such as Alzheimer´s and Parkinson´s disease [76,78,194,214].  
 
The induction of ER stress by cephalostatin 1 was investigated and 
demonstrated by the influence on several classical ER stress markers. The 
chaperone protein BiP is a sensor of ER stress as well as a target gene of the 
unfolded protein response (see III.6.3.2). The increase in BiP levels observed 
the first hour after stimulation with cephalostatin and later in the apoptotic 
process (16 h) probably represents an attempt of the cells to survive ER stress. 
The fast and strong up-regulation of the transcription factor CHOP was a further 
sign of ER stress and, most importantly, could initiate or potentiate apoptotic 
pathways through modulation of its target genes. Overexpression of CHOP has 
clearly shown to lead to cell cycle arrest and/or apoptosis [82,215] and therefore 
an increase of its expression may represent a new anticancer strategy. 
Phosphorylation of the translation initiator factor eIF2α, which leads to an 
attenuation of general protein synthesis, was particularly strong and sustained 
upon cephalostatin 1 treatment. 
 
All these ER stress parameters were also modulated by cephalostatin in the 
carcinoma HeLa cell line and have been described for agents known to induce 
ER stress such as tunicamycin or thapsigargin [83,215,216], supporting the 
assumption that cephalostatin 1 induces ER stress. 
 
The next point of interest was to investigate how cephalostatin induces ER 
stress. Calcium ion (Ca2+) is an intracellular signal playing a dual role in living 
organisms: necessary for cell survival but also trigger of cell death [90-
92,217,218]. It is largely known that disruption in Ca2+ cellular distribution, 
normally provoked by the release of Ca2+ from ER stores, leads to ER stress 
and apoptosis. Cephalostatin did not induce a noticeable increase in global 
cytosolic Ca2+ concentration whereas the positive control thapsigargin did so. It 
was a surprising result in disaccord with the observed calpain activation by 
cephalostatin [193]. A possible explanation is that cephalostatin may disrupt the 
subcellular distribution of Ca2+, leading to calpain activation at the ER or Golgi 
complex membranes. Accordingly, a recent report has proposed that the 
disregulation of intracellular Ca2+ linked to an activation of the mitochondrial 
Ca2+ uniporter is a critical determinant of bortezomib (a proteasome inhibitor) 
cytotoxicity [199]. Treatment with cephalostatin 1 neither increased the 
intracellular production of ROS, which has also been associated with induction 
of ER stress [195,196]. 
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Proteasome inhibitors constitute a group of promising anticancer agents, able to 
sensitise malignant cells and tumours to conventional chemotherapy [219,220]. 
They block the degradation of ubiquitin-targeted proteins, a physiological 
process required for normal protein turnover. Interestingly, proteasome 
inhibitors can induce ER stress and initiate ER-specific apoptotic pathways 
[196-198], probably due to an excessive accumulation of ubiquitinated proteins 
that leads to protein aggregation and proteotoxicity. Importantly, treatment of 
Jurkat cells with cephalostatin 1 induced a progressive increase in the number 
of ubiquitinated proteins with similar kinetics to the induction of ER stress 
markers. According to this observation, it can be hypothesised that 
cephalostatin 1 either promotes the ubiquitination of certain target proteins by 
inducing an ubiquitin ligase or inhibits proteasomal activity leading to an 
unspecific ubiquitination of cellular proteins.  
 
 
3 ASK1/JNK PATHWAY 
Besides the induction of the pro-apoptotic transcription factor CHOP, other 
apoptotic pathways can be initiated at the endoplasmic reticulum. ER stress 
activates JNKs through activation of IRE1 that bind TRAF2, an adaptor protein 
that couples plasma membrane receptors to JNK activation [80]. JNK activation 
can promote cell survival as well as death. However, sustained activation of 
JNK is known to lead to apoptosis and requires activation of ASK1. It is well 
known that ASK1 is activated in cells treated with death receptor ligands and 
oxidative stress [200], but also required for ER stress-induced apoptosis [221]. 
Cephalostatin 1 activates ASK1 very early and induces a strong and sustained 
activation of JNK. The reduction of DNA fragmentation in Jurkat cells 
overexpressing a dominant negative form of ASK1 (ASK1-DN) identifies this 
pathway as an important element in the apoptotic pathway employed by 
cephalostatin 1. 
 
 
4 INITIATOR CASPASES 
The group of caspases activated under conditions of ER stress has not been 
completely defined. Only caspase-12 has been characterised as ER-specific 
initiator caspase [80]. However, functional caspase-12 is lacking in most 
humans [201] due to a frame shift mutation and a premature stop codon. 
Human caspase-4 has been recently identified as a gene homologous to 
caspase-12 and suggested to mediate apoptosis induced by ER stress stimuli 
as thapsigargin or tunicamycin [80,87] and to be involved in neuronal cell death 
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in Alzheimer’s disease [214]. Caspase-2 is an interesting initiator caspase with 
still unclear functions. Some reports have linked it to ER stress-induced 
apoptosis [88,89] and was therefore investigated as a possible mediator of 
cephalostatin 1-induced cell death.  
 
Caspase-4 was processed and participated in apoptosis upon cephalostatin 1 
treatment similarly to the ER stress inducing substances thapsigargin and 
tunicamycin. In addition, caspase-2 was activated by cephalostatin 1 and 
thapsigargin and contributed to apoptosis. These results confirmed the 
importance of ER apoptotic pathways, including members of the caspase 
family, in cephalostatin 1-induced apoptosis.  
 
 
4.1 CASPASE-4 
Caspase-4 was characterised as an apical caspase in cephalostatin 1 apoptotic 
pathway. Given that caspase-9 is essential in cephalostatin-induced apoptosis 
and can be activated by the caspase-4 homologue caspase-12, it was 
hypothesised that caspase-4 may act upstream of caspase-9. Multiple 
experiments confirmed this assumption. Caspase-4 was clearly activated in 
caspase-9-deficient cells but employment of a caspase-4 inhibitor did not 
reduce DNA fragmentation, suggesting that the apoptotic efficacy of caspase-4 
lies on caspase-9. Furthermore, inhibition of caspase-4 inhibited early caspase-
9 activity (4 h) as well as the appearance of caspase-9 active fragments (16 and 
24 h). In contrast, caspase-4 did not seem to be activated the same modus by 
thapsigargin and tunicamycin. Caspase-4 was not processed in caspase-9-
deficient cells, suggesting that caspase-4 activation may be a downstream 
event. However, inhibition of caspase-4 by siRNA dramatically inhibited 
caspase-9 activation. Thus, caspase-4 and caspase-9 may be part of a self-
activating caspase cascade, involving a simultaneous activation of caspase-9 at 
the apoptosome and downstream of previously activated caspase-4. 
 
Two very recent reports argued against the role of caspase-12 and caspase-4 
in ER stress-induced apoptosis [222,223]. Certain cell lines (a murine pro-B cell 
line and a human myeloma cell line) which do not express caspase-12 and 
caspase-4, respectively, were shown to respond to ER stress agents via 
apoptotic cell death, which did not differ from cells retransfected with caspase-
12 [222]. Furthermore, a neural cell line which has been depleted of caspase-12 
by RNA interference was reported to undergo apoptosis upon tunicamycin-
induced ER stress [223]. The data presented in this work certainly support the 
role of caspase-4 in ER stress-induced apoptosis, since it was necessary for 
caspase-9 activation and apoptosis. However, only upon cephalostatin 1 
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treatment caspase-4 was activated upstream of caspase-9. Thus, the role of 
caspase-4 may depend on the cell type and on the mechanism of action of the 
ER stressor. Importantly, the exceptional mechanism employed by 
cephalostatin 1 demonstrates that caspase-4 can be activated independently of 
cytochrome c release and apoptosome formation. 
 
Several mechanisms for the activation of caspase-12 and possibly caspase-4 
have been proposed. For example, calpain, a protease that can be activated by 
calcium released from ER upon ER stress starts cleavage of caspase-12 [99]. 
Caspase-7 for instance is reported to cleave caspase-12 [224], but is not able to 
cleave caspase-4 upon sustained ER stress [87]. Caspase-12 and possibly 
caspase-4 could also be activated via TRAF2 [206] or through the recently 
described “ERaptosome” [75,225], a putative caspase-activating complex 
including caspase-12 and caspase-9. A possible role of JNK in caspase-4 
activation has also been described [197]. The proteasome inhibitor bortezomib 
induces ER stress and leads to apoptosis via a mechanism where JNK seems 
to be responsible for caspase-4 activation. However, cephalostatin 1-induced 
caspase-4 activation was neither affected by overexpression of ASK1-DN nor 
inhibition of JNK. 
 
 
4.2 CASPASE-2 
Caspase-2 activation may be a downstream event [204], but it is accepted that 
it can be also activated upstream of mitochondrial damage [226]. Indeed, 
caspase-2 was activated upstream of caspase-9 when cephalostatin 1 or 
thapsigargin were used. In addition, a caspase-2 specific inhibitor blocked early 
caspase-9 activation by cephalostatin 1 and reduced the processing of 
caspase-9 to its active fragments at a later time point. On the contrary, 
treatment with tunicamycin, which also activates caspase-2 in parental Jurkat 
cells (data not shown), did not lead to processing of caspase-2 in caspase-9-
deficient Jurkat cells, pointing to a downstream activation by caspase-9.   
 
Caspase-2 can be activated by recruitment into a large multiprotein complex 
independently of Apaf-1 and cytochrome c [203]. This putative complex has 
been proposed to be the PIDDosome [64], formed by association of the protein 
PIDD (p53-induced protein with a DD), RAIDD (RIP associated ICH-1/CED-3-
homologous protein with DD) and procaspase-2. The PIDDosome was 
proposed to regulate caspase-2 activation and apoptosis induced by genotoxic 
agents. Upon recruitment to the complex, caspase-2 was activated and 
autoprocessed, but it was not clear whether activated caspase-2 was involved 
in cell death. RAIDD together with caspase-2 has been recently demonstrated 
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to participate in the induction of apoptosis under conditions of trophic factor 
withdrawal but not DNA damage [112], arguing against the exclusive formation 
of the caspase-2 activation complexes by genotoxic stress [64]. Since caspase-
2 is able to bind to a range of adaptor proteins [111], different protein 
complexes may be formed depending on the stimulus and cell type and result in 
caspase-2 activation. In fact, caspase-2 can form another large complex with 
TRAF2 and RIP1, leading to a CARD-dependent activation of NF-kB and p38 
MAPK [227]. Hence, cephalostatin 1 treatment may induce recruitment of 
caspase-2 to a multiprotein complex, where it would be activated and 
subsequently participate in activation of caspase-9. 
 
 
5 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
The present work has demonstrated that the ER stress response evoked by 
cephalostatin 1 activates several apoptotic pathways that, in turn, are able to 
induce apoptosis efficiently independently from cytochrome c release and 
apoptosome formation. The ASK1/JNK cascade and ER-associated caspases 
as caspase-4 were identified as the primary molecular players being involved in 
apoptosome-independent execution of cell death.  
 
Notably, the identification of caspase-2 and caspase-4 as initiator caspases 
provided an explanation of how caspase-9 can be activated independently from 
apoptosome. The dramatic reduction in apoptosis observed upon caspase-9-
deficiency was comparable to that observed through the concomitant inhibition 
of caspase-4 and -2. The mitochondrial protein Smac, which is released 
selectively upon cephalostatin 1 treatment [193], could act as a stabilisator of 
active caspase-9 by avoiding its sequestration by XIAP.  
 
Three major questions remain to be answered and require further studies: i) 
which is the primary target of cephalostatin?, ii) how is ER stress induced? and 
iii) how is caspase-4 activated by cephalostatin 1? The proteasome complex 
appears a plausible candidate target for cephalostatin 1. The accumulation of 
ubiquitinated proteins and the necessity of JNK and caspase-4 for apoptosis are 
features common to the proteasome inhibitor bortezomib [197].  
 
The novel mechanism of action of cephalostatin 1 makes it a good candidate for 
the sensitisation of chemotherapy-resistant tumour cells. Engagement of the ER 
apoptotic pathway by cephalostatin provides a range of promising targets. 
Caspase-4 is one of the genes stimulated by interferon (INF) treatment and 
seems to be involved in the sensitisation of tumour cells to apoptosis mediated 
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by death ligands as TRAIL or FasL [107,109]. The transcription factor CHOP 
could contribute to cell death by promoting the transcription of the TRAIL 
receptor DR5 and other target genes.  
 
 
B. SESQUITERPENE LACTONES 
To understand the cytotoxicity as well as the anti-inflammatory potential of 
sesquiterpene lactones (SQTL) is an ongoing challenge since decades. Starting 
with the pioneering work of Kupchan and co-workers [24], numerous studies 
have been performed that led to the current view that the biological activity of 
SQTL is dependent on the presence of a cyclopentenone group or other α,β-
unsaturated carbonyl functions in addition to an α-methylene-γ-lactone, 
increasing lipophilicity as well as the number of hydrogen-bond acceptors. The 
objective of this work was to try to link both activities and find differences in the 
biological activity depending on the reactive groups. 
 
 
1 INDUCTION OF PCD BY SESQUITERPENE LACTONES   
Early structure-activity relationships reported that the presence of the α-
methylene-γ-lactone group was essential for the cytotoxic activity of SQTL and 
an α,β-unsaturated ester or cyclopentenone strengthened this property [24,25]. 
On the contrary, studies on helenalin derivatives showed that the most active 
compounds possess both reactive structural elements, but the contribution of a 
cyclopentenone group to cytotoxicity is considerably higher than that of the 
methylene lactone group (summarized in [23]). Interestingly, the present study 
shows that treatment of Jurkat T cells with the α-methylene-γ-lactone 7-
hydroxycostunolide (HC) results in a lower IC50 value (26.5 µM) than treatment 
with the α,β-unsaturated cyclopentenone 11α,13-dihydrohelenalin acetate 
(DHA) (45.8 µM), in agreement with the first studies comparing different SQTL. 
This may be partly due to the freely accessible hydroxyl group in the vicinity of 
the lactone moiety of HC, which may facilitate anchoring the molecule to the 
respective proteins [33]. In accordance with all studies, a higher number of 
reactive centers as in 4β,15-epoxymiller-9Z-enolide (EM) increases cytotoxicity.  
 
But the most striking differences were observed in the characteristics of cell 
death induced by SQTL, especially when comparing the monofunctional DHA 
and HC. The morphology of DHA (cyclopentenone)-induced cell death meets 
the classical characteristics of apoptosis. In contrast, the α-methylene-γ-lactone 
SQTL, HC induces an “atypical” form of PCD. The induction of apoptotic 
VI Discussion 
117 
morphology was incredibly rapid (<4 h), accompanied with a strong 
phosphatidylserine (PS) externalisation and caspase activation, hallmarks of 
classical apoptosis. In contrast, DNA fragmentation, maybe the parameter 
mostly used to differentiate apoptosis from other forms of PCD, was not 
observed upon HC treatment. After long incubation periods (24 h) with HC and 
EM, both containing an α-methylene-γ-lactone, non-apoptotic cellular 
morphologies were observed, including swollen cells with a dilated plasma 
membrane and condensed cytoplasm. At that time point and when compared to 
DHA, the plasma membrane of HC-treated cells was more permeable to the 
intracellular enzyme LDH whereas the permeability to PI was very similar, 
indicating that late apoptotic cells treated with HC may release some 
intracellular components but membrane integrity is generally maintained. 
 
Whereas the α,β-unsaturated cyclopentenone group of cytotoxic SQTL induces 
classical apoptosis, the α-methylene-γ-lactone group is responsible for the 
induction of an atypical form of “apoptosis-like” PCD characterised by caspase 
activation, strong PS externalisation but absence of DNA fragmentation. 
 
 
2 ANTI-INFLAMMATORY EFFECT 
The anti-inflammatory activity of SQTL has been linked mainly to an inhibition of 
the activity of the transcription factor NF-κB, although there is no agreement in 
whether the primary target is the transcription factor itself [28,39] or the kinase 
complex involved in NF-κB activation [38]. Since SQTL are known not only to 
alleviate inflammation locally but also to exert cytotoxicity, it was hypothesised 
that in addition to the NF-κB-inhibitory effect, SQTL may contribute to local 
inflammation/immune resolution by induction of apoptosis in immune cells and 
subsequent phagocyte removal of dying cells, accompanied by a shift from pro- 
to anti-inflammatory cytokine release. Several studies had suggested that the α-
methylene-γ-lactone moiety was the most important for the anti-inflammatory 
activity [31,33]. The results obtained in the study of PCD agreed with this 
hypothesis, since the α-methylene-γ-lactone SQTL induced a stronger PS 
translocation, the most prominent “eat-me” and immunomodulatory signal on 
the surface of apoptotic cells. 
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2.1 EFFICIENT REMOVAL OF DYING CELLS 
Indeed, the levels of PS in SQTL-treated Jurkat cells were in accordance with 
the observation that macrophages showed a significant better phagocytic 
response to HC-treated compared to DHA-, EM-, etoposide-treated or heat-
killed (necrotic) Jurkat cells. Phagocytosis of Jurkat cells was investigated by 
flow cytometry studying different parameters. The increase in cell size of 
macrophages which had been fed with Jurkat cells correlated perfectly with the 
levels of PS induced by SQTL treatment. Staining of target cells and measure of 
the fluorescence of macrophages after co-culture ruled out differences due to a 
different kinetic in the phagocytosis. It could be questioned whether PS induced 
a gain of function in the phagocytic activity of macrophages or more 
macrophages were mobilised to engulf dying cells. Comparing the results 
obtained when measuring the fluorescence intensity or the percentage of 
fluorescent macrophages, it seems that PS recruits more macrophages to 
phagocytose but specially increases their engulfing capacity. Confocal 
microscopy experiments demonstrated that all the target cells had been 
efficiently engulfed and not only recognised by macrophages.   
 
The mechanisms of phagocytosis depend on the apoptotic cell type, the means 
of induction of cell death, the stage of apoptosis, the type and state of 
differentiation of the phagocyte, and the surrounding microenvironment [120]. 
THP-1 cells have been reported to express several receptors including the PS 
receptor [138], αVβ3 (vitronectin receptor), CD36 [228], CD14 and scavenger 
receptors (acetylated/oxidized LDL receptors, [229]). They also contain lectin-
like proteins on their surface that recognise sugar chains on the target cell 
[230]. Factors present in serum as protein S [231] or C-reactive protein [148] 
could bind to PS and enhance phagocytosis. Thus, the “phagocytic synapse” of 
THP-1 and Jurkat cells appears a complex system. Viable Jurkats are 
phagocytosed probably due to the inherent activation of THP-1-derived 
macrophages and the binding to Jurkat cells of molecules present in serum that 
increase their immunogenicity and make them attractive to macrophages. 
SQTL-treated Jurkat cells are probably engulfed through the ligation of PS by 
the PSR and the vitronectin receptor, and the binding of oxidised membrane 
structures (favoured by the depletion of glutathione that SQTL produce) by 
scavenger receptors, among others. Cell debris of late apoptotic cells may be 
recognised by opsonins and receptors of the innate immune system. Etoposide 
(classical chemotherapeutic drug)-treated Jurkats were phagocytosed similarly 
to viable Jurkat cells, which could be explained by a very low or absent PS 
exposure [232]. Heat-killed cells (necrotic) should be basically removed through 
mechanisms of the innate immune system. 
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2.2 RELEASE OF CYTOKINES BY MACROPHAGES 
After confirming the importance of PS in the phagocytosis of SQTL-treated 
Jurkat cells, a possible modulation of the cytokine profile of engulfing 
macrophages was studied. This hypothesis was based on in vitro observations 
that apoptotic cells increase release of anti-inflammatory cytokines as IL-10, 
TGF-β1, PAF and reduce release of TNF-α, IL-1β, IL-12, IL-8, GM-CSF from 
phagocytating cells [153-156]. In vivo models of inflammation had shown that 
clearance of apoptotic cells in inflammatory lesions leads to accelerated 
resolution of inflammation, mediated by the increased production of TGF-β1 
[136,153,154,166,170], cytokine which would also explain the wound healing 
effect of SQTL. 
 
To check this notion, the concentration of the pro-inflammatory cytokine TNF-α 
and the anti-inflammatory TGF-β1 were measured in culture supernatants. 
These cytokines and the time points of analysis were chosen according to the 
literature. Surprisingly, a moderate increase but not a reduction in TNF-α level 
in the supernatants of macrophages incubated with SQTL was observed. Viable 
and etoposide-treated Jurkats slightly reduced TNF-α concentration. 
Interestingly, the ability of SQTL-mediated cell death to increase the number of 
phagocytating macrophages tended to correlate with the early TNF-α production 
by macrophages, although only HC-treated Jurkat cells significantly increased 
TNF-α level in macrophage supernatants. The most pronounced increase in 
TNF-α production was observed in response to phagocytosis of heat-killed 
necrotic cells, suggesting that HC-mediated Jurkat cell death shares some 
features with necrosis. In accordance with this, a recent study [233] reported a 
necrosis-like cell death induced by some ent-kaurene diterpenes possessing 
also an exocyclic α,β-unsaturated carbonyl group. However, in this study, 
“necrotic” cell death seemed to be caspase-independent and apoptotic cell 
death was exclusively evaluated by DNA parameters and permeability to trypan 
blue [234]. 
 
The analysis of TGF-β production did not help to establish differences between 
the SQTL in study but to confirm that SQTL-treated Jurkat cells do not behave 
as necrotic cells. In fact, they affected TGF-β levels similarly to apoptotic cells 
(etoposide-treated). Only necrotic cells reduced TGF-β concentration 
significantly after 18 h of co-culture when compared to viable cell feeding.  
 
The relative dominance of the receptors engaged in the interaction 
macrophage-target cell determines the final outcome. For instance, signalling 
through the immunoglobulin Fc receptor in macrophages can override signalling 
through the PSR, which in turn appears to override that derived from the Toll-
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like receptor 4 [155,235]. Since HC-treated Jurkat cells exposed high levels of 
PS, a pro-inflammatory stimulus must accompany and temporally override the 
anti-inflammatory effect of PS but disappear later, because after 18 h of co-
culture these cells behaved as classic apoptotic cells. This could be explained 
by the participation of innate immune stimuli, which normally stimulate pro-
inflammatory cytokine production to efficiently eliminate the invading agent. 
Supporting this hypothesis, an interesting study has shown that the combination 
of apoptotic cells and ligands for Toll-like receptors (members of the innate 
immunity) induced an early and sustained secretion of TNF-α by macrophages 
which was followed, however, by increased late TGF-β1 release [236]. 
 
In summary, phagocytosis of SQTL-treated immune cells induces an unusual 
profile of cytokine secretion in macrophages characterised by a transient TNF-α 
release proposed to stimulate the immune response and a later unmodified or 
slightly increased level of TGF-β1 that ensures the proper resolution of 
inflammation. 
 
 
3 CONCLUDING REMARKS 
Phagocytosis and subsequent physiological consequences of cells dispatched 
by PCD other than classical apoptosis have yet been poorly studied. In some 
forms of necrotic-like PCD, where subsequent phagocytosis was PS-
dependent, macrophages were found to react very similarly (if not equally) as to 
apoptotic cells reducing TNF-α levels [167]. Moreover, the ligation of PS 
receptor has been proposed as the primary mechanism to block the release of 
pro-inflammatory cytokines in vitro and in vivo [170]. This contrasts to this study, 
which shows that a rapid and strong PS externalization and subsequent 
phagocytosis may be also accompanied by a transient increase in TNF-α 
release.  
 
Besides the intriguing concept that cytokine modulation in response to apoptotic 
cell clearance by macrophages may contribute to resolution of inflammation, 
phagocytosis per se is an essential anti-inflammatory process by protecting 
tissues from harmful exposure to the inflammatory or immunogenic contents of 
dying cells. The extremely fast and strong exposure of PS in HC-treated cells 
ensures that they are properly engulfed by phagocytes, avoiding secondary 
necrosis and long-term negative consequences for the organism. The ability of 
HC to stimulate the immune system by increasing the phagocytic activity of 
macrophages and TNF-α levels transiently would agree with prior structure-
activity investigation of the anti-inflammatory activity.  
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It is highly unlikely to separate the normally wanted anti-inflammatory activity of 
SQTL from side effects such as toxicity due to unspecific alkylation of biological 
structures. Preparations from Arnica should be used only externally because of 
the reported gastrointestinal and cardiac toxicities [237]. Even though the 
anticancer potential of SQTL is attracking increasing interest [26], structures 
with lower systemic toxicity should be found before their chemotherapeutic use. 
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VII. SUMMARY 
A. CEPHALOSTATIN 1 
The present study demonstrates that the ER stress response evoked by 
cephalostatin 1 induces specific signalling pathways that lead to apoptosis 
(represented in Figure VII.1). Interestingly, caspase-9 was found to be 
necessary for cephalostatin 1-induced apoptosis despite the absence of an 
apoptosome. Cephalostatin 1 initiates a rapid endoplasmic reticulum (ER) 
stress response characterised by phosphorylation of the translation initiator 
factor eIF2α and increased expression of the chaperone BiP/GRP78 as well as 
the transcription factor CHOP/GADD153. Activation of apoptosis signal-
regulating kinase 1 (ASK1) and c-Jun N-terminal kinase (JNK), presumably 
activated at the ER membrane through TRAF2, are involved in cephalostatin 1-
induced apoptosis, as assessed by stable expression of a dominant negative 
ASK1. The ER-associated caspase-4 is required and acts upstream of caspase-
9 in cephalostatin 1-induced apoptosis. Caspase-2 is activated upstream of 
caspase-9, probably in a specific complex at the ER nearby, and participates in 
caspase-9 activation and apoptosis.  
 
 
 
Figure VII.1: Schematic illustration of cephalostatin 1-induced ER stress markers and 
apoptotic pathways. 
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Thus, cephalostatin 1 uses the ER stress pathway rather than the classical 
intrinsic mitochondrial pathway, which might be of advantage in the treatment of 
tumours chemoresistant due to defects in the mitochondrial pathway. 
 
 
B. SESQUITERPENE LACTONES 
This work sought to characterise the mode of cell death induced by distinct 
sesquiterpene lactones (SQTL) and investigate its consequence on 
macrophage function as a putative anti-inflammatory mechanism. It was found 
that the α,β-unsaturated cyclopentenone SQTL, DHA, induces classical 
apoptosis whereas HC, bearing an α-methylene-γ-lactone group, induces a 
form of “apoptosis-like” programmed cell death that features the following 
striking characteristics: i) caspase activation, DNA condensation and a rapid 
and strong induction of apoptotic morphology and translocation of 
phosphatidylserine (PS); ii) strong induction of the phagocytic response of 
macrophages that correlates with PS exposure on target cells; iii) a transient 
increase in TNF-α levels in supernatants after co-culture.  
 
 
Table VII.1: Cell death characteristics of 11α,13-dihydrohelenalin acetate (DHA) and 7-
hydroxycostunolide (HC). 
 
Thus, the external application of HC or similar SQTL in inflammed zones may 
induce a transient activation of the immune response but a final contribution to 
inflammation resolution by the clearance of apoptotic inflammatory cells and 
invading microorganisms. These features may contribute to the beneficial 
effects attributed to SQTL in the treatment of inflammation and in the wound 
healing process. 
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Amaxa Cologne, Germany 
Amersham Biosciences Freiburg, Germany 
BD Biosciences Heidelberg, Germany 
Beckman Coulter Krefeld, Germany 
Biomers.net Ulm, Germany 
Bio-Rad Munich, Germany 
Biotrend Cologne, Germany 
Biozol Eching, Germany 
Calbiochem Schwalbach, Germany 
Cell Signalling/New England Biolabs Frankfurt/Main, Germany 
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